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Crohn’s disease has a prevalence of 1 in 650 people in the UK.  Of these, 30% will develop an anal fistula. 
This debilitating condition requires multiple medical and surgical interventions. Treatment goals may be 
preference sensitive for patients. This thesis assesses the evidence base for treatment of Crohn’s anal 
fistula, explores clinician preferences, and patient informational needs. Systematic literature review 
identified 27 trials of pharmacological therapies. Anti-tumour necrosis factors (TNF) drugs were associated 
with induction (RR, 2.01; 95% CI, 1.36-2.97) and maintenance of response (RR 1.94 CI 1.25-3.02). Review 
of the surgical literature identified 63 studies, of which three were randomised-controlled trials. 
Interpretation of the literature was impeded by poor outcome reporting and methodological issues of 
included studies. A survey of gastroenterologists showed thiopurines and anti-TNF were first-line agents. 
Variation was noted in time to reassessment following treatment, and selection of subsequent 
interventions. A survey of colorectal surgeons showed consistency in the treatment in the acute setting, 
but a wide range in the definitive surgical procedures offered. Clinicians offered consistent indications for 
faecal diversion. Assessment of treatment pathways across three tertiary centres found the median time 
to receive anti-TNF agents was 204 days. The study suggested challenges in cross-specialty working. A 
consensus exercise conducted with colorectal surgeons and agreed a framework for surgical treatment. 
Semi-structured interviews with 17 patients found that participants wanted to participate in decision-
making and suggested information needed to inform decisions. This informed the a survey conducted 
across 10 centres. Principal component analysis identified three items to inform decisions; immediate 
aftercare, effect on perianal region, severity of operation. This thesis shows variation in clinical practice. 
Patients wish to participate in decision-making about their treatment. The items identified may form the 





Clinicians and patients lack evidence-based information and guidelines for the management of Crohn’s 
anal fistula, leading to variation in practice. Informational needs of patients when decision making may 
differ from that which is currently provided. 
 
1.2 Aims 
The aim of this thesis is to define current practice and evidence for the management of Crohn’s anal 
fistula, and to explore patient preferences and informational needs around the surgical management of 





1. To undertake a systematic review of the literature to assess the evidence for surgical treatments 
of Crohn’s anal fistula 
2. To undertake a systematic review of the literature to assess the evidence for medical treatments 
of Crohn’s anal fistula 
3. To undertake a survey of Consultant Colorectal Surgeons to describe current surgical 
management of Crohn’s anal fistula 
4. To undertake a survey of Consultant Gastroenterologists to describe current medical 
management of Crohn’s anal fistula 
5. To establish consensus in the surgical management of Crohn’s anal fistula 
6. To describe current patient pathways from presentation to treatment of Crohn’s anal fistula 
7. To describe patient experiences and preferences related to surgical treatment of Crohn’s anal 
fistula through semi-structured interviews 













2.1 Crohn’s disease 
2.1.1 Overview and incidence 
Crohn’s disease may affect any part of the gastrointestinal tract1 2. It has an incidence and prevalence in 
the United Kingdom of up to 11.4 per 100,000 and 262 per 100,000 respectively3. It can affect any age 
group, although 90% of patients are diagnosed between 10-40 years of age. There is a slight female 
preponderance.  The highest incidence is in Northern Europe2. Disease onset at a younger age tends to 
predict a more severe course. 
2.1.2 Pathology appearance 
Crohn’s disease is a granulomatous inflammation of the full thickness of the bowel wall2. Whilst it may 
affect any part of the gastrointestinal tract, it commonly affects the ileocolic region (approximately 42.5% 
cases), the colon only (30.8%) or ileum only (26.4%)4 . Macroscopically, it is characterised by skip lesions, 
a cobblestone appearance of bowel mucosa, and mucosal oedema. There is typically rectal sparing. The 
affected bowel wall may be thickened, or fibrosed. There is typically encroachment of mesenteric fat onto 
the bowel wall, and a proliferation of mesenteric lymph nodes. Microscopic inspection shows transmural 
inflammation, intra-mural lymphoid aggregates, submucosal oedema, mucosal ulceration, and non-
caseating granuloma in the bowel wall or lymph nodes2. There is also often evidence of peri-neural 
inflammation and angiogenesis within the mesentery5. 
 
2.1.3 Disease behaviour 
Crohn’s disease tends to follow distinct phenotypical behaviours in terms of distribution and behaviour of 
disease. These can be classified using the Montreal classification system1. This system uses three 
components: age at onset of disease, distribution of disease, and whether the disease causes 
23 
 




 1 2 3 4 
Age at diagnosis 
(A) 
<16 years old 17-40 years old >40 years old - 
Location (L) Terminal Ileum Colon Ileocolonic Isolated upper GI 
Behaviour (B) Non-stricturing, 
non-penetrating 
Stricturing Penetrating - 
 
Table 1 Summary of components of Crohn’s disease phenotypes.  
If perianal disease is present, a modified of ‘p’ is added. 
 
 
The clinical presentation of Crohn’s disease varies according to underlying disease behaviour. Clinical 
presentations include abdominal pain, diarrhoea, mouth ulcers, weight loss, anaemia, intestinal 
obstruction or intestinal perforation.  It often follows a relapsing-remitting course with periods of 
increased or decreased disease activity6.  Onset of symptoms before the age of 40, and perianal disease 






Crohn’s disease is thought to have a complex, multifactorial aetiology. It is most likely related to an 
aberrant immune process with a genetic basis, which is modified by other lifestyle and environmental 
factors.  
 
2.1.1 Genetic evidence 
The role of genetic  susceptibility has long been recognised due to familial segregation of the disease in 
related individuals6. Cohort studies have demonstrated that relatives of Crohn’s patients tend to follow 
the same disease phenotype. Advances in technology such as gene sequencing, gene arrays and the 
creation of huge genetic population consortia have facilitated recent advances in our understanding of 
the genetic underpinnings of the disease. A genome-wide association study, which included more than 
16,000 patients with Crohn’s disease, demonstrated strong associations between three genetic loci and 
disease phenotype. These loci were 3p21, 6p21, and 16q12, which code for Macrophage Stimulating 1 
Gene, class 2 and 3 Major Histocompatability Complex genes, and Nucleotide-binding Oligomerization 
Domain-containing-2 respectively8. 
 
Macrophage Stimulating 1 gene (MST1): This gene has a role in the innate immune system, as it codes 
for Macrophage Stimulating Protein (MSP). In the presence of inflammation, MSP is activated, and attracts 
macrophages through chemotaxis. It has a role in suppressing the production of inflammatory mediators 
and cytokines by macrophages. Missense mutations of MST1 have been detected in association with 
Crohn’s disease 8. These mutations are associated with loss of function of the gene. This is supported by 
the presence of downstream inflammatory markers which should otherwise be suppressed, in the 




Major Histocompatability Complex (MHC): This refers to a region of genetic coding material on the short 
arm of chromosome 6, also known as the Human Leucocyte Antigen region. Variation at this locus is 
associated with a number of autoimmune diseases11. This region codes for molecules which present 
antigens to the host immune system. There are three main classes of MHC molecules. Class I MHC present 
peptide fragments from ‘normal’ cells to CD8+ T cells – those presenting recognised fragments are 
tolerated by the immune system. Class II MHC are typically found on B-cells, macrophages, dendritic and 
other antigen presenting cells. These present peptide fragments from abnormal cells as antigens to 
stimulate the activity of CD4+ cells, stimulating an immune response12. Whilst there are associations 
between MHC variants and both forms of IBD, variants affecting class II MHC alleles have shown a strong 
association with the development of Crohn’s diseases i.e. HLA-DRB1*07, HLA-DRB1*0103, HLA-DRB1*04, 
and HLA-DRB3*030111 13. Class III MHC genes are related to immune function, and lie between the Class I 
& II coding regions14. These genes are also implicated in the development of Crohn’s disease, and 
polymorphisms can lead to up-regulation of Tumour Necrosis Factor, a pro-inflammatory cytokine8 13. 
 
Nucleotide-binding oligomerization domain-containing-2 (NOD2): This gene codes for a NOD-like 
receptor, which has a role in sensing and triggering a response to bacterial wall peptides. Polymorphisms 
in this gene causes loss of immune function and reduce rates of bacterial clearance, leading to changes in 
the intestinal microbiome15. 
 
2.1.2 Evidence for the role the microbiome in Crohn’s disease 
The role of bacteria in the aetiopathogenesis of Crohn’s disease is not yet clear. Patients with Crohn’s 
disease have changes in their intestinal microbiome when compared to healthy individuals, but it is not 
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clear whether this is cause or effect 16 17 18. It is well established that the microbiome shifts towards one 
with less diversity, and with the presence of more invasive species of bacteria in Crohn’s disease16 19. 
Faecal microbiota transplanted from healthy individuals into those with Crohn’s disease have been shown 
to restore biodiversity and leads to a clinical response or remission in small studies20 21. Laboratory studies 
have also demonstrated the role of bacterial antigens in stimulation of run-away inflammatory processes 
which are commonly seen in Crohn’s disease22. 
2.1.3 Environment and lifestyle factors 
Lifestyle and environmental factors have a role in the development of Crohn’s disease. This is partly 
supported by the increased rate of illness seen in migrants moving from low prevalence areas to high 
prevalence areas 23. Smoking is one of the most widely investigated factors and shows a strong positive 
association with the development of Crohn’s disease, as well as subsequent complciations 24. Smoking 
triggers the inflammatory process through activation of CD4+ T cells25. Aside from the direct effects of 
inflammation, smoking may also increase intestinal permeability. Escherichia coli species have been found 
in the intestinal wall of smokers, which may lead to a sustained inflammatory stimulus26. Smoking is 
associated with a significant reduction of bacterial species with anti-inflammatory properties in the 
Crohn’s population27.  
 
Being breastfed as a child is protective. Breast milk may modify the intestinal microbiome and provide 
additional benefits to the immune system. It is interesting to note that the protective effect is greater in 
Asian populations than Caucasian populations28. Other factors implicated in the development of Crohn’s 
disease include use of antibiotics before age of 15 years, high intake of fast food, and childhood BCG 
vaccination29 30. Having a pet dog may also confer protection, although evidence for this is weak29. 
 








2.2 Crohn’s Anal Fistula 
2.2.1 Definition of a fistula 
A fistula is an abnormal connection between two epithelial surfaces. In the context of a perianal fistula, 
this is an abnormal connection between the anorectum and perianal/perineal skin or pelvic organs such 
as the vagina or bladder31. When this occurs in the presence of Crohn’s disease, it is referred to as Crohn’s 
anal fistula. This is a sub-phenotype of penetrating Crohn’s disease in the Montreal classification .  In 
around 15% of cases, anal fistula is the first presentation of Crohn’s disease32. It can occur at any point 
during the disease, and therefore can affect patients of any age. 
 
2.2.2 Clinical presentation of a fistula 
Crohn’s anal fistula can present to clinicians in a number of different ways. Patients may complain of anal 
pain, or bleeding. If the fistula has completed the connection between anus and surrounding skin, the 
patient may complain of foul smelling discharge or incontinence-like symptoms. If the tract has not 
completed the connection between the two surfaces, this means it is blind ending. This allows a space for 
discharge to stagnate, becoming infected and eventually forming an abscess. 
2.2.2 Aetiopathology of fistula in Crohn’s 
The classic theory of fistula formation was described by Parks’ in his cryptoglandular hypothesis 33. This 
postulates that the anal glands become blocked, leading to accumulation of mucus which is normally used 
for lubrication in the anal canal. The resulting accumulation of mucus discharges through the path of least 
resistance, which is typically through the skin. In some cases, the path remains open, leading to the 
formation of a fistula. 
 
The aetiology of perianal fistula in Crohn’s disease differs from the cryptoglandular theory, in part due to 
the underlying disease process, and in part due to the different behaviour of the fistula. The two key 
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mechanisms involved in the formation and persistence of Crohn’s anal fistula are epithelial-mesenchymal 
transition and matrix-metalloproteinase activity, both described in detail below. This mechanism is 
summarised in Figure 2. 
 
 
Figure 2 Summary of proposed mechanisms underlying anal fistula formation in Crohn’s disease. 
 
2.2.2.1 Epithelial-Mesenchymal Transition 
The cells present on the gastrointestinal surface are of epithelial type. These cells can transition to become 
mesenchymal type (i.e. transitional cells), gaining the ability to penetrate surrounding tissues – a 
behaviour also seen in primary and metastatic cancers34. Support for this theory comes from the 
identification of transitional cells with epithelial origins within fistula tracts22 35. Mechanistic evidence has 
shown that this epithelial-mesenchymal transition can be induced by high levels of pro-inflammatory 
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cytokines including Tumour Necrosis Factor (TNF)-α22. This leads to upregulation of Transforming Growth 
Factor (TGF)-β, which in turn upregulates expression of interleukin (IL)-13 in intestinal epithelial cells, 
promoting invasive behaviour of cells36. High levels of these cytokines are present in the anorectal mucosa 
of patients with Crohn’s disease37. This may be in response to bacterial antigens22. 
 
2.2.2.2 Matrix MetalloProteinases 
Matrix metalloproteinases (MMP), are enzymes with a role in the remodelling of the extracellular  matrix. 
They may have a role in micro- and macroscopic remodelling of the gastrointestinal tract, leading to fistula 
formation. MMPs have been implicated in the pathogenesis of Crohn’s disease, as deletion or silencing of 
relevant MMP regulatory genes confers protection in murine models of colitis, wheareas over expression 
of these genes worsens disease phenotype38. In humans, increased MMP activity is seen in inflammatory 
bowel disease, although activity seems to be higher in Crohn’s disease versus Ulcerative colitis39. Differing 
activity of  MMP subtypes has been noted in Crohn’s disease – raised MMP-1 activity is seen in active 
luminal disease, whereas MMP-9 activity may be downregulated in perianal disease40. This may partly 
explain the differing behaviour seen in different disease phenotypes. Examination of resected fistula 
specimens has shown increased presence and activity MMP-3 & MMP-9, particularly in relation to 
mononuclear cells and fibroblasts within the associated inflammatory infiltrate41. These data are drawn 




2.2.3 Clinical impact of Crohn’s anal fistula 
Crohn’s anal fistula has been identified as a priority condition in two research prioritisation exercises in 
the last five years42 43. It is recognised that rates of healing are low; around 20% of patients in trial placebo 
groups achieve fistula closure44, and as few as 30% of actively treated patients achieve long term healing 
in observational studies45. 
 
The poor rates of healing and response have a direct impact on the health and well-being of patients46 47. 
Trials in Crohn’s anal fistula using patient reported outcomes have measured the effect of treatments on 
quality of life using a range of tools. The generic tools used include the Short form survey (SF)-36, or the 
European Quality of Life 5 dimensions tool (EQ5D). These address factors related to quality of life in 
general, and do not address items or factors specific to inflammatory bowel disease or Crohn’s disease. 
The Short-Inflammatory Bowel Disease Questionnaire (S-IBDQ), is a validated and disease-specific four 
domain tool addressing bowel symptoms, systemic symptoms, emotional impact of disease and social 
impact. The Work Productivity Assessment Index for Crohn’s disease (WPAI:CD) has been shown to 
correlate with quality of life and assess the impact of disease behaviour on absenteeism, presenteeism 
(attending work when unfit or unwell), and the proportion of this attributable to inflammatory bowel 
disease. Other less frequently used tools include assessments of disability due to IBD using the IBD 
Disability Index, fatigue using generic fatigue measures, and anxiety and depression, again using generic 
measures46. When these tools are used to compare patients with fistula to the healthy population, or to 
compare poorly controlled Crohn’s disease to controlled Crohn’s disease, they demonstrate a significant 
negative impact on quality of life. 
 
A survey of 130 patients treated for Crohn’s anal fistula identified anal pain, anal discharge, physical 
activity restriction, sleep interference and perceived cleanliness as highly important to patients48. A 
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criticism of this study was that it is not clear how the list of quality of life items was generated. This means 
that the patient voice may not be present in this list, and therefore the report is incomplete. A separate 
report of the same study assessed self-reported depressive symptoms. This found that patients with a 
stoma were more likely to feel that life is not worth living (OR 8.67 (95% C.I. 2.7-27.4)). This is likely to be 
the effect of severe perianal disease along with stoma, rather than the effect of a stoma alone. A history 
of anal stricture or anal stenosis was associated with suicidal feelings (OR 11.2 (95% C.I. 2.1-5.9). The study 
notes that there was an association between longer duration of disease and both of these measures49. 
This may however be confounded as these complications are more likely to develop over a longer disease 
course. The finding that a stoma is associated with a poorer quality of life is interesting. A study comparing 
quality of life in patients with perianal disease between those with and without stoma, found no 
difference in global quality of life measures. It did find a small difference in the gastrointestinal symptoms 
domain of the gastrointestinal quality of life index50. 
 
The literature suggests that people with Crohn’s disease have impaired sexual function compared to the 
healthy population, with greater impact in women51. One study reports quality of life following surgery 
on a retrospective cohort of patients who had undergone surgery for Crohn’s anal fistula, and compared 
their sexual function to healthy controls using the Female Sexual Function Index for women, and the 
International Index of Erectile Function for men. There was a trend towards lower scores in the operated 
female group, but this was not apparent in the male group52. This study excluded patients with a stoma, 
and lost a significant number of responses as a result. This, in combination with the separate analyses of 





2.2.4 Classification of fistulae 
A number of systems can be used to describe Crohn’s anal fistula. These varyingly describe anatomy and 
disease behaviour. There is no common consensus on a tool for common use; each of the systems 
described below fulfils a specific role, to describe anatomy, disease activity, or associated manifestations 
of Crohn’s disease 
2.2.4.1 Parks’ Classification 
Parks’ classification was originally proposed for fistulae of cryptoglandular origin53. This describes the 
anatomical location of a fistula in relation to the anal sphincters, and whether it lies close to the anal verge 
(low), or away from it (high). This classification system is widely used as it clearly communicates the 
anatomy of the fistula. It does not provide prognostic data, nor provide a treatment framework based 
upon anatomic classification. 
2.2.4.2 Cardiff-Hughes 
The Cardiff-Hughes system is a classification system designed for perianal Crohn’s disease. It recognises 
the presence of ulceration, fistula or stricture, and allocates up to two points for severe presentations of 
these disease manifestations. These numbers are added together to give an overall score; the higher the 
score, the worse the perianal disease is54. The major criticism of this score is that it is not specific to fistula, 
and does not allow meaningful description or classification of a fistula to guide clinical treatment. 
 
2.2.4.3 Van Assche MRI Score 
The Van-Assche score is based upon magnetic resonance imaging of the pelvis to describe fistula activity 
and number. It records data on whether fistulae are single or multiple, branched or unbranched, the 
location of the tract in relation to the sphincters and levators, hyper intensity on T2 imaging; the presence 
of collections and evidence of rectal wall involvement55. Intra-rater reporting of this measure is only 




2.2.4.4 American Gastroenterology Association 
The American Gastroenterology Association (AGA) dichotomises Crohn’s anal fistula into ‘simple’ or 
‘complex’. It defines a ‘simple’ fistula as a low sub-sphinteric fistula without proctitis. Mid or high 
transphincteric or intra-sphincteric fistulae, or those associated with proctitis or recto-vaginal 
involvement are considered complex. As with Park’s classification, this provides broad groups of fistula 






3. Assessment and treatment of a patient with Crohn’s anal fistula 
 
3.1 Assessment of patients with suspected Crohn’s anal fistula 
A number of investigations are available to assess the patient with suspected Crohn’s anal fistula. These 
can be broken down into endoluminal assessment, measures of disease activity, and radiological 
assessment. A potential minimum investigation set is presented in Table 2. 
 
3.1.1 Endoluminal assessment 
Endoluminal assessment refers to a range of investigations that allow visual inspection of the intestinal 
and colonic mucosa. These are categorised according to mechanism of visualisation, and anatomic region 
assessed. Current endoluminal investigations are capsule endoscopy and fibreoptic endoscopy of colon. 
 
2.3.2 Capsule endoscopy 
In capsule endoscopy, a small capsule containing a camera, light source and transmitter is swallowed by 
the patient. This takes photographs at frequent intervals and transmits them to a receiver worn by the 
patient. Capsule endoscopy is typically used for the detection of small bowel Crohn’s when other 
investigations are inconclusive. It has high sensitivity for detection of Crohn’s (100%) but moderate 
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2.3.3 Fibreoptic endoscopy 
This investigation uses a flexible endoscope to visualise the colonic mucosa from rectum to the 
ileo-caecal valve, allowing inspection of the terminal ileum (colonoscopy). Biopsies may also be 
taken. The procedure is aided by insufflation of the colon with air or carbon dioxide gas – this 
distends the lumen and allows passage of the endoscope58. This procedure is not without risk. 
Some patients are not able to tolerate flexible endoscopy, despite adequate use of analgesia. The 
procedure is technically difficult in some patients, especially where there has been previous 
pelvic surgery. There is also the risk of bleeding from a biopsy site, and the risk of colonic 
perforation. This risk is higher in colonoscopy than sigmoidoscopy, with rates as high as  5%    vs 
0.08% respectively59.  
 
2.3.4 Assessment of disease activity 
Disease activity can be assessed in a number of ways. These include faecal calprotectin, composite 
measures of global disease activity, and composite measures of perianal activity. 
 
2.3.4.1 Faecal Calprotectin 
Faecal calprotectin is a 35kDa protein which binds calcium and zinc. Levels of this are typically raised in 
the presence of increased neutrophil activity60. The diagnostic performance of faecal calprotectin in the 
diagnosis of IBD has a sensitivity of 93% and a specificity of 96%61.  It is reproducible and a non-invasive 
test and may therefore be of value in the diagnosis and monitoring of inflammatory bowel disease, 
particularly in primary care61 62. 
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2.3.4.2 Crohn’s Disease Activity Index 
The Crohn’s disease activity index (CDAI) is a clinical assessment of disease activity which has previously 
been widely reported in clinical trials in Crohn’s disease. It is not widely used in clinical practice. However 
it correlates poorly with direct assessments of mucosal inflammation63. The index includes deviation from 
ideal body weight, frequency of liquid or soft stools, abdominal pain, abdominal mass, general wellbeing, 
anti-diarrhoeal drug use, haematocrit and the presence of extra-intestinal manifestations to assess 
activity. Wellbeing, pain and abdominal mass are rated on an ordinal scale from 0-3, and other categories 
rated 1 if present, 0 if absent. Multipliers are applied to each response, and a total composite score is 
reached. A CDAI <150 indicates remission of disease, a CDAI >450 indicates severe disease64. 
 
2.3.4.3 Harvey Bradshaw Index 
Harvey-Bradshaw Index (HBI) was proposed in 1980 as a refinement of the CDAI and remains in use.  This 
composite measure addresses five domains: general wellbeing, abdominal pain, number of liquid stools 
per day, abdominal mass, complications of disease. Wellbeing, pain, and abdominal mass are scored 0-3 
on an ordinal scale. Similarly to CDAI, it shows limited correlation with mucosal inflammation65. 
2.3.4.4 Perianal Disease Activity Index 
Both the CDAI and HBI focus on global disease activity and do not assess perianal disease 
specifically. The Perianal Disease Activity Index (PDAI) was first described in 1995. It includes five 
domains rated 0-4. The domains are discharge, pain/restriction of activities, restriction of sexual 
activity, type of perianal disease and degree of induration. Three domains are rated by patients 
and two by clinicians66. Despite the relative subjective nature of this index, it performs well when 




2.3.5 Radiological assessment 
A number of radiological tools are available for the assessment of the extent and complications of Crohn’s 
disease. These include cross-sectional imaging with Computed Tomography (CT) and Magnetic Resonance 
Imaging (MRI). Endoanal Ultrasound has also been described in the assessment of perianal disease. 
 
2.3.5.1 Computed Tomography Imaging 
CT scanning provides three dimensional images of the structures being assessed, using X-ray technology. 
It is accepted as an appropriate modality in Crohn’s disease68. Whilst it can demonstrate inflammation of 
a viscus, it is typically more helpful in the assessment of complications of disease such as fistula or abscess. 
It performs poorly in assessment of the perianal region69. 
 
 
2.3.5.2 Magnetic Resonance Imaging 
MRI scanning relies on the use of powerful magnets to affect the spin of protons in the tissue undergoing 
assessment. The resulting images can be viewed as ‘T1’, where tissues containing water are dark, or ‘T2’, 
where tissues containing water are bright. Tissues which are bright on T2 imaging are typically inflamed. 
MRI assessment of the small bowel can provide evidence of inflammation and stricturing and provide 
more accurate data on the location of the pathology than is possible with CT scanning. Given the nature 
of T1 and T2 sequences, it is also possible to tell whether strictures in small intestine are active (high signal 
on T2) or inactive (low signal on T2). This suggests whether disease may be amenable to a trial of medical 
therapy, or, if it is burned out disease, it is likely to require surgical intervention. Small bowel MRI has 
sensitivity and specificity of 97% and 96% respectively70. MRI assessment of the pelvis is well established 
in the context of perianal fistula. If can be used to describe the relationship of a fistula track to the 
sphincter muscles and surrounding structures, identify abscesses deep within the pelvis or ischiorectal 
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fossa, and identify secondary tracks68. Sensitivity and specificity for detection of fistula using MRI is 87% 
and 69% respectively71. There has been recent exploration of 3-dimensional rendering of MRI pelvis 
images, although these are still in an exploratory phase72. Whilst activity and inflammation may be 
assessed in MRI of the abdomen, equivalent tools to assess for inflammation in the pelvis have yet to be 
developed. 
 
2.3.5.3 Endoanal Ultrasound 
Endoanal ultrasound is performed by insertion of an ultrasound probe into the anal canal. This allows 360 
degree assessment of the sphincter complex, and for any surrounding sepsis. Sensitivity and specificity 
for this modality are 0.87 and 0.43 respectively71. This investigation is performed by limited numbers of 
physicians as it is operator dependent, and not as widely available as other imaging modalities. 
 
3.2 Current management 
Current treatment options for Crohn’s fistula involve multidisciplinary management, and are 
typically shared between gastroenterologists and colorectal surgeons73. The interventions 
offered can be split into medical and surgical therapies. Whilst considered separately here, they 
are typically offered as a package of treatments. 
 
3.3 Medical Treatments 
Drugs used in the treatment of Crohn’s anal fistula include biologic agents, immunosuppressants, and 




3.3.1 Systemic Monotherapy 
The currently favoured systemic medical therapy is one of the class of drugs which impedes anti-TNF-α 
signalling and so reduces the inflammatory process. Infliximab is a chimeric anti-TNF-α monoclonal 
antibody. Present and colleagues undertook a three-armed randomised controlled trial of Infliximab in 94 
patients with fistulating Crohn’s, of whom 90 had perianal disease. The primary endpoint (a 50% reduction 
in the number of fistulae), was reached by 8/31 (25.8%) patients in the placebo group and 39/63 (61.9%) 
patients in the treatment arms 74.  In the randomised ‘A Crohn’s Disease Clinical Trial evaluating Infliximab 
in a New Long-Term Treatment Regimen in Patients with Fistulizing Crohn’s Disease’ (ACCENT II), patients 
were allocated to a 5mg/kg dose of Infliximab or placebo 75. This included patients with fistulating Crohn’s 
disease, 90% of whom had perianal fistula. The primary outcome was defined as a reduction in the number 
of draining fistulae of 50% or more across two visits four or more weeks apart. When assessed at week 54 
of the study, complete fistula resolution was seen in 36% of treated patients vs 19% in the placebo group 
(p=0.009).   A post-hoc subgroup analysis from this trial found that in treated patients, 64% had closure 
of their recto-vaginal fistula. This subgroup represents just 25 patients, of whom only 14 were included in 
the treatment arm, so caution should be exercised in interpreting these results 76.  
 
Adalimumab is a humanised recombinant monoclonal antibody to TNF-α. The Crohn’s Trial of the Fully 
Humanized Antibody Adalimumab for Remission Maintenance (CHARM) trial was designed to assess 
Adalimumab in the induction and maintenance of remission of Crohn’s disease 77. This study assessed the 
outcomes of enterocutaneous and perianal fistulae as one entity, and demonstrated fistula closure rates 
of 30% vs 13% in the treated and placebo groups respectively (p=0.04). Patients with fistula response were 
entered into a two-year open label trial where adalimumab was administered on a weekly or alternate 
week dosing regime vs placebo for two years. At the end of this study, patients on placebo had a mean of 
1.88 draining fistulae vs 0.88 in the treatment groups (p=0.002). A four-year open label extension of this 
trial found that fistulae remained closed in 25% of patients who entered the study with a draining fistula78. 
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The effect of adalimumab as a ‘rescue’ therapy for fistulating disease has been assessed in the Crohn’s 
Disease WHO Failed Prior Infliximab to Collect Safety Data and Efficacy via Patient-Reported Outcome 
Measures (CHOICE) trial 79. This trial took patients who had never responded to Infliximab (PNR), or had 
initial response, which was lost (PI).  Follow-up data were 
 available at 4-36 weeks for the 88 patients with fistulae, 34 of whom demonstrated clinical remission. 
 
Certolizumab, a pegylated Fab fragment, did not show any difference in fistula closure rates between 
placebo and treatment groups in the Pegylated Antibody Fragment Evaluation in Crohn’s Disease: Safety 
and Efficacy 1 (PRECISE 1) trial (31% vs 30% at 34 weeks) 80 In the subsequent Pegylated Antibody 
Fragment Evaluation in Crohn’s Disease Safety and Efficacy 2 (PRECISE 2) trial, 54% of patients treated 
with certolizumab had fistula closure, vs 43% of the placebo group (p=0.064) at 26 weeks 81. Post-hoc 
analysis of the 58 patients with fistulating disease found a 100% fistula closure rate at 26 weeks in 4/30 
placebo treated patients and 10/28 treatment arm patients (p=0.038). The number of patients with 50% 
closure of fistulae was 7/30 and 11/28 respectively (p=0.125) 82. 
 
These studies suggest significant benefit from these drugs alone. On review of the baseline 
characteristics of participants there is evidence of combination of therapies including aminosalicylates, 
steroids and thiopurines. A summary of additional therapeutic agents received in monoclonal antibody 











Study ACCENT II CHARM CHOICE PRECISE I PRECISE II 
Monoclonal Antibody Infliximab Adalimumab Adalimumab Certolizumab Certolizumab 
Total N 282 854 673 659 425 
Additional therapies:      
5-aminosalicylates 132 334 239 - - 
Thiopurines 92 356 - - - 
Methotrextate 5 90 - - - 
Steroids 81 376 285 256 153 
Antibiotics 83 - - - - 
‘Immuno-suppressants’ - - 277 247 173 
Table 3 Summary of additional medical therapies in anti-TNF-α trials reporting fistula outcomes.  
Demonstrates polytherapy in up to 50% of patients. The CHOICE, PRECISE I & II trials did not 
report on specific immunosuppressants used. 
 
 
3.3.2 Local monoclonal antibody 
Infliximab has also had open-label trials assessing local injection of the drug into the fistulating area rather 
than traditional systemic administration. Allesandroni and colleagues 83 assessed the efficacy of local 
Adalimumab in a case series of twelve patients. Four were withdrawn from the trial due to the need for 
systemic therapy. Seven of the eight patients treated had fistula closure at twelve months 83. This assessed 
the outcome of 20mg local injections of infliximab into the fistulae of eleven patients. After a mean of 
10.5 months, 6 patients had complete response and four had remission of symptoms 84. Tonelli assessed 
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local injection of adalimumab into the fistula of twelve patients and demonstrated complete response in 
nine patients, with symptomatic response in the remaining three 85. These are small trials with only one-
year follow-up. This approach or other combined modalities such as anti-TNF impregnated collagen paste 
would be interesting ways to develop this. These studies did not assess local absorption or tissue 
concentrations. To understand mechanisms and dosing of therapy, this pharmacodynamic and 
pharmacokinetic data are required. 
 
3.3.3 Combination Therapy 
The monoclonal antibody class of drugs have been the focus of most clinical trials reporting fistulating 
Crohn’s disease in the last decade, although fistulating perianal disease was assessed as post-hoc 
subgroup analyses rather than as a primary focus of the study. As these have not achieved total resolution 
of fistulating Crohn’s, therapeutic studies have addressed ‘augmented’ therapy. Recent studies have 
assessed combinations of anti-TNF therapy with other classes of drug. Thiopurines (Azathioprine, 6-
Mercaptopurine) have been evaluated in a prospective cohort study. This non-randomised investigation 
followed a protocolised management plan, with changes in treatment where clinical remission was not 
achieved. In this study, thiopurines were combined with Infliximab (n=32) or Adalimumab (n=9) in the 
case of Infliximab non-response. This study reported a clinical response in 40% of patients for the first 18 
months of therapy, falling to 37% at 36 months 86. This study reported that at 36-months of follow-up, 
infliximab induced clinical remission and response rates of 33% and 33% respectively. The Adalimumab 
group had remission and response rates of 0% and 43% respectively. Whilst this study commenced with 





Further studies have compared the effect of combining multiple medical therapies. Dewint and 
colleagues87 undertook an RCT comparing adalimumab (anti-TNF-α) monotherapy vs adalimumab 
combined with ciprofloxacin (quinolone antibiotic) – (the adalimumab combined with ciprofloxacin was 
superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease (ADAFI) trial). The arm 
combining adalimumab and antibiotic therapy showed a trend towards increased rates of fistula closure 
after 12 weeks of therapy (65% vs 33%, p=0.09). The power calculation was based upon an open label 
study of 36 patients and the effect size estimate was optimistic at 20% absolute increase in patients 
reaching the primary outcome (closure of at least 50% of fistula). As well as being unable to detect the 
true effect size, it is likely that the study did not adjust for other variables associated with disease in the 
randomisation process such as fistula duration or anatomic complexity.  West and colleagues undertook 
randomised placebo controlled trial of Infliximab with ciprofloxacin vs infliximab with placebo. This 
included a total of 24 patients with 12 allocated to each arm. This found no statistically significant 
difference in rates of clinical response at week 18; 8 (73%) responded in the intervention group vs 5 (39%) 
in the control group, although numbers were small 88. The authors did not perform a power calculation or 
sample size estimate, and the study seems to have been conducted with convenience determining the 





































Thiopurine 41 - 42%** 
West 
2004 
RCT Infliximab Ciprofloxacin 24 62% 91%* 
Table 4 Studies assessing impact of augmented anti-TNF.  
*outcome at week 12. **outcome at 12 months. 
3.3.4 Stem cell therapy 
 
Stem cells have been used in trials of healing chronic wounds during recent years89. This has been 
extended to assessment of efficacy in Crohn’s anal fistula90, but the exact mechanism of healing in a fistula 
is not clear. Studies in analogous conditions such as chronic wounds suggest that stem cells in such an 
environment release signalling molecules including micro-RNA’s to promote fibroblast development and 
angiogenesis91. Adipose derived, autologous mesenchymal Stem cells are administered directly into the 
fistula during a surgical procedure, however they are considered here as a medical therapy due to their 
mechanism of action. One randomised trial has been completed in which 50% of patients receiving stem 
cells into their fistula achieved remission at 24 weeks vs 34% in the control arm (p=0.024)92. This response 
rate is notable as it is double that typically seen in placebo arms of trials in this condition44.  The control 
arm included extensive fistula track preparation and closure of the internal fistula opening, suggesting 
that the stem cells were not the only aspect of the intervention which supported healing. 
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3.4 Surgical management 
 
Whilst there are trials reporting the outcomes of medical therapy for this condition, albeit post-hoc 
analysis of subgroups, there have been no large randomised controlled trials of surgical therapies. This 
may be due to the high degree of heterogeneity inherent in the disease. This includes factors relating to 
disease course (phenotype of Crohn’s disease, mild or fulminant disease, duration of disease), prior 
treatment (anti-TNF antibodies, loss of response to treatment), and fistula anatomy (simple vs complex, 
number of fistula tracks, primary and secondary track behaviour). As all these factors could impact on 
clinical decision making and therefore a well-designed surgical trial would either need to stratify 
recruitment for these variables or limit recruitment to very specific characteristics which would make 
recruitment of adequate numbers challenging. Senejoux and colleagues recruited a small number of 
patients with tightly controlled characteristics to a trial evaluating a fistula plug and obtained a negative 
result93. This study is discussed below. There is currently a trial running with very rigorous entry criteria 
which may limit its’ ability to recruit to time and target94. 
 
Several small studies have assessed results from a range of surgical therapies including; 
I. Seton drainage alone 
II. Fistula plug  
III. Mucosal advancement flap 
IV. Intersphincteric ligation of fistula tract (LIFT) procedure 
V. Over the scope clip (OTSC). 
VI. Fibrin glue 
VII. Faecal diversion procedures 
 
These are summarised in table 5 and discussed in more detail below. 
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3.4.1 Seton drainage 
A seton is a length of thread or a rubber sling which is inserted into the fistula track and secured to itself, 
allowing continued drainage. Where the surgical procedure is seton drainage alone, it is usually combined 
with adjunctive medical therapy. Two recent observational studies have assessed seton drainage 
combined with anti-TNF therapy, followed by removal of the seton. These reported fistula closure rates 
of 50-75%, with low levels of long-term recurrence, offering improvement above anti-TNF therapy alone 
95 96. A similar study in adolescents showed response to treatment (partial or complete remission) in 85% 
of patients 97. This result is particularly impressive given that it was limited to patients with complex 
perianal fistulae. 
 
3.4.2 Fistula plug 
A fistula plug is an option for closure of the track. This is typically a cone of collagen that is inserted into 
the fistula from inside the anal canal, effectively blocking it. Where this is done, a flap of mucosa may be 
advanced to cover the plug, sealing off the track. A systematic review of use of a plug for anal fistula 
included 42 Crohn’s patients. Use of this treatment lead to closure of the tract in 55% 98. A subsequent 
trial randomised 106 patients with Crohn’s fistulae to sepsis drainage followed by fistula plug alone vs 
sepsis drainage with seton alone. This demonstrated no significant benefit from the use of an anal fistula 
plug. Remission rate at 12 weeks was 34% (95% CI 19.5%-45.5%) vs 23.1% (95% CI: 12.5–36.8%) in the 
control arm93. This study required patients to be receiving a stable dose of medication for the previous 3 
months and did not mandate the use of biologic-class agents. There was no difference in remission, 
response, disease specific quality of life, disease activity or MRI scores at 12 weeks or 12 months. The 
analysis of this study is compromised as 12 patients (22.2%) in the intervention arm were lost to follow-
up before week 12, compared to 1 in the control arm. As a result, the study does not meet the minimum 
of 52 patients in each arm to detect a 30% difference.   Subsequently, these results do not compare 
favourably with seton drainage and/or anti-TNF therapies, although no direct comparison has been made. 
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This comparison is further complicated as there is no consensus or standardisation on the timing of seton 
removal. 
3.4.3 Advancement flap 
An advancement flap is a sphincter-sparing approach for a transphincteric fistula. In this treatment, a full 
or partial thickness ‘U’ shaped flap of rectum is raised adjacent to the internal defect, and advanced to 
cover the defect. A review by Soltani and Kaiser found 35 studies reporting outcomes following 
advancement flaps; these were predominantly retrospective cohorts. Of these, six reported the outcomes 
for patients with Crohn’s fistula, and estimated a success rate of 64% in Crohn’s disease, and an associated 
incontinence rate of 9.4%99. Concomitant medical therapy and disease activity were not reported. 
3.4.4 Ligation of intersphincteric fistula tract (LIFT) 
The LIFT procedure was first described in 2007 then modified in 2009 100 101. This technique preserves the 
anal sphincters by approaching the fistula track through the intersphincteric plane and ligating it, then 
closing the internal portion and excising the external portion of the fistula. There is little data specifically 
on use of LIFT in Crohn’s disease. A prospective study published in 2014 reported outcomes of fifteen LIFT 
procedures for Crohn’s fistulae 102. The procedure was successful in nine cases at two-month follow-up. 
At twelve-month follow-up, one repair had failed and three patients had developed a new fistula. In 
clinical practice, a definitive procedure such as LIFT would often be preceded by placement of a drainage 
seton. A subgroup meta-analysis of 228 patients compared the effect of pre-operative seton placement 
or no seton in patients undergoing LIFT and showed no difference in success rates 103. Reporting of Crohn’s 
disease in the included studies was incomplete so this may not be generalisable to the Crohn’s population.  
3.4.5 Over the scope clip (OTSC) 
Over the scope clip (OTSC) is a relatively novel technique. The external portion of the track is cored out. 
The internal opening of the fistula is identified, and the fistula track cleared of debris using a narrow brush. 
A small circle of mucosa 8-10mm in diameter is excised around the internal opening to expose the 
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underlying muscle. Interrupted sutures are placed to close the defect in the muscle. The suture ends are 
left long and passed through the clip applicator. After 2-3 sutures have been placed, the clip applicator is 
guided down the suture to the site for clip application. The applicator deploys an oval ‘bear claw’ metal 
clip. The grips on the edge of the clip hold the muscle edges together, facilitating fistula healing. This has 
been used successfully in upper gastrointestinal fistulae. There is a single paper reporting on the use of 
this technique in ten anal fistula patients, of whom six had Crohn’s disease.  Treatment was successful in 
five of these patients with a follow-up period ranging from 157 to 523 days 104. 
3.4.6 Fibrin glue 
Fibrin glue is applied into the fistula tract as a paste and activates the thrombin system, causing 
mechanical obstruction of the fistula tract. Grimaud and colleagues undertook a trial with patients 
randomised to fibrin glue or observation. At eight weeks, the primary end-point of fistula closure was seen 
in 38% of the fibrin group compared to 16% of the observation group (OR 3.2 (95% C.I. 1.1-98) p=0.04) 105. 
The same group reported that 14 patients with refractory fistulating Crohn’s disease underwent fibrin 
glue treatment. This study found clinical improvement in 75% of patients at three months follow-up and 
complete healing at two-years in 57% of patients 106. Despite this, fibrin glue has fallen out of favour with 








Author & Year Design of 
reporting study 
Number of Crohn’s 
patients treated 
Success rate in 
Crohn’s patients 
Seton only Haennig 2014 Retrospective 
Observational 
81 75% 
 Hukkinen 2014 Retrospective 
Observational 
13 77% 
 Kotze 2015 Retrospective 
Observational 
78 52% 
 Senejoux 2015 Randomised 
Controlled Trial 
52 23%* 
Fistula plug O’Riordan 2012 Systematic 
Review 
42 55% 
 Senejoux 2015 Randomised 
Controlled Trial 
54 31% 
LIFT Gingold 2014 Case series 15 60% 
Fibrin Glue Vitton 2005 Case series 14 57% 
 Grimaud 2010 Randomised 
Controlled Trial 
34 38% 
OTSC Menningen 2015 Case series 6 83% 
Table 5 Surgical procedures for Crohn’s disease and their outcomes.  
Observational studies of seton-only with anti-TNF therapy show excellent results, but when compared 




3.4.7 Faecal diversion procedures 
This group of procedures includes two main interventions; stoma formation and proctectomy. In current 
practice, these are typically reserved for recurrent complex perianal sepsis, or patients with poor 
continence and anorectal/pelvic muscle function. 
Stoma 
A stoma is described based upon the part of the intestine from which it is formed i.e. if it is formed from 
the ileum, it is an ileostomy, from the colon, a colostomy. In a patient with extensive colonic disease, it 
may be preferable to form a proximal stoma using the ileum. This diverts faeces from the perineum and 
tends to improve colonic disease. In the presence of extensive small bowel disease, but no colonic disease, 
it may be preferable to form a colostomy. In many cases, these will be loop stomas. This allows easier 
reversal in the future, although in reality as few as 22% patients have their stoma reversed107. A definitive 
end stoma will be formed where there is a clear intention to excise the distal diseased segment. 
 
The procedure to form a stoma is relatively simple, and can be achieved using conventional open surgery, 
or using a laparoscopic approach. Using either approach, an appropriate segment of bowel is identified. 
This is mobilised and brought to the abdominal wall in a tension free manner. Parastomal hernia is a 
relatively common long-term complication, occurring in 30-50% of patients108. Other complications 
include stenosis and retraction of a stoma. In Crohn’s disease, there is also the risk of fistulation from the 
stoma to the surrounding skin. Stoma is one of the few surgical interventions where a clear benefit in 
quality of life has been demonstrated50. 
 
Proctectomy and end colostomy 
Proctectomy is typically performed after stoma formation to improve the surgical field and allow the 
clearance of residual sepsis, although there is still a risk of pelvic abscess formation109. The employment 
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of strategies to reduce perineal dead space and control sepsis pre-operatively may reduce the risk of 
perineal wound complications110. 
 
3.4.7 Selection of surgical procedure 
Considerations around disease behaviour, fistula anatomy, and treatment goals all factor into the 
selection of a procedure. Procedures may also be placed into three main groups according to treatment 
aim: ‘drainage’, ‘fistula closure’, and ‘faecal diversion’.  Procedures and indications in this framework are 
presented in Figure 3. 
 
Figure 3 Surgical procedures for Crohn’s anal fistula and their indications 
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As can be seen from the overview above, treatment strategies are highly variable and only some of the 
treatments have been evaluated with comparative randomized trials, some of which have been flawed or 
underpowered, and many of the local therapies only evaluated with case series at the present time.   A 
further significant hindrance to establishing an optimized treatment pathway is the lack of standardisation 
of reported outcomes and the co reporting of Crohn’s and non-Crohn’s fistulae in aggregate.    
 
3.5 Current guidance 
The European Crohn’s and Colitis Organisation (ECCO) offers the following advice on surgical management 
in their 2016 guidelines111: 
• Sepsis control with a draining seton is the first step in management. This should be supported 
with anti-TNF-α therapy. 
• A ‘low’ fistula might be considered for fistulotomy. 
• Fistula plug and advancement flap might be considered as reparative procedures that can aid 
healing. 
• Faecal diversion or proctectomy may be required in patients who do not respond to medical 
therapy. 
 
There is no clear guidance on the subsequent management, including escalation and de-escalation of 
medical therapy.  
 
3.6 Summary 
The above studies describe the value of combining medical therapy with surgical therapy to obtain the 
optimal outcome, whether it is minimalist surgery such as a seton, or other procedures such as a fistula 
plug. A recent systematic review assessed outcomes of studies comparing surgical monotherapy vs 
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combined surgical and medical therapy. This descriptive analysis found that healing rates were 
approximately double in the multimodal group (55% vs 25%) 112. The authors noted that heterogeneity of 
data and variable outcome measures precluded meta-analysis112. 
 
The literature shows consensus on early sepsis control, with abscess drainage and seton placement. The 
optimum choice and combination of subsequent therapies is not clear. Because of challenges in 
controlling factors related to disease severity and additional medications, it may not be feasible to 
undertake a high quality randomised trial to answer questions around optimum drug combination and 
timing whist controlling for these other variables. Given the incidence of Crohn’s anal fistula, such a trial 
would take a long time to complete. If this is the case, careful  consideration should be given to how  






4 Making decisions about treatment 
Where there is no clear answer on which treatment offers the most likelihood of a cure, then the factors 
informing the decision may change. The treatment selected may be offered as one likely to reach a 
patient’s treatment goals e.g. reduce drainage from a fistula, or as one to minimise harm e.g. prevent 
future abscess formation. The priority and values attached to these goals may vary, depending upon who 
is making the decision, making this a ‘preference sensitive’ decision. 
 
Decision making in medicine can be broadly divided into three categories: paternalistic, consumer-driven, 
and shared. The paternalistic approach was historically prevalent113. In this model, the physician shares 
only the information needed to obtain consent and makes all decisions themselves. This places the locus 
of control firmly with the clinician.  In the consumerist approach, all information necessary to decision 
making is given to the patient by the physician, and all decisions are made by the patient, placing the locus 
of control with the patient. Shared decision making is a model with two way communication between the 
patient and physician, and both parties contribute to treatment decisions, sharing the locus of control 
between the two parties114. The above descriptors cover three common models of decision making, 
although it is also important to consider aspects of agency in decision making. Agency refers to the state 
where the patient has delegated to the physician some, or all, of their authority to make decisions. For 
the clinician to make the ‘best’ decision for the patient, one which takes into account their preferences 
and perceived utility of outcomes, they must be a ‘perfect’ agent. This implies extensive knowledge of 
treatments, and a holistic understanding of the patient to make a decision that is concordant with the 
preferences and needs of the patient115. The concept of perfect agency appears favourable, although in 
real-life it is likely to be challenging and time consuming. Given this, two-way communication and 




The concept of shared decision has been supported by the National Institute for Health Care Excellence 
(NICE) since at least 2012116. This model has been brought into the spotlight by the recent Montgomery 
vs Lanarkshire Health ruling117, and subsequent guidance from the Royal College of Surgeons of England118.  
 
4.1 Benefits of shared decision making 
The perceived benefit of a shared decision making approach is that engagement of both parties in the 
decision making, allows the ‘best’ decision to be made, supports patient autonomy, and improves patient 
satisfaction with decisions119. The use of a decision aid as part of shared decision making has been shown 
to reduce the rate of additional investigations, or select less invasive diagnostic tests120. 
 
The nomenclature used in these schema focuses on decision making, and specifically, where the locus of 
control lies. This may be misleading to an extent. Qualitative work exploring shared decision making across 
a range of conditions in general practice found that patients who experienced a high degree of 
information sharing reported a high level of satisfaction, regardless of where they felt the locus of control 
was, and who made the decision about treatment121. 
 
4.2 Shared decision making in inflammatory bowel disease 
Given the chronic nature of inflammatory bowel disease, and the nature of decisions made, it is a 
condition where shared decision-making might be of use. Surveys of US gastroenterologists suggest that 
they are willing to employ this model of decision making, and many already incorporate elements of it in 
their practice122. The same study identified a number of barriers to this, including the time required, the 
need for supporting materials, and appropriate reimbursement. Similar survey work has demonstrated 
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that patients drawn from the general IBD population would also like to participate in shared decision 
making about their care123. 
4.3 The process of shared decision making 
The process for conducting a consultation using a shared decision making approach has been described 
by Elwyn in the ‘three talk’ model124 (Figure 4). It is conceivable that this process could be completed in 
one single clinic visit, however it is likely to require two or more visits. The first talk highlights that a 
decision must be made, and typically assesses whether the patient wishes to participate in that decision. 
The second talk involves the presentation of options including the trade off between risk and benefits, 
exploration of patient preferences, sharing of physician ideas and supported deliberation, which may use 
a decision aid. In the third talk, the decision for treatment and the underlying reasons are confirmed. 
 
The literature has identified a number of barriers to the embedding of shared decision making in clinical 
practice. The most common barrier relates to the extra time required to do this well. The Shared Decision 
Model is typically supported by a well-designed decision aid specific to the condition. There is no such 




Figure 4 The three talk model for shared decision making 
 
 
4.4 What makes a decision aid? 
A decision aid is used to support deliberation of treatment options by providing patients with 
information in an accessible manner. The key components of a decision aid have been defined by the 
Cochrane Collaboration120 and are summarised in Table 6. It is important to recognise that a decision aid 
is designed to support shared decision making126. Use of a decision aid in lieu of supported deliberation 








Information tailored to patient’s health status Information should be related to the disease 
which has triggered the decision. It should list 
potential treatment options, and the risks and 
benefits of each of these. 
Values Clarification This involves the exploration of risks and benefits 
of choosing each treatment option, and the value 
placed upon each of these by patients. 
Examples of other patients The risks and benefits of each treatment can be 
illustrated with examples of what other patients 
chose and why. 
Guidance in shared decision making Decision aids support patients with the 
identification of their values in treatment, and the 
discussion of how this affects their treatment 
choice. This facilitates shared decision making.  
Delivery format Decision aids can be delivered in a number of 
ways. These can include decision boards, option 
grids, interactive webpages, and leaflets. 

















4.4.1 When is it appropriate to use a decision aid? 
Four scenarios have been proposed where a decision aid, and by extension shared decision making 
principles, may be of benefit127. These are: 
• When the potential treatment options have major differences in outcomes or potential 
complications; 
• Decisions where a trade-off must be made between short term and long term outcomes; 
• One or more treatment options carry a small chance of a serious complication; 
• Where there are marginal differences in outcomes between options. 
• Where there is no single best option but a range of options that may provide similar outcomes, 
(or a lack of evidence proving superiority of any option) as is the case in Crohn’s 
 
These are quite broad terms of reference, and may be interpreted to encompass all of medicine. The 
exclusion is most likely in acute settings where time constraints prevents full exploration of treatment 
options, or where there is one proven treatment e.g. antibiotics in meningitis. 
 
4.5 Developing a decision aid 
Development of a decision aid is more complex than simply writing a leaflet. The International Patient 
Decision Aid Society (IPDAS) have provided a frame work to ensure that newly developed aids meet 
specific standards in development of the aid128. This includes: 
• Systematic review, appraisal and synthesis of the evidence base. This can include highlighting the 
lack of evidence as communication of uncertainty is important. 
• Establishing what treatment options are available 
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• Establishing what potential users of the tool want to know. This can be achieved using a range of 
research methodologies, including interviews, focus groups, and surveys. 
 









5 Aims and significance 
 
5.1 Aim 
The aim of this thesis is to define current practice and evidence for the management of Crohn’s anal 
fistula, and to explore patient preferences and informational needs around the surgical management of 
this condition. This will provide the basis for development of a future decision aid. 
5.2 Significance 
Anal fistula affects a significant proportion of patients with Crohn’s disease. This is a condition which 
typically requires multiple treatments and has a significant negative impact on the lives of those affected. 
This work provides a reflection of current practice, a synthesis of current best evidence, and an exploration 
of patient informational needs and preferences when considering surgery. This provides the basis to 








































































Systematic review is a widely practiced method of secondary research. This allows collation of findings of 
prior studies to identify where there is certainty, or to identify gaps in the literature.  
6.1 Methodology of systematic review 
Systematic reviews follow a common methodology, the practice of which  is largely guided by the 
Cochrane collaboration, who have developed a methodological handbook to guide the conduct of 
systematic reviews129 
6.1.1 Formulation of research question 
Formation of an appropriate question within the PICO framework (population, intervention, comparator 
and outcome). This can be adapted depending on the nature of systematic review being undertaken e.g. 
intervention can be substituted for performance of a diagnostic test. 
6.1.2 Defining inclusion criteria 
Selection of inclusion and exclusion criteria. With the question set, inclusion and exclusion criteria must 
be set. The team conducting the systematic review need to carefully consider the studies of interest. They 
may wish to restrict by study design (e.g. randomised trial, cohort study), they may wish to limit by date 
of publication, by disease state or by language of publication. Each of these factors may introduce their 
own elements of bias, so should be considered carefully with the authors able to provide justification for 
each of these.  
6.1.3 Development of search strategy 
Development of search strategy. There are a number of electronic databases through which articles can 
be identified i.e. PUBMed, EMBASE, CINAHL, Cochrane Central. Each of these has different search engines 
and search terms. The correct Medical Subject Heading (MeSH) terms and operators must be used. The 
appropriate combination can be developed through identification of manuscripts of interest and ‘mining’ 
67 
 
the MeSH terms and combinations that have been applied to them. This allows the development of a 
comprehensive list of terms, allowing searches to encompass all potential candidate papers.  
6.1.4 Registration of protocol 
Registration of a protocol is not a strict requirement for publication. Development and registration of a 
protocol for the conduct of a systematic review may encourage the researcher to consider aspects of the 
planned research which require clarity, and to define meta-analyses in advance. Evidence suggests that 
registration is associated with better reporting of domains identified in reporting guidelines, indirectly 
improving reporting of such studies130. 
 
6.1.5 Study selection  
In this phase, a minimum of two reviewers independently screen abstracts against the review eligibility 
criteria. Results are cross checked and conflicts resolved by a third reviewer. This exercise is then repeated 
with the full texts of manuscripts. If the study is excluded at this stage, the reason for exclusion is recorded. 
Results are again cross checked and conflict resolved by a third reviewer129. 
 
6.1.6 Data extraction 
Key information on study reference, design, participants, interventions and other factors of interest are 
recorded into a pre-designed study proforma by two independent reviewers. Results are cross checked 
and conflicts resolved by a third reviewer129. 
 
6.1.7 Bias and quality assessment 
As well as extraction of data, the reviewers assess the paper for bias. This is done systematically using a 
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recognised tool such as the Cochrane risk of bias tool131, the risk of bias in non-randomised studies tool 
(ROBINS-2)132, or other tools relevant to the review question.   
6.1.8 Qualitative synthesis of data 
In this stage, data is presented with outcomes or study types grouped. For example reporting the benefits 
of treatment in studies in one section, and reported harms or complications from treatment in another. 
This is purely narrative and does not include narrative synthesis.   
6.2 Meta-analysis 
Meta-analysis allows the combination of data across studies to estimate event rates, with adjustment for 
the contribution of each dataset based upon sample size. Pooling of data improves the precision and 
accuracy of estimates of effect sizes, and allows generalisation to the wider population. 
 
The pooled data may be presented in a number of ways, including odds ratio or relative risk, along with a 
95% confidence interval for the effect. These can be presented graphically as Forrest plots, with a 
summary estimate accounting for effect and study size. Pooling of data is typically undertaken using one 
of two analysis models; fixed effects or random effects. 
 
A fixed effects model assumes that the effect size of an intervention is the same in all populations, and 
independent of the study size. This leads to the assumption that any variation in effect size comes from 
errors in the measurement of effect within the study. A random effects model assumes there to be a 
distribution of effect sizes across studies, and attempts to estimate the general trend of the effect. This 
assumes that there are different effects in different populations and allows for variation within the 




Meta-analysis is not always possible due to a small number of studies, or limitations in reporting e.g. 
inconsistent use of outcomes. Even where meta-analysis is possible, the quality or reliability of findings 
are only as good as the studies upon which they are based134. 
 
In addition to pooled effect sizes, it is possible to assess for heterogeneity within the reported effects – 
i.e. do all studies point the effect in the same direction and have overlapping effect sizes. This 
heterogeneity is reported using the I2 statistic, where 0% suggests no heterogeneity and 100% suggests a 
high degree of heterogeneity of results129.  
 
6.3 Publication bias 
Where five or more studies report the same outcome, it is possible to assess for publication bias through 
the use of a funnel plot. This assesses the effect size and sample size against the pooled effect and its 
confidence interval. If a study falls outside this window, it is possible that it is subject to publication bias129. 
6.4 Clarity of reporting 
In order to ensure that a study has been conducted in a methodologically robust manner, it should be 
reported according to accepted standards. For systematic review and meta-analysis, the above points are 
addressed in preferred reporting items in systematic review and meta-analysis (PRISMA) guidelines135. 
6.5 Selection of methodology 
As outlined in Chapter 3, it is important to collate data from the literature in order to describe the 
outcomes from treatment. It also allows us to judge the quality of the literature, and understand potential 
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As described in chapter 2, Crohn’s disease can be associated with a penetrating phenotype, i.e. one 
associated with fistula formation. Classification of fistula is based upon location and connection to 
contiguous organs or anatomic structures. External fistula, including perianal and abdominal forms, are 
most common, respectively representing 55% and 6% of all cases.136 Approximately one-third of fistula 
are internal, including enteroenteric, enterovesical, enterouterine or enterovaginal types. There is likely 
a common pathological pathway underlying fistulation regardless of origin, so it is reasonable to consider 
the medical management as one process regardless of location. 
 
As outlined in chapter 2, current evidence supports the role of uncontrolled inflammatory response in the 
propagation of fistulating disease, including TNF-α and downstream cytokines. The role of anti-TNF-α 
antagonists in the treatment of fistulating CD was established almost 15 years ago137. More recently, novel 
therapies and biologics with alternative mechanisms of action such as anti-integrins and inhibitors of the 
interleukin (IL) 12/23 pathway have emerged, although their efficacy in the management of fistulating 
disease is uncertain. In the treatment of inflammatory bowel disease, the use of drugs falls into two broad 
categories: induction and maintenance. The use of a drug as an induction agent means that it is used to 
change the disease state from active to controlled, responding, or in remission, depending on the study 
design and terminology. This may be measured based upon anatomical manifestations of disease (fistula) 
or upon disease activity. Maintenance refers to the use of a drug in a patient where disease is controlled, 
and the ability of the drug to keep the patient in that state. It is important to understand the role of 





The aim of this study was to perform a systematic review and meta-analysis of all published randomized 




7.3.1 Protocol and registration 
This systematic review and meta-analysis was conducted using the methods described in the Cochrane 
Handbook of Systematic Reviews129, and reported  according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement.139 
 
7.3.2 Eligibility criteria 
Eligible studies were randomized, placebo- or active comparator-controlled trials that enrolled adult CD 
patients (16 years or older) with any form of fistulating disease (i.e. perianal, enterocutaneous, 
enteroenteric, enterovesical, enterovaginal or enterouterine fistula). The decision to include all forms of 
fistula was made for two reasons. As outlined in the earlier chapter  
 
Interventions of interest included any pharmacological treatment administered alone or in combination. 
In the case of crossover trials, only first-stage data were collected. Evaluation of surgical therapies, or their 
combination with medical therapies, were not evaluated as they have been previously described112 140. 
Surgical conditioning of tracks with seton or other treatments was permitted.  
 
7.3.3 Outcomes 
The primary outcome was the proportion of patients with fistula response (closure of >50% external 
openings and absence of discharge on compression74). Secondary outcomes included the proportion of 
patients who achieved fistula remission; fistula resolution by diagnostic imaging (i.e. magnetic resonance 
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imaging or computed tomography); and maintenance of fistula closure. Data on health-related quality of 
life, incontinence or similar functional outcomes were also extracted when available.  
 
7.3.4 Search strategy 
The MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) databases were 
searched from inception to December 13, 2016 using pre-defined strategies (Appendix A). Language and 
date restrictions were not applied. The bibliographies of relevant articles retrieved from the electronic 
databases and conference proceedings from Digestive Disease Week and United European 
Gastroenterology Week (2012 to 2016) were hand searched to ensure that all eligible studies were 
identified. Fully published papers as well as abstracts and conference proceedings were included. 
7.3.5 Screening and data extraction 
Two authors (MJL and ST) screened the search results in parallel using the Covidence web tool.141 The 
same two authors independently extracted information on the design, intervention, comparison, baseline 
characteristics, outcomes and risk of bias of the included studies using a standardized spreadsheet (Excel, 
Microsoft Corp., Redmond, WA, USA). Discrepancies encountered during screening or data extraction 
were resolved by discussion or recourse to a third author (CEP). In the case of unclear or missing data, 
attempts were made to contact the original study authors for clarification. 
7.3.6 Risk of bias assessment 
The Cochrane risk of bias tool was used to assess the methodological quality of the included studies.142 
Seven domains (i.e. random sequence generation, allocation concealment, blinding of participants and 
personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and 




7.3.7 Data synthesis and analysis 
In studies with multiple dose arms, outcome data from the intervention groups were combined. If 
outcome data were reported at multiple timepoints, the pre-defined primary timepoint was used. 
Response and remission data were respectively combined regardless of whether the outcome definitions 
varied. All outcomes of interest were expressed dichotomously, with intervention effects reported as 
pooled risk ratios (RRs) and corresponding 95% confidence intervals (CIs).  A fixed-effect model was used 
to pool data, however, we planned to use a random-effects model in the case of significant, unexplained 
heterogeneity. Data were analysed according to the intention-to-treat principle, and statistical analyses 
were performed using RevMan 5.3 (The Nordic Cochrane Centre for The Cochrane Collaboration, 
Copenhagen, Denmark).  
 
A sensitivity analysis was conducted to determine whether excluding studies evaluating fistula disease 
activity as a secondary endpoint impacted on the strength of the results. Subgroup analysis according to 
fistula type (i.e. perianal versus other) was not pre-specified, since we anticipated that most studies would 




The relative amount of observed heterogeneity was quantified using the I2 statistic, which ranges from 
0%-100%.143 A value of 0% indicates no observed heterogeneity, and substantial heterogeneity was 




7.3.9 Quality of the evidence  
The GRADE approach was used to assess the quality of evidence for the primary and secondary outcomes. 
Results from RCTs were initially considered high-quality, but potentially downgraded due to risk of bias; 
indirectness of evidence; unexplained heterogeneity; publication bias or sparse data.144 Outcomes with 
less than 35 events were reduced by two GRADE levels; outcomes with less than 300 events were reduced 





7.4.1 Search results 
Electronic database and hand searching identified a total of 802 records, from which 164 duplicates were 
removed. Of the remaining 638 records, 604 were deemed ineligible based on the information provided 
in the title and abstract.  Full-text review was required for 34 records. Seven of the 34 records were 
excluded:2 had no control or comparator arm, 2 had a mixed patient population, one was not available in 
English, and one was a post-hoc analysis of trial data. This left 27 studies enrolling a total of 2106 fistula 
patients met the eligibility criteria. The flowchart for studies through the review is shown in figure 7. 
 




7.4.2 Description of included studies 
A description of the included studies and definitions are provided in Table 7. Twenty-four RCTs compared 
a drug intervention to placebo.92 137 145-164 Two antibiotics (ciprofloxacin and metronidazole) were 
evaluated in one study (n = 25).163 Thiopurines, including azathioprine and 6-mercaptopurine (6-MP), were 
studied in five RCTs enrolling a total of 69 patients.150 152 154 155 164 Tacrolimus was evaluated in one primary 
study of CD fistula, and one subgroup analysis (n = 58).149 158 Four TNF-α antagonists (adalimumab, 
CDP571, certolizumab pegol and infliximab) were evaluated in eight RCTs (n = 821).137 145 148 156 157 159 160 162 
One post-hoc analysis of the GEMINI 2 RCT reported on the anti-alpha4beta7 (α4β7) antibody 
vedolizumab (n = 165).146 Fistula results from five trials of ustekinumab, an anti-IL-12/23 antibody, were 
presented in one conference report (n = 318)161 Two RCTs assigned patients to mesenchymal stem cell 
therapy (n = 233).92 151 AST-120, an oral intestinal spherical carbon adsorbent, was evaluated in two studies 
enrolling a total of 311 patients.147 153 Combination therapy with a TNF-α antagonist and an antibiotic 
versus treatment with a TNF-α antagonist and placebo was studied in two RCTs (n = 96).87 165 Data from a 
single study comparing azathioprine to methotrexate (n = 10)166 could not be meta-analysed.  
 
The vast majority of included studies focused on patients with perianal fistulating disease. Eleven RCTs 
solely enrolled patients with perianal fistula,87 92 147 149 151 153 161 163 165 eight trials included patients with both 
perianal and abdominal fistula,137 145 148 155 158-160 166 and in three studies including various fistula types, the 
majority of patients were indicated to have perianal fistula.150 152 162 Four additional studies included 
various fistula types, but did not specify whether the majority were perianal fistula,146 156 157 164 and in one 




7.4.3 Risk of bias assessment 
The results of the risk of bias assessment are presented in Appendix B. All included studies received low 
or unclear risk of bias appraisals except for Ardizzone 2003, an investigator-blind trial that was rated as 
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TOTAL     5,980  2,099   
Table 7 Characteristics of included studies 
1Timepoint of outcome assessment in weeks 
2Concomitant medications for entire study population (not the fistula subgroup) 
3Interpreted as partial (≥50%) or complete (100%) closure 
4The most common types in descending order were perianal, abdominal-wall, enteroenteric, rectovaginal, and vulva 
5Response and remission criteria had to be met at >2 consecutive study visits 
6Enterocentric and rectovaginal data not reported; enterocutaneous data not meta-analyzed since both patients received AZA 
7Women with rectovaginal fistulae were included if >1 abdominal draining fistula was present 
8Treat-right-through design; non-responders at week 14 randomized to IFX or placebo 
9Includes seton placement, fistula incision or fistula drainage 
10Ciprofloxacin 
11Ciprofloxacin or metronidazole 
 
Abbreviations:  
5-ASA, 5-aminosalicylates; 6-MP, 6-mercaptopurine; ABX, Antibiotic; ADA, Adalimumab; AZA, Azathioprine; CS, Corticosteroid; CZP, Certolizumab Pegol; IFX, 
Infliximab; IM, Immunosuppressive; MSC, Mesenchymal stem cells MTX, Methotrexate; NS, Not stated; PCDAI, Perianal Crohn’s Disease Activity Index; SD, 





7.4.4 Drug therapy versus placebo  
Antibiotics.  Thia and colleagues (2009) provided data on induction of fistula response and 
remission rates among patients assigned to ciprofloxacin, metronidazole or placebo.163 A total 
of 29% (5/17) of patients receiving antibiotics achieved fistula response compared to 12.5% 
(1/8) of placebo patients. However this effect was not statistically significant (RR 1.68, 95% CI 
0.34-8.22, p = 0.52; Figure 8, 1.1.1). There was no observed heterogeneity (I2 = 0%) and the 










Figure 9 Forest plots of drug therapy versus placebo for induction of fistula remission 
A total of 18% (3/17) of patients receiving antibiotics achieved fistula remission compared to 
12.5% (1/8) of placebo patients. Again, the pooled RR indicated that this effect was not 
89 
 
statistically significant (RR 1.20, 95% CI 0.17-8.38, p = 0.85; figure 9). The overall quality of 
evidence for this outcome was considered low due to very sparse data (Appendix C).  
 
Thiopurines. Four studies assessing azathioprine or 6-mercaptopurine versus placebo 
reported on induction of fistula response150 152 154 164. Thirty percent (12/40) of patients 
assigned to active treatment achieved fistula response compared to 16% (4/25) of placebo 
patients. The pooled RR failed to show a statistically significant effect between groups (RR 
1.86, 95% CI 0.73-4.75, p = 0.20; Fig 8 1.1.3). There was no observed heterogeneity, and the 
quality of evidence was considered low due to very sparse data (Appendix C).  
 
With respect to induction of fistula remission, 29% (10/34) of patients receiving a thiopurine 
achieved remission compared to 9% (2/22) of patients receiving placebo. The pooled RR was 
3.38 (95% CI 0.76-15.71, p = 0.11; Figure 9 1.2.2), indicating no statistically significant 
difference in effect between treatment groups. The observed heterogeneity was not 
substantial, and the overall quality of evidence was considered low due to very sparse data 
(Appendix C).  
 
Rosenberg 1975 was the only included study to report on maintenance of fistula response155. 
In this small study, the one fistula patient who responded to active therapy failed to maintain 
response, while the one fistula patient who responded to placebo successfully maintained 
response (Figure 10, 1.3.1). A reliable estimate of the RR for this study could not be estimated, 





Figure 10 Drug therapy versus placebo for maintenance of fistula response 
 
One head-to-head trial of immunosuppressives was identified.166 In Ardizzone 2003, 67% (4/6) 
of patients receiving methotrexate achieved fistula remission compared to 30% (2/6) of 
patients receiving azathioprine (RR 2.0, 95% CI 0.56-7.09; p = 0.28; Figure 11). This effect was 
not statistically significant, and the quality of evidence was considered very low due to very 




Figure 11 Methotrexate versus azathioprine for induction of remission 
 
 
Tacrolimus. Two trials reported on induction of fistula response, and fistula remission.149 158 
Thirty-seven percent (10/27) and 10% (3/31) of tacrolimus and placebo patients achieved 
response, respectively (RR 3.82, 95% CI 1.17-12.40, p = 0.03). The between-group difference 
in effect was statistically significant. Heterogeneity was low (I2 = 23%), and the quality of 
evidence was considered low due to very sparse data. With respect to fistula remission, 11% 
(3/27) of patients randomized to tacrolimus achieved remission compared to 6% (2/31) of 
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placebo patients. The pooled estimate failed to demonstrate a statistically significant 
between-group difference (RR 1.58, 95% CI 0.33-7.51, p = 0.57). No heterogeneity was 
observed, and the quality of evidence was considered low due to very sparse data.  
 
TNF-α antagonists. Fistula response was reported in seven trials of TNF-α antagonists.137 148 156 
157 159 160 162 Forty percent (115/286) of patients receiving a TNF-α antagonist achieved fistula 
response compared to 26% (57/223) of placebo patients. The pooled RR was 1.44 (95% CI 
1.09-1.90, p = 0.01), demonstrating a statistically significant effect in favour of TNF-α 
antagonist therapy. A low degree of heterogeneity was observed (I2 = 11%), and the quality of 
evidence was considered moderate due to sparse data.  
 
Six RCTs evaluating TNF-α antagonists reported on the proportion of patients who achieved 
fistula remission.137 148 156 159 160 162 Thirty-four percent (90/267) of patients in the TNF-α 
antagonist therapy group achieved fistula remission compared to 16% (26/165) of patients in 
the placebo group. The pooled RR was 2.01 (95% CI 1.36-2.97, p < 0.001; Figure 9, 1.2.), 
demonstrating a statistically significant effect in favour of TNF-α antagonist therapy in 
comparison to placebo. There was no observed heterogeneity, and the quality of evidence 
was considered moderate due to sparse data (Appendix B).  
 
Maintenance of fistula response was evaluated in two studies160 162. A total of 43% (53/124) 
of patients receiving a TNF-α antagonist maintained response compared to 22% (28/129) of 
placebo patients. The between-group difference in effect was statistically significant (RR 1.97, 
95% CI 1.34-2.89, p < 0.001; Figure 14). No heterogeneity was observed, and the quality of 
evidence was rated as moderate due to sparse data (Appendix B). The same two studies 
reported on maintenance of fistula remission. Thirty-five percent (43/124) of patients treated 
with a TNF-α antagonist maintained remission compared to 18% (23/129) of patients receiving 
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placebo. The pooled RR was 1.94 (95% CI 1.25-3.02, p = 0.003; Figure 13), demonstrating a 
statistically significant effect in favour of TNF-α antagonist therapy. There was no observed 
heterogeneity, and the quality of evidence was considered moderate due to sparse data 
(Appendix B).  
 
 










Vedolizumab. The GEMINI 2 trial was the only included study that assessed fistula healing 
among patients randomized to vedolizumab. In a post-hoc analysis of data from the GEMINI 
2 trial reported in abstract form,146 28% (11/39) of patients in the vedolizumab group achieved 
fistula remission compared to 11% (2/18) of patients in the placebo group. However, the 
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relative improvement in fistula remission with vedolizumab was not statistically significant 
(RR 2.54, 95% CI 0.63-10.29, p = 0.19; Figure 9). The evidence supporting this outcome was 
considered low due to paucity of data (Appendix B).  
 
Ustekinumab. A post-hoc pooled analysis of data from the CERTIFI, UNITI-1 and UNITI-2 trials 
(reported in abstract form) provided data on induction of fistula response and remission 
rates.161 Twenty-four percent (39/161) of patients receiving ustekinumab responded to 
treatment versus 16% (12/77) of placebo patients. The pooled RR (1.55, 95% CI 0.86-2.80, 
Figure 8.) revealed a numerically, but not statistically, significant effect in favour of 
ustekinumab. The quality of evidence for this outcome was considered moderate due to 
sparse data (Supplementary Table 3).  
 
For fistula remission, twenty-three percent (37/161) of patients assigned to ustekinumab 
achieved fistula remission compared to 13% (10/77) of placebo patients. The difference in 
effect between groups was not statistically significant (RR 1.77, 95% CI 0.93-3.37, p = 0.08), 
and the quality of evidence was considered moderate due to sparse data (Appendix B).  
 
Two studies reported on maintenance of response. In the IM-UNITI and CERTIFI-M trials, 54% 
(21/39) of patients assigned to active therapy maintained response compared to 27% (11/41) 
of placebo patients (95% CI, 1.82 1.04-3.17, p = 0.04), suggesting a statistically significant 
difference in favour of ustekinumab. The quality of evidence was considered low due to very 
sparse data (Appendix B).  
 
AST-120. Data from two trials of the oral spherical carbon adsorbent AST-120 were pooled for 
analysis.147 153 Among patients assigned to AST-120, 18% (27/149) had a response compared 
to 15% (24/157) of placebo patients. The pooled RR indicated that there was no statistically 
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significant difference in effect between AST-120 and placebo (RR 1.19, 95% CI 0.72-1.97. p = 
0.50; Figure 8), however, the observed heterogeneity was high (I2 = 79%). Likewise, the pooled 
RR for induction of fistula remission failed to demonstrate a statistically significant between-
group difference in effect (RR 1.45, 95% CI 0.79-2.66, p = 0.22), and observed heterogeneity 
was also substantial (I2 = 66%) for this outcome. While Fukada 2008 reported a statistically 
significant treatment effect in favour of active treatment (RR 3.70, 95% CI 1.14-12.06), a large, 
multi-national, follow-up study by Reinisch et al. failed to confirm these findings (RR 0.84, 95% 
CI 0.47-1.52). Potential explanations for the discordant results include differences among the 
study populations with respect to nationality, genetics, diet, age, body mass index, prior TNF-
α antagonist exposure and baseline disease activity153.  
 
Mesenchymal stem cell therapy. Two trials compared mesenchymal stem cell therapy to 
placebo for induction of fistula response.92 151 Sixty-six percent (80/122) of patients receiving 
stem cell injections responded versus 52% (58/111) of placebo patients. The pooled RR was 
1.27 (95% CI: 1.02-1.59, p = 0.03; figure 9), indicating that stem cell therapy was effective for 
inducing fistula response. There was no observed heterogeneity for this outcome (I2 = 0%), 
and the overall quality of evidence was considered moderate due to sparse data.  
 
Fifty-two percent (64/122) of patients in the stem cell therapy group achieved fistula 
remission versus 41% (45/111) of placebo patients. The pooled RR revealed that stem cell 
therapy was not more statistically effective than placebo for induction of fistula remission (RR 
1.31, 95% CI 0.98-1.73, p = 0.06; Figure 1.2.). There was no observed heterogeneity (I2 = 0%), 






7.4.5 Biologic combined with antibiotic versus biologic alone 
Two trials compared combination therapy with a TNF-α antagonist and an antibiotic to TNF-α 
antagonist monotherapy.87 165 Seventy percent (32/46) of patients in the combination therapy 
group had fistula response compared to 44% (22/50) of patients in the monotherapy group. 
The pooled RR demonstrated that a TNF-α antagonist coupled with an antibiotic was more 
effective than a TNF-α antagonist administered alone for induction of fistula response (RR 
1.58, 95% CI 1.09-2.28; p = 0.01; Figure 14). No heterogeneity was observed (I2 = 0%), and the 




Figure 14 Biologic versus biologic combined with antibiotic for induction of response 
 
 
One study reported on fistula remission rates. Sixty-one percent (22/36) of patients receiving 
combination therapy achieved remission versus 32% (12/37) of patients assigned to placebo. 
This difference in effect was statistically significant (RR 1.94, 95% CI 1.14-3.29, p = 0.01; Figure 
15) and the overall quality of evidence was considered low due to very sparse data. None of 
the included studies in this review presented fistula-specific data on resolution by diagnostic 










7.4.6 Sensitivity analysis 
Ten of the 27 included studies evaluated fistula disease activity as the primary outcome and 
therefore exclusively enrolled patients with fistulating CD, whereas in 17 trials fistula disease 
activity was assessed as a secondary outcome. Sensitivity analyses showed that omitting the 
17 RCTs that studied fistula disease activity as a secondary outcome did not change the overall 
results (Appendix C). Eleven of the 27 included studies solely included patients with perianal 
fistulae. Sensitivity analysis demonstrated that omitting the 16 RCTs with mixed fistula 
populations had a minimal impact on the overall results (Appendix D).  
 
7.4.7 Assessment of bias between studies 
Visual assessment of funnel plots was undertaken for induction of fistula response (figure 16), 





















This systematic review and meta-analysis has identified one  class of drug (anti-TNF-α agents) 
with consistent evidence of benefit in fistulating Crohn’s disease. Development of novel 
therapies for the treatment of fistulating disease is a large unmet need in the management of 
CD, and is recognised as a research priority42 167. 
 
7.5.1 Summary of evidence 
In this meta-analysis, 27 RCTs evaluated 14 separate pharmacotherapies. Our key finding was 
that anti-TNF-α agents are the only drug class proven to both induce and maintain fistula 
response and remission. As a class, they were associated with an approximately 1.5-fold 
increase in likelihood of induction of fistula response, and a two-fold increase in likelihood of 
induction of fistula remission, maintenance of fistula response and maintenance of fistula 
remission. Furthermore, when combined with antibiotics, a statistically significant higher rate 
of induction of fistula response and remission was observed in comparison to a TNF-α 
antagonist administered alone. Future studies should focus on the efficacy of combination 
therapy with immunosuppressives and the relationship between anti-TNF-α trough levels and 
response status within the context of treatment optimization for fistulating CD.  
 
While thiopurines were not found to be superior to placebo for induction of fistula response 
or remission, oral tacrolimus may be effective for induction of response. Unfortunately, the 
side effect profile associated with this agent has limited its use. 
 
Recently, two additional biologic agents, ustekinumab (Stelara; Janssen Biotech, Horsham, 
PA)168 and vedolizumab (Entyvio; Takeda, Deerfield, IL)169, have become available in clinical 
practice for the management of moderate-severely active CD. Ustekinumab, a fully human 
IgGK monoclonal antibody that blocks the common p40 subunit of IL-12 and IL-23, was 
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approved for the treatment of moderate-to-severely active CD on the basis of demonstrated 
efficacy for induction (UNITI-1 and UNITI-2) and maintenance (IM-UNITI) in both TNF-α 
antagonist naïve and failure patients.168 To date, no phase 4 trial is underway to specifically 
investigate its effectiveness for the treatment of fistulating disease. In the absence such a 
study, a post-hoc analysis of patients in the pivotal trials provides some signal of treatment 
efficacy for patients with perianal fistulating CD. Pooled data from one phase 2 (CERTIFI) and 
two phase 3 induction trials (UNITI-1 and UNITI-2) of ustekinumab revealed a statistically 
significant 1.5-fold increase in the likelihood of inducing fistula response. These findings are 
not conclusive, but they should support future trials.  
 
The α4β7 integrin antibody vedolizumab inhibits trafficking of subpopulations of T-cells to the 
gut mucosa. In the pivotal registration trial, at week 6, 14.5% (versus 6.8% in placebo, p = 0.02) 
and at week 52, 39.0% and 36.4% of patients who received vedolizumab every 8 and 4 weeks 
respectively were in clinical remission (versus 21.6% in the placebo group, p < 0.001 and p = 
0.004 respectively). Post-hoc, exploratory analyses published in abstract form reporting on 
the efficacy of vedolizumab for induction of fistula remission (mixed fistula population) 
demonstrated a trend in favour of active treatment, although this was not statistically 
significant. The efficacy of vedolizumab for the induction and maintenance of perianal fistula 
response and remission is subject to a phase 4 clinical trial that is currently underway 
(NCT02630966). 
 
Intra-lesional injection of stem cell therapy is a promising treatment for patients with 
refractory perianal fistulating disease. The pooled analysis of a small trial of bone marrow 
derived mesenchymal stromal cells and a larger phase 3 trial of adipose derived stem cells 
using an a combined clinical and imaging endpoint demonstrated a 30% increase in the 
likelihood of achieving fistula remission over placebo.92 151 High rates of placebo remission 
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were observed in the trial of adipose derived stem cells through surgical curettage and 
injection of saline in fistula tracts, indicating the importance of good adjunctive surgical 
techniques in the management of perianal fistulating disease. A phase 3 trial is underway in 
North America (NCT03279081).  
7.5.2 Limitations 
There are several limitations to this review and meta-analysis. This review does not take 
surgical or combined medical-surgical treatments of fistulating CD into account, as a 
comprehensive review of this topic already exists112. Systematic reviews are only as good as 
the studies upon which they are based. As Crohn’s anal fistula is a relatively rare condition, 
the included RCT’s are limited both in number of studies and number of participants. Whilst 
the majority of patients in the eligible studies had perianal fistulating disease, some had other 
fistulating disease, therefore it is unclear whether our findings are generalisable to all fistula 
types. A post-hoc subgroup analysis of data from the ACCENT II study that assessed the 
efficacy and safety of infliximab for the treatment of rectovaginal fistula was the sole report 
identified that exclusively focused on a non-perianal fistula population.170 Only results from 
the main ACCENT II study were pooled for meta-analysis in the current systematic review. A 
small number of trials contained pooled results of mixed fistula populations, although it is 
reasonable to hypothesize that biological treatment effects are similar regardless of fistula 
origin. Results arising from trials of the newer biologics, ustekinumab and vedolizumab, 
should be considered exploratory as they come from post-hoc analyses published in abstract 
from involving a small number of patients. Finally, there was some heterogeneity in endpoint 
definitions for fistula response and remission, although this is previously summarized in the 
field of IBD171 and initiatives are underway to develop core outcome sets to standardise 





Within the current literature, anti-TNF-α agents are the only drug class to demonstrate 
efficacy for induction and maintenance of fistula response and fistula remission. Injection of 
stem cell therapy into fistula tracts offers a promising therapy for those with fistulae resistant 
to conventional pharmacological treatment, and may be an appropriate treatment for 
patients who do not respond to first line therapy. and more efficacy data are needed on the 
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Chapter 4 shows that drugs have a role in the treatment of Crohn’s anal fistula. However, even 
in modern studies just one in three patients will achieve long term fistula healing174. This is a 
condition which should be managed in concert between a surgeon and physician112. Published 
guidelines advocate sepsis control and use of anti-TNF-α therapy175 176. Some patients will 
improve or heal with this treatment, although many will require further surgical intervention. 
The selected intervention may vary, dependent upon whether the treatment aim is cure, or 
symptomatic relief/palliation. 
 
Previous work has shown that a range of surgical techniques are used177.  These include the 
use of a draining seton alone, anal fistula plug, fistulotomy, stoma and proctectomy. Newer 
techniques such as video assisted anal fistula treatment (VAAFT) (Karl Storz GmbH (Tuttlingen, 
Germany)) and over the scope clip ©(OTSC) (Ovesco Endoscopy AG, Tübingen, Germany) have 
also been used by some. This variation in practice suggests that either a widely acceptable 
and reproducible procedure has not yet been identified, or that additional factors may 
influence choice. Given the range of procedures offered there is a need to collate available 
data on surgical outcomes for this condition.  
 
8.1.1 The IDEAL Framework 
It is well recognised that surgical research lags behind medical intervention178. In response to 
this, the IDEAL framework was devised as a tool to describe the developmental state of 
surgical innovation. This categorises interventions from the ‘idea’ demonstrated with case 
series (stage one), through development, evaluation (including safety), and assessment, onto 
long term follow-up179. This allows a better understanding of the state and applicability of 




There is no current systematic assessment of all potential surgical interventions for the 
treatment of perianal Crohn’s fistula. 
 
8.2 Aim 
The aim of this chapter was to collate data on the outcomes, including complications, of 





8.3.1 Protocol and registration 
This systematic review was registered on the PROSPERO database (CRD42016050316) prior 
to commencement. It was conducted in line with PRISMA guidance. 
8.3.2 Eligibility 
Studies were selected for inclusion if they reported a Crohn’s perianal fistula specific outcome 
(including as part of studies on all types of perianal fistula), or treatment outcomes of Crohn’s 
perianal fistula, following a surgical procedure. Only primary studies and bibliographies from 
identified systematic reviews were considered. Conference proceedings were included if 
related full text could be identified. Ineligible manuscripts were those which reported 
outcomes of Crohn’s perianal fistula as part of all fistula types, or those with fistula related to 
ileoanal pouch only. Studies reporting on outcomes of Crohn’s rectovaginal fistula only were 
excluded – surgeons in the field approach rectovaginal fistula as a separate entity to perianal 
fistula, and offer a different range of surgical options177.  Eligible papers were limited to those 
published in English and since 1995 since when supporting medical therapy has changed 
significantly 74.  
8.3.3 Information sources 
The following databases were searched: MEDLINE, EMBASE and Cochrane Library from 1995 
to current dates. 
8.3.4 Search strategy 
Searches were performed in March 2016. We combined the terms ‘Crohn Disease’, ‘Rectal 
fistula’ or ‘anal fistula’, ‘surgery’, ‘Ligation of inter-sphincteric fistula tract’ (LIFT), ‘seton’, 
‘fistula plug’, ‘advancement flap’, ’VAAFT’, ‘OTSC’ ‘stoma’, and ‘proctectomy’ (Appendix E).  
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.3.5 Study selection 
Abstracts were screened by two of six reviewers against eligibility criteria. To progress to the 
next stage, two reviewers had to agree on inclusion. Where there was disagreement, this was 
arbitrated by a third reviewer (SB). The same six reviewers assessed the full text of these 
studies against inclusion and exclusion criteria. To progress to the next stage, two reviewers 
had to agree on inclusion. Where there was disagreement, this was arbitrated by a third 
reviewer (SB). If a study was excluded at this stage, the reason for exclusion was recorded.  
 
8.3.5 Data collection process 
Data were extracted from studies eligible for inclusion after full text review. Two reviewers 
recorded extracted data independently into a pro-forma. These were compared and any 
variation was discussed with a third reviewer. Where data were missing or unclear, the 
corresponding author was contacted by email for clarification. 
 
8.3.6 Data items 
Data items collected included study descriptors, data on patient cohort, primary outcome 
used (including definition) and corresponding event rate. Study descriptors were year of 
publication, first author, study design, number of participants and number of participants with 
Crohn’s disease, originating hospital and country of author. Patient descriptors included mean 
or median age of patient cohort, gender, duration of Crohn’s disease, fistula anatomy (defined 
either using Parks’ classification or the American Gastroenterology Association definition), 
and where available, coincident medical therapy. Intervention details captured focussed on 
the primary surgical intervention, e.g. seton placement, LIFT procedure, fibrin glue, etc. 
Primary outcome was taken as defined by each paper, as was the interval to assessment. 
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Additional outcomes including complications such as abscess and incontinence were 
recorded. Rates of long -term recurrence were recorded where available. 
8.3.7 Risk of bias 
Risk of bias was assessed using the ROBINS-I tool for non-randomised interventions132, and 
the Cochrane tool for bias assessment in randomised trials129. Bias was independently 
assessed by two reviewers and then reconciled. Where there was disagreement between the 
two reviewers, a third reviewer acted as an arbiter. 
 
8.3.8 Summary measures, synthesis of results and risk of bias across studies 
During protocol design, we considered the landscape of the literature on perianal fistula in 
Crohn’s disease. Given the perceived paucity of randomised controlled trials and prevalence 
of small case series, we intended to undertake qualitative synthesis only. No assessment of 
heterogeneity, publication bias, or any other statistical assessment was planned. Studies were 





8.4.1 Study Selection 
Initial searches identified 1628 references, of which 791 were duplicates. These were removed 
and 837 studies were screened against the eligibility criteria, with 685 of these excluded. Full-
texts were retrieved and assessed for 152 references, of which 89 were excluded, leaving 63 
studies reporting outcomes of 1,584 patients for inclusion in the qualitative synthesis. This 









Of the studies, 22 originated from the USA, 7 from Germany, 5 from Italy, 4 from the 
Netherlands, 3 from the UK, Australia, France, Spain and South Korea, 2 from Japan, Finland 
and Canada, and 1 each from Turkey, Sweden, Serbia, Saudi Arabia and Brazil. The studies 
were published between 1995 and 2016. 
 
Study design was defined as retrospective cohort in 40 studies and prospective cohort in 15 
studies. The design was open label or single arm trial in 5 studies, and there were three 
randomised controlled trials. The number of perianal Crohn’s fistula patients ranged from 1-
41 in prospective cohort studies, 1-119 in retrospective cohorts and 10-33 in open label/single 
arm trials. There were 106 patients in the RCTs.  
 
The surgical interventions described were draining seton, examination under anaesthetic with 
local anti-TNF-α therapy, fistulotomy, fistulectomy, fistula plug, fibrin glue, advancement flap, 
LIFT procedure, VAAFT, OTSC©, Carbon Dioxide laser therapy, diverting stoma and 












Author & Year Country of 
origin 
Study design Total 
number of 
patients 
Number of pCD 
patients 
Intervention(s) 
Buchanan 2003 UK Retrospective 
Cohort 
24 6 Seton 
Chung 2010 Canada Retrospective 
Cohort 
51 40 Seton, AFP 
Gligorijevic 2010 Serbia Prospective 
cohort 
24 24 Seton 
Gottgens 2015 Netherlands Pilot trial 10 10 Seton 
Hukkinen2014 Finland Retrospective 
Cohort 
13 13 Seton 
Kotze 2014 Brazil Retrospective 
cohort 
78 78 Seton 
Schiaduone 2010 Canada Retrospective 
Cohort 
35 35 Seton 
Sugita 1995 Japan Retrospective 
Cohort 
67 67 Seton 
Tanaka 2010 Japan Retrospective 
cohort 
14 14 Seton 
Uchino 2011 Japan Retrospective 
Cohort 
62 62 Seton 
Graf 2015 Sweden Retrospective 
Cohort 
119 119 Seton, Fistulotomy 
Thornton 2005 Australia Retrospective 
Cohort 
28 28 Seton 
Dursun 2014 USA Retrospective 
Cohort 
81 81 Seton, Fistulotomy 
Alessandroni 2011 Italy Prospective 
cohort 
12 12 Local TNF 
Asteria 2006 Italy Prospective 
cohort 
11 11 Local TNF 
Faucheron 1996 France Retrospective 
Cohort 
41 41 Fistulotomy, Seton 
Halme 1995 Finland Retrospective 
Cohort 
35 35 Fistulotomy 
Scott 1996 UK Retrospective 
Cohort 
59 59 Fistulotomy, Seton 
van Koperen 2009 Netherlands Retrospective 
Cohort 
61 61 Fistulotomy, MAF 
de Paredes 2010 France Retrospective 
Cohort 
30 11 Fibrin glue 
113 
 
Sentovich 2003 USA Retrospective 
Cohort 
48 6 Fibrin glue 
Sentovich 2001 USA Retrospective 
Cohort 
40 4 Fibrin Glue 
Park 2000 USA Prospective 
cohort 
25 2 Fibrin Glue 
Loungranath 2004 US Retrospective 
Cohort 
39 13 Fibrin Glue 
Zmora 2003 USA Retrospective 
Cohort 
37 7 Fibrin Glue, MAF 
Mizrahi 2002 USA Retrospective 
Cohort 
106 28 MAF 
Hyman 1999 USA Prospective 
cohort 
33 14 MAF 
Jarrar 2011 USA Retrospective 
Cohort 
98 19 MAF 
Joo 1998 USA Retrospective 
Cohort 
26 26 MAF 
Makowiec 1995 Germany Prospective 
cohort 
32 32 MAF 
Ozuner 1996 USA Retrospective 
Cohort 
101 47 MAF 
Rieger 1999 Australia Retrospective 
Cohort 
35 6 MAF 
Sonoda 2002 USA Retrospective 
Cohort 
99 44 MAF 
Marchesa 1998 USA Retrospective 
Cohort 
13 13 MAF 
Van der Hagen 2006 Netherlands Retrospective 
Cohort 
103 21 MAF, Fistulotomy 
Nelson 2000 USA Retrospective 
Cohort 
65 17 Dermal Advancement 
Cintron 2013 USA Prospective 
cohort, 
multicentre 
73 8 AFP 
El-Gazzaz 2010 USA Retrospective 
Cohort 
33 13 AFP 
Ky 2008 USA Prospective 
cohort 
45 14 AFP 
O'Connor 2006 USA Prospective 
cohort 
20 20 AFP 
Ommer 2012 Germany Retrospective 
Cohort 
40 4 AFP 
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Owen 2010 Australia Retrospective 
Cohort 
35 3 AFP 
Schwander 2009 Germany Prospective 
cohort 
16 10 AFP 
Schwander 2008 Germany Prospective 
cohort 
19 7 AFP 
Senejoux 2015 France RCT 106 106 AFP, Seton 
Zubaidi 2009 Saudi Arabia Prospective 
cohort 
22 2 AFP 
Gingold 2014 USA Prospective 
cohort 
15 15 LIFT 
Molendijk 2015 Netherlands Phase II trial 21 21 ASC 
Cho 2013 Seoul Phase I trial 10 10 ASC 
Cho 2015 Seoul Observational 
study 
41 41 ASC 
Ciccocioppo 2011 Italy Phase I Trial 12 12 MSC 
de la Portilla 2013 Spain Open label trial 24 24 ASC 
Garcia-Olmo 2015 Spain Prospective 
cohort 
10 3 ASC 
Garcia-Olmo 2009 Spain Open label 49 14 ASC, Fibrin Glue 
Lee 2013 South Korea Phase II 43 33 ASC 
Schwander 2013 Germany Prospective 
cohort 
13 11 VAAFT 
Pini Prato 2016 Italy Prospective 
cohort 
9 1 VAAFT 
Menningen 2015 Germany Retrospective 
Cohort 
10 6 OTSC 
Reguiero 2003 USA Retrospective 
Cohort 
32 32 EUA 
Schlegel 2015 Germany Retrospective 
Cohort 
11 11 IAR 
Yamamoto 2000 UK Retrospective 
Cohort 
31 31 Stoma 
Schaden 2007 Austria Retrospective 
Cohort 
69 5 Myocutaneous flap 
Mattioli 2015 Italy Retrospective 
Cohort 
11 11 Cone resection 
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Ozturk 2014 Turkey Retrospective 
Cohort 
10 1 Free Cartilage 
Bodzin 1998 USA Retrospective 
Cohort 
7 7 CO2 Laser 
Moy 2006 USA Retrospective 
Cohort 
27 27 CO2 Laser 
Table 8 Summary of included studies. 
RCT = Randomised controlled trial, MAF = Mucosal advancement flap, ASC = Adipose 
derived stem cells, MSC = Mesenchymal derived stem cells, AFP = Anal Fistula Plug, 
LIFT = Ligation of intersphincteric tract, VAAFT= Video Assisted Anal Fistula 
Treatment, OTSC = Over the Scope Clip, EUA = Examination under anaesthetic, IAR = 




















8.4.3 Risk of bias within studies 
Bias assessment of the identified studies was performed using the ROBINS-2 and Cochrane 
Risk of Bias) tools for non-randomised and randomised studies respectively. Summary tables 
are presented in appendix F and G respectively. Overall, bias in non-randomised studies 
tended to decrease as publication dates approached the present.  
 
Potential bias from confounders arose in studies with mixed populations (i.e. cryptoglandular 
and Crohn’s fistula), with incomplete characterisation of the cohort. This bias was reduced in 
cohorts limited to Crohn’s fistula, where patient and disease factors were usually (but not 
always) more clearly defined. Characterisation was still suboptimal with regards to 
classification of fistulas, use of medical therapies, distribution of disease, smoking status, and 
duration of perianal fistula. 
 
Selection bias was an issue in retrospective studies reporting outcomes of interventions in a 
single centre over a number of years. The criteria for offering interventions to patients were 
not clear – several studies stated that patients offered a procedure ‘typically’ had certain 
characteristics. Studies from teaching hospitals reported outcomes of patients referred to 
their centre. This introduces selection bias as this subset of the population may have disease 
that is particularly challenging to manage, and skews outcomes. 
 
Bias associated with the classification of intervention tended to be low in studies reporting 
outcomes from one specific procedure. This detailed the procedure and perioperative care 
clearly. In studies reporting the use of setons, some issues arose around the timing of removal, 





Bias due to deviation from intervention was limited as these were typically retrospective 
studies with no pre-defined protocol. It was difficult to judge the impact of missing data as 
little information was given on this domain. Some studies reported use of patient surveys to 
capture missing clinical data, although this was uncommon. 
 
Outcome measurement was an area of significant concern. Many studies reported healing, 
without clear definition, as their primary outcome. Other commonly reported measures 
included absence of drainage from a fistula when compressed with a finger182, or closure of 
the external and internal opening of a fistula tract. This was performed at variable timepoints 
in clinic settings. Occasional use of MRI to confirm fistula fibrosis was reported83. One study 
reported a successful outcome as ‘one the patient and surgeon are both satisfied with’183.  
 
Bias was introduced in the selection of outcome measures as those which are easy to measure 
(absence of drainage, closure of external opening of fistula) were used. Whilst used in trials, 
fistula drainage is a snapshot assessment of a dynamic state – a fistula may discharge collected 
fluid prior to a clinic assessment where it is found to be dry. The person measuring outcomes 
was also a potential source of bias. Some authors had financial interests in their procedure 
and this might lead to conflicts of interest in reporting. Only one study had blinded assessors 
– a panel of three surgeons who reviewed perineal photographs to confirm fistula closure182.    
 
In the randomised trials, the main concerns were around allocation concealment and blinding 
of participants. One stem cell study had patients allocated to receive liposuction to harvest 
cells only if they were undergoing the intervention arm. The trial of fistula plug vs seton 
removal will have had similar difficulties of patient blinding as the absence of a seton likely 
feels different to the insertion of a fistula plug.  
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8.4.4 Outcomes after seton insertion 
Setons were used in a number of different ways. Use of a seton alone, with removal at various 
time-points, was reported in six retrospective fistula cohort studies, and included a total of 
329 Crohn’s fistulae184-189. In the four studies which looked at short term healing, success rates 
ranged from 13.5-80.9%185-188. One study looked at symptom improvement, defined as 
improvement by at least one point in all domains of the perianal disease activity index. This 
endpoint was achieved in 72.2% of patients189. Long term recurrence was reported in 42.8%187 
and 83.3%184 of patients. Further drainage of abscess was required in 42.8% and in one study, 
two patients developed a cancer related to their fistula189.  
 
Long term seton was used for symptom control in one study of 28 patients, of whom 26 noted 
symptomatic improvement. The two patients without improvement went on to have 
proctectomy or defunctioning stoma190. 
 
Seton therapy combined with anti-TNF-α therapy was the focus of two retrospective cohort 
studies180 191 and one prospective cohort study181, accounting for a total population of 126 
patients. There was incomplete characterisation of group demographics. The timing of anti-
TNF-α therapy in relation to sepsis drainage or seton insertion was not clear in these studies. 
Short term success was defined as absence of drainage in two studies (although the time point 
for measurement was unclear)180 181 and complete fistula healing in one191. These outcomes 
were achieved in 30-45.8%, 52.5%, and 78.5% of patients respectively. Recurrence rates 
(where reported) were between 9.0-27.7%181 191. Abscesses occurred in up to 8.3%181. One 
study reported no serious adverse effects related to systemic drug therapy191. Seton with anti-
TNF-α therapy also formed the control arm of a randomised trial, and found short term 




8.4.5 EUA with local or systemic anti-TNF-α therapy 
Two prospective studies assessed responses to examination under anaesthetic and local 
injection of anti-TNF-α drugs.  In the first of these, patients received between 3 and 5 
injections, and eight of eleven patients achieved remission (cessation of fistula drainage) at 
the end of the treatment course193. 
 
The second prospective observational study reported outcomes of twelve patients with 
perianal Crohn’s fistula who underwent fistulectomy and local anti-TNF-α injection. Definition 
of healing was based on clinical and MRI appearances at 1 year. With four patients lost to 
follow-up, healing was achieved in 87.5% (47.4-99.6%). One patient developed a new perianal 
abscess and one patient developed pulmonary tuberculosis following treatment194. 
 
One retrospective study assessed the use of EUA as an adjunct to systemic anti-TNF-α therapy, 
and found no discharge from fistulas at three months, although subsequent recurrence 
occurred in 44%195.  
 
8.4.6 Fistulotomy 
Seven studies reported on the outcomes of fistulotomy in 178 patients, all retrospective in 
nature183 186 196-200. Although baseline factors are poorly reported, these were typically for low 
fistulae, i.e. those involving a small part of sphincter where division would not alter function. 
Outcomes were defined as initial healing186 or three month healing196. 
 
Short term healing was successful in 72.2%-100% of patients186 196 197 199. Longer term (i.e. 6 
months or more after treatment) fistula recurrence occurred in 5/28 patients200, and 3/9 
patients at 12 months198. One study found that 22 of 27 patients had a ‘satisfactory’ outcome, 
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although the 5 unsuccessful cases developed significant incontinence183. Higher rates of 
continence disturbance were seen in other studies200. 
 
8.4.7 Fibrin glue 
Six studies reported the use of fibrin glue for fistula. Five were retrospective201-205, including 
one report of long-term follow-up in a cohort previously described201. The sixth study was a 
prospective cohort206. In one of the retrospective cohorts, two patients had fibrin glue 
inserted into their fistula track, with endoanal advancement flap to close the internal 
opening203. These six studies included 140 patient, but only 26 of these had Crohn’s disease. 
The long-term follow-up cohort only captured 4 of the 6 Crohn’s patients from the original 
study201. As a result, details of fistulae in the Crohn’s subgroup were not available. 
 
Short-term success rates for fibrin glue ranged from 40.0-66.6%202-204 206. In the study reporting 
long term follow-up, three of four patients remained healed201. One of the two patients 
treated with a combined procedure achieved short term healing. 
 
8.4.8 Fistula Plug 
Results of anal fistula plug were reported in 11 papers, and a total of 191 patients with 
perianal Crohn’s fistula. Study design included one RCT192, six prospective cohort studies 207-
212, and four retrospective cohort studies185 213-215. In the cohort studies, follow-up ranged from 
0.75-29 months post-procedure. Definition of baseline demographics was poor in these 
studies, and included 14 complex fistula patients in one study (including 4 rectovaginal 
fistula)208, patients with a single transphincteric track and no proctitis in another210. In the RCT, 
the American Gastroenterology Association (AGA) classification216 was used, and included 18 
complex fistula patients and 78 with simple fistula. Male:Female ratios were 3:1 and 41:68 
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where reported, and age ranged from 26-43 years old. Disease duration prior to the RCT was 
3-13 years. One study included the use of faecal diversion in addition to the anal fistula plug 
in some cases209. 
 
Success rates of fistula plug ranged from 15.4-85.7%. Where reported, postoperative abscess 
formation occurred in 3.7-53.8% of patients192 208 213 214. Additional complications included one 
wound dehiscence214, five plug extrusions and two significant pain episodes192. 
8.4.9 Advancement flaps 
Eight retrospective185 198 217-222 and two prospective observational studies223 224 reported the 
outcome of mucosal advancement flaps in both Crohn’s and cryptoglandular perianal fistulous 
disease. Of the 624 reported procedures, 240 of these were performed for Crohn’s fistula. 
Where reported, treated fistulae were predominantly transphincteric, although studies 
included some rectovaginal fistulae.  
 
Success in short term healing was seen in 50.0%-85.0% of patients. Where reported, 
recurrence at >1 year was 30.0%-50.0%198 223. Complications were reported in only one study, 
with occurrence of haemorrhage and flap retraction occurring in 6.6%218. 
 
A retrospective study has reported on the use of a circumferential advancement flap for 
severe and multiple fistula tracks in 13 patients, combined with stoma formation in 8 of 
these225. This led to symptomatic improvement in 8 patients, although all patients also had a 
stoma either prior to, or as part of their procedure. 
 
One retrospective study reported on the use of dermal flaps to close the fistula opening, with 




An augmented approach was used in a pilot trial. This involved placement of a seton, followed 
by local treatment with with platelet rich plasma (PRP) and mucosal advancement flap in 10 
patients 227. Participants also received multiple concomitant medical therapies. At one-year 
follow-up, 70% of participants had a dry fistula. 
8.4.10 Outcomes of LIFT procedure 
One study reported the outcomes of patients undergoing LIFT228. This was a retrospective 
study of 15 patients with transphincteric fistula, followed-up for one year.  At two-month 
follow-up, 9 (60%) had healed. At one year, 8 of these remained healed. Complications such 
as abscess were reported for this study, however they were calculated as mean numbers for 
the cohort. The author was contacted, but data from this study was no longer available. 
 
8.4.11 Outcomes of Stem Cell therapy 
Six studies reported the outcome of stem cell therapy; five open label/phase I or II trials229-233, 
with longer-term follow-up of the cohort initially reported by Cho in 2013234 assessed adipose 
derived stem cells (ASC) in a total Crohn’s disease cohort of 143 patients. One phase I trial 
reported outcomes of mesenchymal stem cell treatment in 12 patients235. Follow up in these 
studies ranged from 8 weeks to 24 months. Cohorts were predominantly male and young, 
with median age of 32 years in several studies.  Duration of Crohn’s disease was approximately 
4.5 years where reported. The anatomy of treated fistulae was predominantly transphincteric.  
 
Success rates for healing ranged from 29.2%-78.8%. Improvement in symptoms was noted in 
a large proportion of patients. This was assessed for at 8 weeks231, defined as a variable time-
point of ‘no discharge for 6 weeks’233, or at clinic appointments at 12 and 24 months234. These 




As this treatment has been explored predominantly through clinical trials, reporting on 
complications has been thorough. Symptoms associated with disease flare such as abdominal 
pain and diarrhoea were reported in up to 60%232 and 7%234 respectively. Local complications 
included anal pain 19%232, anal inflammation 7.3%234, perianal swelling 28.5%233, and perianal 
abscess in 16.6-19.0% of patients232 233. 
 
A single study of recurrent anal fistula with a subgroup of 3 Crohn’s patients found that one 
patient healed and one improved when ASC were injected into the fistula and the internal 
opening closed.236 
 
8.4.12 Outcomes of VAAFT© 
This procedure involves insertion of a fistuloscope through the external opening of the track. 
Secondary tracks are then identified and electrocautery performed through the scope. The 
internal opening is identified and closed using a full-thickness advancement flap, with excision 
of the primary track where possible. 
 
One prospective study reported outcomes of patients treated with Video Assisted Anal Fistula 
Treatment237.  
 
Thirteen patients were treated, of whom 11 had anal fistula related to Crohn’s disease237. Four 
patients were male. Of these fistulae, 9 were transphincteric, 1 was suprasphincteric, and 1 
was rectovaginal. The mean age was 34. This study combined VAAFT with a rectal 
advancement flap and faecal diversion. ‘Short-term success’ was achieved in 9 patients. There 




8.4.13 Outcomes of OTSC© 
Over the scope clip © is performed in lithotomy position. The track is prepared using a fistula 
brush. Anal mucosa is excised circumferentially around the internal fistula opening. Sutures 
are placed into the internal anal sphincter around the internal fistula opening and loosely tied 
all together in a knot with a few centimetres of length. The knot is then pulled through a clip 
applicator that guides a circular Nitinol metal clip onto the internal fistula opening in order to 
close it. 
 
A single case series reported on the use of over the scope clip© in anal fistula238.  Of the 10 
patients treated, 6 had fistula associated with Crohn’s disease. Four of these were female, and 
all had transphincteric fistula. No information was available on mean duration of disease. 
Median follow-up was 230.5 days (156-523).  
 
This study reported short term healing in five of the six patients treated. It was not possible 
to extract complications specific to those treated with Crohn’s fistula from this study.  
 
8.4.14 Proctectomy and faecal diversion 
A retrospective study reported the use of intersphincteric anal resection (IAR) for fistulating 
and fibrosing perianal Crohn’s disease. In this series, 12 patients underwent IAR and 5 
achieved closure of their fistulae239. 
 
A second retrospective case series looked at outcomes of proctectomy with one-stage 
myocutaneous reconstruction (gracilis) in five patients. Perianal fistula healed in four cases, 




Faecal diversion was reported as a sole intervention in a series of 31 patients. In this cohort, 
25 patients achieved early remission, although this was sustained in only 8 patients (median 
81 month follow-up). One patient died as a result of Fourniere’s gangrene and five patients 
developed stoma complications, of whom two required operative revision. No patient 
developed malignancy in the defunctioned rectum241. 
8.4.15 Other therapies 
One retrospective study reported outcomes of patients treated with CO2 laser to the fistula 
track. This included 27 patients, with a mean duration of disease of 36 months. At one month 
follow up, four patients had ceased fistula drainage242. Another retrospective study found that 
laser treatment healed improved symptoms in 5/6 patients243. One other study assessed the 
use of free-cartilage as an interposition material in Crohn’s fistula. This was unsuccessful244. 
8.4.16 Synthesis of results 
No quantitative synthesis of results was performed. 
8.4.17 Risk of bias across studies 
Risk of bias across studies was not assessed. 
8.4.18 Additional analyses 
A summary of the interventions by success rates, complications and highest level of evidence 
is shown in table 9. Interventions were compared to the IDEAL framework to describe 
evolution of surgical interventions for perianal Crohn’s fistula. Only seton, fistulotomy and 
faecal diversion/proctectomy are classified as IDEAL 4 interventions. The majority of 










Intervention Highest level of 
evidence 
Success rates Complication/Harm 
rates 
Seton IIb 13.5-80.9% Abscess 7.1-8.3% 
Fistulotomy IIIb 72.0-100.0% NR 
Fibrin Glue IIIb 40.0-66.6% NR 
Anal Fistula Plug IIb 15.4-85.7% Abscess 3.7-53.8% 
Avulsion 10.4% 
Dehiscence 2.1% 
Advancement flap IIIc 50.0-85.0% Haematoma 6.6% 
Flap retraction 6.6% 
LIFT procedure IV 60.0% NR 
Local stem cells Ib 29.2-78.8% Pain 19.0% 
Anal inflammation 7.3% 
Abscess 16.6-19.0% 
VAAFT IV 8.1% NR 
OTSC © IV 83.3% NR 
Stoma IIc 80.6% Death 5.2% 
Stoma complication 
16.1% 
Table 9 Summary of key outcomes by intervention.  
This includes classification of level of evidence245.N R = Not reported, used where no 
outcomes reported, or outcomes in Crohn’s patients not clear. LIFT = Ligation of 






























Table 10 Summary of surgical interventions according to the IDEAL framework 





8.5.1 Summary of evidence 
This systematic review is the first to collate the outcomes and complications of a range of 
surgical treatments used in the management of fistulating perianal Crohn’s disease, and 
classify them using the IDEAL classification. Seton, advancement flap, anal fistula plug, and 
stem cells have been used in several studies, although success rates vary. 
 
Advances in the medical therapy of fistulating perianal Crohn’s disease have been made 
thanks to large randomised controlled trials74 77 80. The previously identified limitations in 
surgical research178 have again been noted here; only three randomised controlled trials 
comparing therapies were found. It should be noted that a number of feasibility studies were 
performed, particularly in relation to local stem cell therapy. Since searches for this review 
were performed, a randomised trial of stem cells has been reported246. A randomised trial of 




Part of the categorisation used in the IDEAL framework is the number and type of patients, 
with ‘indication’ being an important discriminator179. Whilst draining setons, fistulotomy and 
faecal diversion seem to have broadly agreed indications with long term follow-up, this does 
not appear to be the case for other interventions. Classification of fistula anatomy varies 
between the Cardiff Hughes classification54, Parks classification53 and the American 
Gastroenterology Association definitions247. It is not always possible to consolidate these 
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classifications. Some studies also specified whether or not patients had proctitis210 as this is 
thought to be relevant to prognosis175 176. 
 
Current thinking suggests optimum therapy involves a combined medical and surgical 
strategy. Smaller case series often described the current medical therapy of their patients, but 
larger (retrospective) studies typically failed to do this. It is also likely that medical treatment 
strategies will have varied significantly in one study that included patients treated surgically 
over a 20-year period241. A number of patients also underwent surgical treatment prior to the 
reported procedure – the prior use of setons and formal ‘track preparation’ is poorly reported 
across all studies. 
 
It is impossible to make meaningful comparisons of success rates between interventions, as 
selected outcomes and timepoints are heterogenous. Pooled analysis is further hampered by 
the bias inherent in the preponderance of retrospective studies, and the limited size of their 
cohorts. It is also impossible to compare risk between the operative procedures as reporting 
of complications, with the exception of clinical trials, is very poor. Some studies also reported 
‘long term recurrence’ at the end of their follow-up period. In some cases this was in the order 
of 6-8 years200 241, and we should consider whether this represents recurrence due to the 
surgical procedure or due to the natural history of the disease. 
8.5.3 Findings in context 
The current literature is inadequate to advise with certainty or clarity. Nevertheless some 
broad conclusions can be made; setons provide palliation and can be used long term; 
advancement flap and stem cell therapy may emerge as effective therapies, but require well 
designed randomised trials. A number of other procedures including LIFT, VAAFT and OTSC© 
require further evaluation. Whilst the data on stem cells are promising, it is important to note 
that these patients also receive high-quality basic fistula care, including curettage and 
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drainage, and advancement flap or suture closure of internal openings. These measures may 
have benefits that have not been adequately assessed. The ADMIRE-CD trial, published after 
searches were performed for this review, is a case in point. In this study, both the control and 
intervention procedures included extensive fistula curettage, advancement flap to cover 
internal opening of fistula, and sealing of the external opening with glue. The intervention arm 
had stem cells injected and instilled into their track prior to closure, whereas the control group 
underwent injection of normal saline. Despite this, healing of anal fistula in the placebo arm 
approached 50% at 24 weeks (vs 63% in the intervention arm)246. This chapter includes all 
study designs reporting use of stem cells whereas the previous chapter reported randomised 
trials only.  
 
Studies often capture specific subsets of patients, and selection bias in many of these studies 
means that reported results are not always matched by real-world experience. Additionally, 
the lack of a classification system with prognostic value means that a benefit produced in one 
(unknown and undefined) cohort may be masked by failure in another.   
 
Many of the reported studies excluded patients with proctitis, a phenotype that is often seen, 
and is associated with high rates of proctectomy248. Baseline demographic factors including 
smoking status, disease behaviour and fistula duration are also poorly reported. This was seen 
frequently in mixed cohorts of cryptoglandular and Crohn’s fistulae. On the assumption of 
differing aetiology, whether it is appropriate to mix these cohorts in a study is questionable. 
 
Fibrin glue has largely fallen out of favour and fistula plugs are felt to have limitations, 
including failure and associated sepsis. Advancement flaps may not be technically possible 
with a ‘woody’ rectum, extensive fibrosis or active proctitis. The combination of recurrent 
Crohn’s disease and loose stool means that any sphincter disruption or alteration in 
131 
 
anocutaneous sensation may have an exaggerated impact on continence. Given this, clinicians 
and patients may be understandably keen to avoid procedures that pose additional risk to the 
sphincter, including fistulotomy. Given these technical considerations, fistula anatomy and 
the risk of recurrent episodes of anal perianal sepsis including fistula in the long term, it is 
unsurprising that most clinicians favour conservative interventions such as seton 
placement177. 
 
When considering these studies together, especially over longer-term follow-up, it may be 
inferred that Crohn’s anal fistula is at best palliated by surgical intervention. The majority of 
studies report success in terms of short-term healing, and do not address the management or 
prevention of long-term recurrence. Whilst the idea of healing anal fistula is aspirational, work 
is required to understand how we can best control symptoms and limit recurrence using 
current medical and surgical techniques. In this respect, patient centred outcomes such as 
data on quality of life, impact on personal & social interactions, or lost work-days might be 
more helpful in decision making. For example, faecal diversion has been shown to improve 
gastrointestinal specific domains of quality of life measures in this setting50. 
 
8.6 Conclusion 
There is clearly work to be done to improve the quality of the literature - researchers and 
editorial boards should strive for transparent and thorough reporting on studies involving 
these patients. Development and adoption of a core outcome set including a validated, 
disease-specific quality of life score would help achieve this249.  A classification system based 
on prognostic factors and improved therapeutic options based on an understanding of the 




























9.1 What is a survey 
A survey is ‘a systematic method for gathering information from (a sample of) entities for the 
purpose of constructing quantitative descriptors of the attributes of the large population of 
which the entities are members’250. Surveys allow the collection of data from a large number 
of respondents, focusing on quantity rather than depth of responses. They are commonly 
used by government bodies to report national data, such as a census or unemployment 
rates250-252. 
 
Surveys have been used extensively in healthcare settings and have collected data from both 
patients and clinicians253-255. Whilst a survey can refer to a cross-sectional study of many 
designs, it is frequently used as a short hand term for self-administered questionnaire studies. 
 
9.2 Stages of survey design 
Survey design begins with identification of study aims. Domains or topics for questions are 
selected. These can be identified through a number of different methods, including existing 
literature, the opinion of an expert group, or from prior qualitative work with patients or other 
stakeholders. When the topics for inclusion have been identified, they must be transformed 
into a question format i.e. they must be ‘operationalised’256. This can be achieved using 
previously designed and validated questions. These are questions with well described 
properties related to reliability and validity. Where no validated questions exist, the 
researcher must develop their own questions250 251. The proposed instrument must then be 
assessed by the research team, experts in the field and participants to test validity. The 
proposed instrument may be modified following feedback. The survey then undergoes pilot 
testing with a small sample of the target population. This can be used to refine questions 
further, to test the reliability of instruments, and to assess the acceptability of the 
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questionnaire in terms of wording, design and length. The questionnaire may then undergo 
further refinement before being delivered to the intended sample population250 257. A 
summary of this process is shown in figure 19. 
 
Figure 19 Process for development of a questionnaire. 
 
 
9.3 Ensuring a valid and reliable questionnaire 




Validity refers to the extent to which an answer is a true measure of something, and whether 
it is measuring what the researcher expects it to. There are several different aspects of validity 
which are commonly assessed or reported within questionnaire research. These include: 
Identification of topics Operationalisation of topics
Review of proposed 
instrument




• Face validity: This is the most simple form of validity. When assessed by stakeholders 
and potential respondents, does the question seem to ask what the researcher wants 
i.e. on the face of it, does it seem valid? This can be achieved through focus group or 
similar discussion250 256. 
• Content validity: This form of validity assesses items or domains within a measure for 
their relevance to the research question. It also allows identification of missing items. 
This form of validity can be achieved by asking experts to rate the importance of each 
question, with low scoring items potentially being removed from the instrument250. 
 
9.3.2 Reliability 
Reliability refers to how ‘dependable’ a measure is. This means that when posed, the question 
will lead to a reliable set of results that can be reproduced across different samples of the 
population. There are several forms of reliability in use in questionnaire research. Some of the 
common examples are: 
• Test-retest reliability: This requires administration of an instrument to the same 
person after a short interval. The degree to which the responses correlate across the 
two tests can be used to estimate reliability. This is best used when health or 
psychological states do not change significantly over a short period of time250 256. 
• Internal consistency: This is a form of reliability to assess agreement between two 
measures assessing the same factor, e.g. subscale measures in an anxiety 
questionnaire. If the scale shows internal reliability then it will show positive 
correlation between complimentary statements and negative correlation between 
opposing statements. This is often measured using Crohnbach’s alpha251. 
• Equivalent form: This assessment requires the same constructs to be tested using 
different forms of words. The questionnaires are randomly divided so that each form 
136 
 
of the question is answered by half of all respondents. If there is a strong correlation 
between the two forms, it shows that the construct is reliable. This method can be 
limited by the need to generate multiple forms of questions in long questionnaires256. 
• Split-half reliability: This method involves randomly dividing all items that measure 
the same construct into two sets. Correlation between the two groups can then be 
assessed. If there is a high level of correlation, then the questionnaire can be 
considered reliable. This is only of use where the entire questionnaire assesses the 
same construct throughout256. 
 
9.3.3 Designing questions for quality 
For a questionnaire to be ‘good’ in terms of the above criteria, the individual questions must 
be  designed in an appropriate manner. There is extensive advice on the construction of a well 
written question. This advice focusses on clarity, specificity, and brevity of the question. 
Specific guidance includes250 251: 
• Ensuring the researcher proposes a full question i.e. complete sentences 
• Ensuring neutrality of questions i.e. avoidance of leading statements or prompts 
within the questions 
• Ensuring consistency of meaning across questions i.e. definition of all terms using 
specific terminology, avoidance of terms that could have multiple meanings 
• Ensuring brevity and clarity of the question i.e. avoiding asking multiple questions 
within one stem. 
 
9.4 Limiting errors in surveys 
The aim of a survey is to capture data which is useful, meaningful and relevant to the study 
question250 251. With pragmatism in mind, it is recognised that no study design is perfect, and 
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that trade-offs must be made to complete the project. These constraints can be widely 
defined, but may include cost, resource and time limitations. The study should therefore be 
designed to deliver the ‘best’ results within these limitations. Close attention to areas 
associated with error in design can mitigate these as far as possible within the study 
constraints.  This fits within a paradigm described as ‘total study error’ (TSE)250. TSE refers to 
the accumulation of all errors that may arise in the design, collection, processing, and analysis 
of survey data 
 
The concept of TSE has developed over the 20th Century, and began with the recognition of 
sampling errors250. Work undertaken by the US census bureau demonstrated that it was 
possible to obtain a more accurate estimate of a population response by using a smaller, 
randomly selected population than with a  larger, non-selected population258. Around 10 years 
prior to this,  statisticians had described techniques to estimate variance in a population based 
upon sample size259. The combination of these two pieces of information was used to address 
sampling error250.  It is recognised that errors in survey-based research can also arise from 
‘non-sampling errors’.  These include factors related to measurement items and their delivery, 
as well as factors related to the administration of the survey. These factors are summarised 




Figure 20 Factors associated with survey error. 
 
9.5 Respondent selection 
Errors related to respondent selection can arise in a number of ways. These can be 
addressed by ensuring adequate sample-size selection based upon the desired 
statistical power for the study259. Additional errors can arise when an inappropriate 
population is selected for sampling258. Responder bias; the phenomenon by which 
respondents select themselves to respond to surveys based upon good or bad 
experiences is well recognised, and this can contribute to non-response at the unit 
(person) level250. Strategies to optimise sample size and selection, and to improve 




9.6 Response accuracy 
Response accuracy can be affected by several factors. One of the most important of these is 
measurement error related to interviewer or survey tools. This typically relates to poor 
wording of questions (leading to impaired reliability)256. Non-response to items can limit 
interpretation of findings and may arise due to poor wording of questions or fatigue from 
overly long instruments250.  Non-response may also arise when a respondent is uncomfortable 
disclosing potentially sensitive information with a human interviewer250.  Measurement errors 
relating to the interviewer arise from incorrect capture or recording of data. These 
considerations are intimately related to the reliability of instruments and should be 
considered during the development and pilot phase to limit effect. 
 
9.7 Survey administration 
The management and analysis of data captured by survey is also subject to error. Post-survey 
error typically arises from issues related to data management, for example where a 
participant has not followed instructions and has provided too many or too few responses to 
an item. This can lead to the coder making subjective decisions about the final coding of a  
response250. The mode of response may also have a role, with differing effects of face to face 
survey compared to paper or online responses and those which are anonymous260. 
Comparison error refers to the inaccuracy of estimates of effect difference when comparing 
survey results across nations, cultures, or a significant period of time250. Consideration of 








This chapter has outlined the principles of survey design and considerations to reduce error 
in the conduct of survey-based research. This will be revisited in the subsequent chapters 
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10.1.1 Variation in medical practice 
Variation in medical practice has been described across a number of specialties261. This relates 
to aspects of practice including diagnosis, initial treatment and modification of treatment 
strategies. Variation in care is associated with increased costs262, and variation in outcomes, 
some of which will be undesirable263 264.  As a complex condition, it is likely that there is 
variation in the management of Crohn’s disease both in generalist practice265, and specialist 
practice266 267. 
 
10.1.2 Current evidence and guidance 
There are a number of guidelines for this condition from UK and international bodies111 175 268. 
In broad terms, these advocate treatment of sepsis by a colorectal surgeon, with or without 
an MRI scan to determine anatomy. This should be followed by medical therapy with biologic 
agents, with or without antibiotics or immunosuppression such as thiopurines. These 
guidelines lack explicit detail on the indications for duration of, and timing between, 
interventions. There is also little information on the management of refractory fistulae. Before 
developing clinical pathways and tools to improve the care of these patients, it is important 
to define variation in practice and areas of uncertainty. Chapter 7 provides the background 
evidence for the medical treatment of Crohn’s anal fistula, but it is necessary to assess 




The aim of this study was to explore variations in clinical practice of UK consultant 





10.3.1 Questionnaire design 
 
10.3.1.1 Item generation 
  
The aim of the item generation phase was to develop a list of areas where variation in practice 
might occur. The items were generated using three sources: 1) systematic review, 2) panel of 
clinicians, 3) expert patient input.  A summary of included domains is presented in table 11. 
 
10.3.1.2 Systematic review 
The systematic review of medical therapies (chapter 7) identifies candidate agents for first 
line and maintenance therapy of Crohn’s anal fistula. This supports the inclusion of first and 
second line therapies as a theme. The systematic review of surgical interventions (chapter 8) 
identifies a wide range of techniques. As stoma and proctectomy are considered late stage 
treatments, the theme ‘consideration of stoma’ was added. 
 
The assessment of the clinical pathways presented in chapter 11 supports the inclusion of 
diagnostic tools and selection of first line medical therapy as areas for exploration. Indication 
for referral to a surgeon was also considered a relevant theme. 
 
 
10.3.1.3 Clinician panel 
An expert clinician panel, including two gastroenterologists and two colorectal surgeons, all 
with IBD focused practice, reviewed the themes identified from the systematic review. The 
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panel added time to reassessment of therapy and choice of agents in further treatment as 
themes. 
 
10.3.1.4 Expert patient input 
Patient input on the questionnaire design was solicited from members of the standing ‘patient 
engagement’ panel for the ENiGMA collaboration. This is panel involves patients who have 
been treated for Crohn’s anal fistula. A representative from this group was asked to provide 
an opinion on areas where variation was suspected from the patient perspective. 
 
 
Domain Theme Source 
Acute management Use of antibiotics Systematic review 
Planned assessment of 
patient with fistula 
Use of diagnostic tools 
 
Pathway assessment, 
Management after sepsis 
clearance 
Use of further 
investigations 
Role of MRI 
Pathway assessment, 
systematic review 
Medical therapy Time to reassessment, 
choice of subsequent 
medical agent, choice of 
agent(s) 
Systematic review, 
expert panel, pathway 
assessment, 
















Initial management and assessment 
• Use of antibiotics 
Management after sepsis clearance 
• Route of access to treatment 
• Initial assessment options 
• Preferred imaging modality 
• Minimum investigations required for patient with known Crohn’s disease 
• Minimum investigations required for patient with suspected Crohn’s disease 
First line medical therapy 
• Access to IBD MDT 
• Use of medical therapy for treatment of Crohn’s anal fistula 
• Preferred first line therapy medical therapy 
• Timing of reassessment 
• Second line therapy 
• Dose optimisation strategies 
• Indications for referral to surgeons 
Definitive therapy 
• Second and third line medical therapies 
• Reasons for seeking a stoma 
• Reasons for seeking proctectomy 
 
It is recommended that questionnaires begin their design with questions that neither address 
sensitive areas nor challenge the respondent 256. Given this, each section began with questions 
that were felt likely to fall into common or uncontroversial areas of practice (e.g. use of 
antibiotics in acute perianal sepsis). The section then moved into more in depth questions on 




There were no validated questionnaires available to assess the topics of interest. The 
questionnaire was therefore developed using bespoke items, with validity of questions 
assessed during the pilot phase. The items generated included closed questions with binary 
answers or selections from lists, Likert scales, and free-text boxes. 
 
Closed questions were used where a binary answer (yes/no) was appropriate. These were 
used to establish fact (e.g. whether the respondent had access to an IBD MDT). It was 
anticipated that respondents might have varying opinions or practice. Where this was the 
case, a list of potential responses was offered (e.g. choice of first line drug), with an ‘other’ 
option available. The list of options was generated based upon the literature reviews, pathway 
assessment and the clinical expert panel input. Some questions asked for clinicians to indicate 
the relative frequency of an event in an ordinal manner. A Likert scale was used to capture 
this data. A Likert scale typically offers an odd number of items, allowing respondents to select 
a non-committal response (a central tendency), meaning they appear to conform with the 
population in areas of potential controversy. As this study was designed to identify variation, 
it was decided to remove the middle option in order to force respondents to commit to an 
answer in either direction; a ‘forced’ Likert269. The minimum number of items required for a 
valid Likert scale is four270. 
 
The questionnaire was intended for paper completion and electronic return by local 
collaborators. The cover of the questionnaire included the title, an explanation of the aims of 
the questionnaire, a statement that responses were anonymous and contact details of the 




10.3.1.5 Questionnaire pre-pilot 
 
The questionnaire was subjected to iterative review by the expert clinical group. The group 
ensured revision of questions to be neutral in form, and that all pertinent response items 
(treatment options) were presented.  
 
10.3.1.6 Considerations within Total Survey Error framework 
 

















Sample size Appropriate sample size calculated with reference to 
workforce data. Trade-off in power for attainable sample size 
made. 
Sample coverage No access to trainee networks across all regions, therefore 
recruitment achieved through national meetings. Convenience 
sampling strategy used. 
Non-response at unit 
level 
Questionnaires were delivered through personal approach and 











Non-response at item 
level 
Clear rubric developed through pilot phase and anonymity in 
response to encourage responses which may not match 
practice norms. Limited length of questionnaire to avoid 
fatigue. 
Measurement error 
due to respondents 
Anonymity in response to encourage responses which may not 
match practice norms. Limited length of questionnaire to avoid 
fatigue. 
Measurement error 













Post-survey error Administrative plans for handling data made. Included 
recording of first response only if multiple responses given to 
single response question. 
Mode error Anonymous paper-based survey selected as considered more 
likely to be completed than web survey. 
Comparison error No comparisons planned. 








10.3.2 Eligibility criteria 
Eligibility criteria for participation in the study was set as consultant gastroenterologist 
with a UK practice. 
10.3.3 Questionnaire validation  
The questionnaire underwent a pilot at the British Society of Gastroenterology Inflammatory 
Bowel Disease Clinical Research Group meeting in November 2015. This meeting was 
attended by consultant gastroenterologists. Meeting participants were invited to opt in to the 
pilot and provide anonymous feedback on the questionnaire. The questionnaire was 
accompanied by additional rubric inviting participants to offer feedback on questionnaire 
design.  
 
Face validity was assessed by participants through completion of questionnaire with 
annotation of forms, or opportunity to provide verbal feedback to the investigator present at 
the meeting. Participants were asked specifically to comment on the wording of questions 
and applicability to real world experience. Participants were also asked to comment on any 
questions which were not relevant to the scenarios under discussion, providing a form of 
content validity. Written and verbal feedback was collated and presented to the clinical expert 
panel. Criterion validity was not assessed as there were no related validated questionnaires. 
Construct validity was not assessed as the questionnaire did not assess abstract concepts 




Type of validity How assessed in this 
study 
Reason 
Face validity Verbal feedback from  
steering group and mix of 
written/verbal feedback 
from pilot group. 
 
Content validity Informally assessed by 
steering group which 
included experts in the 
field. 
 
Construct validity Not assessed. No relevant validated 
questionnaires identified. 
Criterion validity Not assessed. No abstract concepts 
assessed. 
Table 13 Assessment of validity of questionnaire 
 
9.3.3 Questionnaire reliability  
Test- retest reliability was considered as an option for this study. In a survey such as this where 
clinical practice is being assessed, a respondent might wish to avoid being seen as an outlier 
in their clinical practice. It is possible that respondents may review guidelines in the period 
between repeat testing. This could significantly change responses in a survey of practice, and 
therefore this form of reliability was not considered appropriate. A summary of reliability 




Type of reliability How assessed in this study Reason 
Test-retest (stability) Not assessed Concerns over changing 
responses as respondents 
may review guidelines or 
refine answers to avoid 
appearing as outliers. 
Alternate form (equivalence) Not assessed Rewording of questions and 
scales would require 
generation of a significant 
question bank, outwith 
resource of the study. 
Internal consistency  Intra-class correlation of  
Likert scales in pilot study. 
- 
Table 14 Assessment of reliability of questionnaire 
 
 
10.3.4 Data capture 
The survey was opened to recruitment at specialist postgraduate gastroenterology meetings 
(British Society of Gastroenterology annual conference and Sheffield Gastroenterology 
Symposium). As there is no corresponding medical trainee research network to facilitate 
delivery, participants were invited to participate by collaborators at these meetings. 
10.3.5 Pilot responses & Face Validity 
Overall, feedback showed questions had face validity. Respondents did not raise concerns 
over any of the aspects of care addressed by the questionnaire, supporting validity of content. 
Respondents suggested additional questions or additional response options. These were: 
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• The question addressing typical route of access to healthcare in acute perianal sepsis 
was removed as all options were frequently selected and this did not offer any 
discriminatory value. 
• Addition of question on investigations for a patient with known Crohn’s disease of a 
patient with a new fistula were converted from frequency, to ‘select all that apply’. 
• Conversion of ‘selected cases’ option to ‘frequently’ and ‘occasionally’ in questions 
on use of immunosuppressant drugs. 
• Questions on the selection of first line drugs were reformatted to allow respondents 
to select single or multiple agents as required. 
• Two questions were added to identify whether or not the presence of proctitis or 
complex fistula anatomy altered choice of treatment. 
• The question on timing of immunosuppression/modulation after sepsis clearance was 
reworded to remove the implication that anti-TNF agents were expected to be used. 
• Responses on evidence of sepsis resolution were converted to ‘select all that apply’. 
• An additional item related to drug dose optimisation was added. 
• A free-text item was added to describe second and third line therapeutic strategies. 
Internal consistency of Likert scales was assessed using intra-class correlation. 
The final questionnaire is presented in Appendix H. 
 
 
10.3.6 Sample size calculation 
The Royal College of Physicians census in 2014 reported approximately 1,100 practicing 
consultant gastroenterologists271. This means that 89 responses were required to achieve a 
10% margin of error with a 95% confidence interval. With an estimated response rate of 




Numerical data from the questionnaire was collated and presented in a descriptive manner 
only. Free text data on indications for stoma and proctectomy were collated and 
representative statements reported. Intra class correlation for internal consistency was 
calculated using a two-way random effect model in SPSS (IBM, Armonk NY). 
 
10.3.8 Ethical approval 
The questionnaire was approved by the University of Sheffield Research Ethics Committee 
(UREC:7595)(Appendix I). Participation was done so on an ‘opt in’ basis, with completion of 









A total of 19 responses were captured during the pilot study. Intraclass correlation was 0.804 
(95% CI 0.562-0.942) showing a high degree of internal consistency of scales. 
 
10.4.2 Full study 
A total of 202 questionnaires were distributed and 111 responses were obtained through the 
various conferences. The overall response rate was 55%. Response rates to questionnaire 
items ranged from 79.2-100.0%. This was an anonymous survey with no demographic data 
captured. 
 
10.4.3 Initial Management and Assessment 
At initial presentation of a symptomatic fistula, 91 of 111 (81.9%) of respondents would 
undertake imaging as their first action. If imaging was required, 108 of 111 (97.2%) of 
respondents would obtain MRI pelvis and 1/111 (0.9%) endoanal ultrasound. Eighteen of 111 
(16.5%) would refer directly to a surgeon. If referral for urgent sepsis management was 
required; 102 of 111 (93.5%) of respondents would refer to a named surgeon, with the 
remaining 7 (6.5%) referring patients to the emergency surgery team. 
 
Respondents indicated that they would ‘Always’ (60/107 (56.0%)) or ‘Frequently’ (45/107 
(42.0%)) use antibiotics in the acutely symptomatic fistula. Only 2/107 (1.8%) indicated they 
would never use antibiotics in this setting. The antibiotic of choice was metronidazole for 
91/107 respondents (85.0%), ciprofloxacin for 67 (62.6%), and co-amoxiclav for 27 (24.2%). 
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Respondents were asked to indicate the minimum set of investigations for a patient with an 
existing diagnosis of Crohn’s disease who presents with a new perianal fistula. MRI pelvis 
would be required by 92/111 (82.9%) of respondents, flexible sigmoidoscopy by 48 (43.2%), 
faecal calprotectin by 35 (31.5%), and colonoscopy by 33 (29.7%). Rigid sigmoidoscopy would 
be requested by 1 (0.9%), barium enema by 1 (0.9%) and examination under anaesthetic by 9 
(8.1%). 
 
A further scenario was described of a patient with a perianal fistula and clinical suspicion of 
underlying Crohn’s disease. Colonoscopy was the preferred investigation in this setting, with 
88/107 respondents indicating they would always request this (figure 21).  
 
 
Figure 21 Use of investigations by gastroenterologists in patients with fistula who are 






10.4.4 Management following clearance of sepsis 
Respondents were asked to describe the interval they would normally leave between the 
clearance of perianal sepsis and the commencement of medical therapy (excluding 
antibiotics). This interval was two weeks for 41/103 respondents (39.8%), four weeks for 39 
(37.8%) respondents, 6 weeks for 18 (17.4%) respondents, and eight weeks for 4 (3.8%) 
respondents. One response (0.9%) indicated an interval of more than nine weeks before 
commencing medical therapy (figure 22) 
 
Figure 22  Timing between clearance of sepsis and commencement of medical therapy. 
 
When asked if respondents required evidence of sepsis clearance prior to medical therapy, 
25/106 (23.6%) indicated they always required evidence, 54 (51%) frequently asked for 
evidence and 27 (25.4%) occasionally asked for evidence. The evidence taken into account 
was surgeons’ report from EUA 80/106 (75.5%), patient symptoms by 74 (69.8%), repeat 
imaging by 76 (71.7%) and overall disease activity by 44 (41.5%).  
 
An IBD multidisciplinary team (MDT) was accessible to 106/108 respondents (98.1%). Of 
these, 25 (23.6%) of respondents indicated they always discuss patients with Crohn’s anal 
fistula in this setting. This was done ‘frequently’ by 54 (51.0%) of respondents and 
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‘occasionally’ by 27 (25.4%). No respondents with access to an MDT reported a practice of not 
discussing these patients in the MDT. 
 
10.4.5 First line medical therapy 
Initial medical therapy was reported by 93 respondents. Of these, fifty-four (48.6%) 
respondents would use thiopurines as first line agent, and 56 (50.4%) anti-TNF-α agents.  
Twenty-seven (29.0%) and 16 (17.2%) would add antibiotics to thiopurine and anti-TNF 
therapy respectively.  Thirty-one (33.3%) would combine antibiotics, thiopurines and anti-
TNF-α therapy, and 9 (9.7%) would use thiopurines and anti-TNF-α therapy alone (figure 23). 
 
Respondents were asked to define their first line anti-TNF-α agent, if appropriate. Of 85 
responses, 74 (87.1%) use infliximab as their first-choice agent, with 11 (12.9%) using 
adalimumab. Free text comments indicated that this reflected clinician preference, but that 
patient choice was often important to this decision. 
 
 
Figure 23 Combinations of first line medical therapy used. 
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Where antibiotic therapy was considered, 89 respondents offered a preference. Of these, 49 
(55.0%) would use ciprofloxacin and 39 (43.8%) would use metronidazole. Co-amoxiclav was 
the preferred agent of one respondent. The typical period of antibiotic therapy was described 
as one week by 2/89 respondents (2.2%), two weeks by 37 (41.5%), one month by 35 (39.3%), 
two months by 10 (11.2%) and more than two months by 5 (5.6%).  
 
When asked if the presence of proctitis altered therapeutic strategy, 70 (68%) indicated that 
it did alter management and 33 (32%) indicated that it did not. Of the 70 where proctitis 
altered management, 21 (30%) said it altered surveillance strategies, 21 (30%) said it altered 
duration of therapy, 56 (80%) would use medications administered per rectum, and 26 (37%) 
said it would change the choice of medical agent. 
10.4.6 Monitoring and escalation 
Following initiation of therapy, 26/87 (29.9%) of respondents would assess response to 
therapy at one month, 52 (59.8%) would assess at three months, 6 (6.9%) at six months, and 
3 (3.4%) indicated variation in follow-up based upon severity of disease. Respondents were 
then asked to define the interval between commencing a drug and escalating therapy. Of the 
108 respondents, one (0.9%) would escalate after one month of therapy, 26 (42.6%) would 
escalate after three months of therapy, 40 (37.0%) would escalate after six months of therapy 
and one each (0.9%) after twelve and twenty-four months (Figure 24). This decision was based 




Figure 24 Duration of therapy before reassessment and escalation of treatment. 
 
To monitor response to treatment after commencement of medical therapy, 66/111 (59.4%) 
of respondents would do so on a clinical basis, and 53 (47.7%) indicated they would usually 
ask for repeat imaging . 
 
In a patient who was stable or improving on first line therapy, 2/107 (1.9%) would stop 
medical therapy, 14 (13.1%) would step-down medical therapy, and 91 (85.0%) would 
continue current therapy (figure 25 a). Thirty respondents offered a choice of step-down 
medical agent: 1 (3.3%) to aminosalicylates (from azathioprine), 16 (53.3%) to thiopurine 
agents (from dual therapy with antibiotic/anti-TNF agents), two to methotrexate (6.6%) (from 
anti-TNF agents), 4 (13.3%) to infliximab (from dual therapy with azathioprine or reduction of 
dose in two cases), and 7 (23.3%) to adalimumab (monotherapy from dual therapy with 
azathioprine). In free text comments on second and third line escalation therapies, 
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Adalimumab was well represented. Vedolizumab was reported as a second or third line option 
by five respondents. A small number of respondents including surgical therapy as a second or 
third line intervention in a deteriorating patient. 
 
In the context of a patient with deteriorating fistulating disease, 32/111 respondents (28.8%) 
would change medical therapy, 56 (50.5%) would undertake further pelvic imaging and 23 





Figure 25 Clinical actions when faced with a) stable or improving fistula b) deteriorating fistula. 
 
Of the 77 respondents who offered a choice of escalation medical therapy, 2 (2.6%) would 
convert to azathioprine (from aminosalicylates or steroids), 41 (53.2%) to infliximab (from 
thiopurines) and 25 (32.5%) to adalimumab (from thiopurines or infliximab). Alternate 
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strategies were proposed by 9 (11.7%) of respondents and were typically escalating doses of 
anti-TNF-α therapy. 
 
When asked about strategies to optimise drug dosages, 78/111 (70.2%) indicated that they 
checked thiopurine blood levels, 78 (70.2%) checked blood anti-TNF-α drug levels, and 61 
(54.9%) screened for anti-TNF antibodies. 
 
10.4.7 Involvement of surgeons 
Respondents were asked to indicate reasons for surgical referral. Long duration on 
immunosuppressant agents was the indication for 17/111 (15.3%), loss of response to drugs 
in 82/111 (73.9%), and impact of fistula on quality of life in 59/111 (53.2%). 
 
Free-text responses were sought on reasons for consideration of stoma. These were typically 
intractable sepsis, fistula refractory to medical therapy, negative impact of disease on quality 
of life and patient choice. One respondent indicated they would refer only if advised by the 
MDT. A second question asked about reasons for referral for proctectomy. The answers to 
this question were virtually identical to consideration of stoma, except for the addition of 
proctitis as an indication. 
 
10.4.8 Synthesis of pathway 
 
A summary of the preferred process related to flow through a patient pathway is presented 











10.5.1 Summary  
This exploratory survey of UK consultant gastroenterologists suggests considerable variation 
in management strategies for fistulating perianal Crohn’s disease. There is notable variation 
in the choice of first line medical therapies and reassessment strategies. Perhaps reassuringly, 
there was wide access to an IBD MDT, and consensus on indications for surgical intervention. 
10.5.2 Findings in context 
Current guidance from the European Crohn’s and Colitis Organisation (ECCO) advocates early 
sepsis control and assessment of anatomy, treatment with metronidazole, anti-TNF with or 
without thiopurine, with clinical assessment at least every three months. Reassessment of 
fistula and consideration of stoma is advised in persistent symptomatic disease 111. British 
Society of Gastroenterology (BSG) guidelines advocate antibiotics and thiopurine agents as 
early therapy, with anti-TNF agents used in severe fistulating disease268. Results from this 
survey do not show strict adherence to either one of these approaches, with a clear split 
between thiopurine first and anti-TNF first. This survey also shows wide variation in how and 
when clinicians escalate therapy; this indirectly suggests that the more complex or difficult to 
manage the fistulating disease is, the less certainty there is on subsequent management steps. 
 
The variation identified may reflect a number of issues; limited evidence base upon which to 
formulate guidance, or limited awareness of guidelines. For example, the use of 
aminosalicylates and corticosteroids reported here is not supported by current evidence 176 
273. This variation might also be attributed to clinician factors, such as disagreement with the 
guidelines, systemic factors, or consideration of guidelines as a suggestion rather than 
requiring strict adherence 274 275. It is also important not to underestimate the clinician’s 
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experience of the local population and their preferences. Patients may disagree with 
treatment strategies in other settings, and omit drugs to avoid side-effects276. 
 
The survey also highlights variation around the timings in the management pathway, including 
intervals between commencing therapy, reassessment, and escalation. There was disparity in 
the suggested interval from drainage of sepsis to commencement of medical therapy, with 
many clinicians expecting an interval of a month or more. It is not entirely clear whether this 
reflects clinician preference or factors related to healthcare system pressures. In addition, 
responses did not reflect a need for a more aggressive medical approach in those with proctitis 
176, with about a third of respondents indicating that it did not alter their management. The 
described indications for stoma and proctectomy agree with published consensus 176.  
 
It has not been possible to identify corresponding work from other countries. A recent cohort 
demonstrated that 60% of patients with perianal fistula were treated using anti-TNF-α 
therapy. The same study noted wide variation in the use of antibiotics277. A retrospective 
cohort also found variation in the use of medical therapies aside from biologics73. Notably, 
both of these studies were performed in centres with a developed IBD service. The study 
reported here did not ask respondents to state whether they worked within a specialist IBD 
centre, or provided services within a more general gastroenterology setting.  
10.5.3 Strengths and limitations 
There are limitations to survey-based research, specifically responder bias and questionnaire 
utility. The response rate of 55% compares favourably with other surveys of 
gastroenterologists 254 278 279. Despite this, the results provide a reflection of variation in UK 
medical management of this condition. Free-text responses confirmed that respondents were 
not only IBD sub-specialists, with a number of respondents indicating that they did not regard 
themselves as IBD experts and would seek advice at second or third line therapy (or earlier). 
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The spread of recruitment across national meetings limits responders to those engaging with 
professional development or research activities, but avoids issues of geographic clustering 
through dissemination in a single hospital.   
 
The decision to include clinicians with specialist and non-specialist practice was an active one 
– the study aimed to record a reflection of ‘real world’ clinical practice. It is recognised that 
the development of subspecialisation will vary across differing units, meaning that non-
specialists may provide care to patients. Despite this, it was judged that the description of 
variation in practice and uncertainty will help identify potential improvements that are widely 
applicable. Whilst our response rate was 55%, this is favourable compared to other recent 
clinician surveys, with response rates of up to 30%255 280. Our corresponding surgical survey 
achieved a response rate in excess of 70%, although this is unusual and probably related to 
trainee driven recruitment at centre level22. Reasons for non-completion might be related to 
unfamiliarity with the condition, or perceived length of the questionnaire.  Surgeons were not 
included in this survey as we have previously undertaken a similar assessment of their 
practice177. In that study, 64% of surgeons would ask for anti-TNF therapy as first line 
treatment, and that indicated that proctitis had an impact on their treatment strategies. 
10.5.4 Implications for practice 
Medical therapy is just one component of a complex stepwise treatment pathway for patients 
with Crohn’s disease and perianal fistulae, and physicians work together with surgeons, 
radiologists and specialist nurses to deliver this. Existing studies suggest benefit of this 
model112 281. It is therefore important that the therapeutic strategy and goal are shared by 
physician, surgeon and patient to help reconcile complex medical and surgical pathways which 
helps ensure timely investigation and intervention. MDT meetings are clearly central to this 
but other steps to facilitate the patients flow between medical and surgical services are 
needed – for example protocols to allow direct referral from IBD specialist nurses to specialist 
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surgical teams. Joint medical and surgical IBD clinics may help, not only in initial assessment, 
but also after an emergency admission and examination under anaesthetic to agree and plan 
anti-TNF therapy.  
 
This survey was intended to provide insight into clinician level management of patients with 
Crohn’s anal fistula as a starting point for work to standardise care.  Areas of practice with 
significant variation are presented in table 15. Areas for further assessment include timing of 
assessment following initiation of medical therapy, and subsequent escalation of medical 
therapy. With the need for strong antibiotic stewardship, the type and duration of antibiotic 
treatment also needs clarifying. It would also be prudent to explore patient experience around 
the treatment of perianal Crohn’s fistula. In the meantime, it is important that UK specialty 
associations recognise and address variation in management through further research, 
educational outreach, audit and guidelines. 
Domain Variation Relevant Research Questions 
Initial Management and 
Assessment 
 
Use of endoscopic 
examination 
 
Impact of proctitis on 
medical management 
 
Use of pelvic imaging 
 
 
What clinicopathologic features 
affect initial management of 
Crohn’s anal fistula? 
First line medical therapy 
 
Biologic first vs thiopurine 
first therapy 
 
Use of antibiotics 
Does combination of anti-TNF, 
thiopurine and antibiotic offer 




Monitoring and escalation 
 
Time to commencement of 
immunosuppression 
 
Time to assessment of 
clinical response 
Can immunosuppression be started 
safely immediately following 
drainage of sepsis? 
 
What is the appropriate time to 
wait for assessment of clinical 
response/escalation of therapy? 
Involvement of surgeons 
 
Indications for referral for 
surgical input 
When does surgical treatment 
offer benefit to patients, including 
improvement in symptoms or 
quality of life? 




There is variation in the choice and timing of medical therapies for perianal Crohn’s fistula. 
This may reflect a limited and uncertain evidence base, rejection of guidelines by clinicians, or 
an absence of national guidelines. Management delays resulting from this variation are likely 
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11.1.1 Variation in surgical practice 
It is recognised that there is a variation in surgical practice, this can occur across nations, small 
geographical areas, or even within the same hospital unit282. The reasons for this are related 
to the fundamental complexity of clinical decision-making, demands and expectations of 
patients and physicians, and the supporting evidence base. Variation in surgical practice does 
not necessarily equate to the volume of procedures being offered, but may also affect the 
type and timing of procedure. 
11.1.2 A framework for understanding variation in surgical practice. 
Variation in surgical practice is a subject of interest, and the topic of several publications283. 
In order to understand variation in surgical practice, Wennberg et al have proposed a 
theoretical framework284. This framework categorises procedures into three groups: 
• Effective care – those procedures that are effective with no significant trade-offs, and 
no conflict between physician and patient on the value of the procedure. 
• Preference-sensitive care – those procedures which require trade-offs around a 
patient’s needs and values e.g. breast reconstruction after breast cancer surgery. 
• Supply-sensitive care – procedures provided in the absence of data or theory guiding 
frequency or timing of use, where those hospitals with a plentiful resource will offer 
the procedure more frequently than those with limited resource e.g use of 
endoscopy to monitor inflammatory bowel disease. 
Wennberg also proposes four main factors that affect the use of each of these modes of 
healthcare. These are medical theory, medical evidence, per capita supply of resources, and 
patient preferences284. Medical theory and evidence play a strong role in effective care. 
Medical theory and patient preferences tend to be most important in preference sensitive 
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care, and per capita supply of resources is the most important in supply sensitive care. 
Correspondingly, there is good quality evidence that the use of clinical guidelines and patient 
decision aids reduces variation in volume of surgical procedures283. 
 
11.1.3 Describing variation in the management of Crohn’s anal fistula 
As discussed in chapter 8, the evidence for specific surgical procedures is limited. Surgical 
management of this condition is also likely to be ‘preference sensitive’. Coupled with the 
sparse guidance offered in clinical guidelines, it is not clear how surgeons are currently 
managing patients with Crohn’s anal fistula. The first step to address clinical variation is to 
explore current practice, and explore whether there is variation and in which aspects of care 
it occurs. 
11.2 Aim 
To report current colorectal practice in the surgical management Crohn’s anal fistula in the 
United Kingdom (UK). 
11.3 Method 
11.3.1 Questionnaire design 
11.3.1.1 Item generation 
The aim of the item generation phase was to develop a list of areas where variation in surgical 
practice might occur. The items were generated using three sources: 1) systematic review, 2) 




11.3.1.2 Systematic review 
The systematic review of surgical therapies (chapter 8) reports a range of surgical options for 
definitive treatment of fistula. This supports the inclusion definitive therapies as a theme. This 
review also reports stoma and proctectomy as late stage treatments, the theme 
‘consideration of stoma’ was added. 
 
The assessment of the clinical pathways presented in chapter 12 supports the inclusion of 
diagnostic tools and acute surgical management as themes. The systematic review of medical 
therapies identifies candidate medical therapies, therefore adjunctive medical management 
was added as a theme. 
11.3.1.3 Clinician panel 
An expert clinician panel including three colorectal surgeons and two gastroenterologists, all 
with IBD focused practice, reviewed the themes identified from the systematic review.  
11.3.1.4 Expert patient input 
Patient input on the questionnaire design was solicited from members of the standing ‘patient 
engagement’ panel for the ENiGMA collaboration. This is panel involves patients who have 
been treated for Crohn’s anal fistula. A representative from this group was asked to provide 






Domain Theme Source 
Initial 
management/assessment 
Use of antibiotics 
Investigation to identify 
Crohn’s disease or fistula, 
Systematic review, 
expert panel, patient 
panel 
Acute management Who performs procedure 




expert panel, patient 
panel 








Access to MDT 
Preferred adjunct agents 
Expert panel, 
systematic review 
Definitive surgical therapy Surgical interventions for 
fistula closure 
Effect of fistula location 
on strategy 
Indications for diversion 
or proctectomy 
Systematic review, 
expert panel, pathway 
patient panel 





The expert clinical panel collated these themes and proposed a set of fields to include in the 
study: 
Initial management and assessment 
• Use of antibiotics at first presentation 
• Additional diagnostic tests required 
Acute management 
• Respondents practice in acute perianal sepsis 
• Respondents recommendations to others treating acute perianal sepsis 
Elective management 
• Choice of interventions at first planned examination under anaesthesia 
• Further investigations required 
• Additional medical therapy offered 
Multidisciplinary management 
• Access to IBD MDT 
• Preferred drugs to support fistula treatment 
Definitive surgical therapy 
• Procedures offered as definitive surgical treatment of anal fistula 
• Procedures offered as definitive surgical treatment of rectovaginal fistula 
• Indications for stoma and proctectomy 
 
It is recommended that questionnaires begin their design with questions that neither address 
sensitive areas nor challenge the respondent 256. Given this, each section began with questions 
that were felt likely to fall into common or uncontroversial areas of practice (e.g. use of 
antibiotics in acute perianal sepsis). The section then moved into more in depth questions on 




There were no validated questionnaires available to assess the topics of interest. The 
questionnaire was therefore developed using bespoke items, with validity of questions 
assessed during the pilot phase. The items generated included closed questions with binary 
answers or selections from lists, Likert scales, and free-text boxes. 
 
Closed questions were used where a binary answer (yes/no) was appropriate. These were 
used to establish fact (e.g. whether the respondent had access to an IBD MDT). It was 
anticipated that respondents might have varying opinions or practice. Where this was the 
case, a list of potential responses was offered (e.g. choice of first line drug), with an ‘other’ 
option available. The list of options was generated based upon the literature reviews, pathway 
assessment and the clinical expert panel input. Some questions asked for clinicians to indicate 
the relative frequency of an event in an ordinal manner. A Likert scale was used to capture 
this data. As in the previous chapter, a forced Likert scale was used. 
 
The questionnaire was intended for paper completion and electronic return by local 
collaborators. The cover of the questionnaire included the title, an explanation of the aims of 
the questionnaire, a statement that responses were anonymous and contact details of the 
research team in case of query. 
 
11.3.1.5 Questionnaire pre-pilot 
 
The questionnaire was subjected to iterative review by the expert clinical group. The group 
ensured revision of questions to be neutral in form, and that all pertinent response items 




11.3.1.6 Considerations within Total Survey Error framework 
 
A summary of design considerations within the total study error framework are presented in 
Table 17. 











Sample size Appropriate sample size calculated with reference 
to workforce data. Trade-off in power for attainable 
sample size made. 
Sample coverage Trainee networks provide coverage across UK in 
general surgery285. 
Non-response at unit level Questionnaires were delivered through personal 
approach and responses were anonymous. Both 










Non-response at item level Clear rubric developed through pilot phase and 
anonymity in response to encourage responses 
which may not match practice norms. Limited 
length of questionnaire to avoid fatigue. 
Measurement error due to 
respondents 
Anonymity in response to encourage responses 
which may not match practice norms. Limited 
length of questionnaire to avoid fatigue. 














Post-survey error Administrative plans for handling data made. 
Included recording of first response only if multiple 
responses given to single response question. 
Mode error Anonymous paper-based survey selected as 
considered more likely to be completed than web 
survey. 
Comparison error No comparisons planned. 







11.3.2 Eligibility criteria 
Eligibility criteria for participation in the study was set as consultant colorectal surgeon with 
a UK practice. 
11.3.3 Questionnaire validation  
The questionnaire underwent a pilot at the Digestive Diseases Federation meeting in June 
2015. This meeting was attended by a range of clinicians providing care for gastrointestinal 
disease, including surgeons. Meeting participants were invited to opt in to the pilot and 
provide anonymous feedback on the questionnaire by researchers attending the event. The 
questionnaire was accompanied by additional rubric inviting participants to offer feedback on 
questionnaire design.  
 
Face validity was assessed by participants through completion of questionnaire with 
annotation of forms, or opportunity to provide verbal feedback to the investigator present at 
the meeting. Participants were asked specifically to comment on the wording of questions 
and applicability to real world experience. Participants were also asked to comment on any 
questions which were not relevant to the scenarios under discussion, providing a form of 
content validity. Written and verbal feedback was collated and presented to the clinical expert 
panel. Criterion validity was not assessed as there were no related validated questionnaires. 
Construct validity was not assessed as the questionnaire did not assess abstract concepts.  








Type of validity How assessed in this study Reason 
Face validity Verbal feedback from  
steering group and mix of 
written/verbal feedback 
from pilot group. 
 
Content validity Informally assessed by 
steering group which 
included experts in the 
field. 
 
Construct validity Not assessed. No relevant validated 
questionnaires identified. 
Criterion validity Not assessed. No abstract concepts 
assessed. 
Table 18 Assessment of validity of questionnaire 
 
11.3.3 Questionnaire reliability  
Test- retest reliability was considered as an option for this study. In a survey such as this where 
clinical practice is being assessed, a respondent might wish to avoid being identified as an 
outlier in their clinical practice. It is possible that respondents may review guidelines in the 
period between repeat testing. This could significantly change responses in a survey of 







Type of reliability How assessed in this study Reason 
Test-retest (stability) Not assessed Concerns over changing 
responses as respondents 
may review guidelines or 
refine answers to avoid 
appearing as outliers. 
Alternate form (equivalence) Not assessed Rewording of questions and 
scales would require 
generation of a significant 
question bank, outwith 
resource of the study. 
Internal consistency  Intra-class correlation of  
Likert scales in pilot study. 
- 
Table 19 Assessment of reliability of questionnaire 
11.3.4 Pilot responses & Face Validity 
In the pilot phase, 20 questionnaires were distributed and 15 were returned (response rate 
75%). Feedback showed questions had face validity. Respondents did not raise concerns over 
any of the aspects of care addressed by the questionnaire, supporting validity of content. 
Respondents suggested additional questions or additional response options. These were: 
• Endoanal ultrasound was added as a response option for all items discussing imaging. 
• Addition of question item on frequency of post-operative imaging 
• Additional question on modality of choice 
• Addition of item on frequency of repeat EUA in elective setting 




The final questionnaire is presented in Appendix J. 
11.3.4 Data capture 
The full questionnaire was run through the UK surgical trainee research collaboratives, led 
jointly by the South Yorkshire Surgical Research Group (SYSuRG) and the North-West Research 
Collaborative (NWRC). There are fifteen general surgery research collaboratives which are 
organised on a regional basis (e.g. South Yorkshire, West Midlands, Wales, London) and have 
potential for wide delivery of surveys. Collaborators were asked to deliver the questionnaire 
to consultant colorectal surgeons in their units. Initial contact was made via the National 
Research Collaborative email lists and electronic contact made to local collaborative leads and 
cascaded locally. Collaborators were asked to support delivery of hard-copy questionnaires 
locally to Consultants and return at least three completed questionnaires to the Research 
Electronic Data Capture™ (REDCap) system, hosted by the University of Sheffield286. Although 
questionnaires were anonymous at respondent level, the number of centres and participants 
included was recorded by collaborators.  
11.3.5 Sample size calculation 
ACPGBI reports 1,000 consultant members. This means that 88 responses were required to 
achieve a 10% margin of error with a 95% confidence interval. With an estimated response 
rate of 60%272, this required 146 questionnaires to be distributed. Sampling was undertaken 
using a convenience approach, with hospital participation defined by trainees responding to 
invitation to participate. 
 
11.3.6 Analysis 
Numerical data from the questionnaire was collated and presented in a descriptive manner 
only. Where binary answers were changed to four-point answers for the final study, yes and 
no options were analysed as ‘always’ and ‘never’ responses respectively. Free text data on 
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indications for stoma and proctectomy were collated and representative statements 
reported. Intra class correlation for internal consistency was calculated using a two-way 
random effect model in SPSS (IBM, Armonk NY). 
11.3.7 Ethical approval 
The questionnaire was approved by the University of Sheffield Research Ethics Committee 
(UREC:7386)(Appendix K). Participation was done so on an ‘opt in’ basis, with completion of 





11.4.1 Pilot of survey & reliability 
In the pilot, twenty questionnaires were distributed to eligible participants and fifteen were 
returned (75% response rate). Inter-rater reliability for Likert-based tools was assessed using 
intra-class coefficient ‘good’ correlation across average measures at 0.830 (95% CI 0.701-
0.920).  
11.4.2 Full survey 
In the full review phase, 133 responses were received from 179 distributed questionnaires 
(74.3% response rate). Of these, 70 respondents practised in district general hospitals and 63 
in teaching hospitals. This accounted for 32 different centres across the UK, including centres 
in Wales and Scotland according to collaborator location. Location is not reported here as 
responses were anonymous. For final analysis, both phases were pooled, giving a total of 154 





11.4.3 Acute management of perianal sepsis 
This section addressed patients admitted acutely with perianal symptoms. There was 
variation in the use of perioperative antibiotics in the acute setting, with 39.6% of respondents 
always using them and 5.8% never using them. Most respondents (42.2%) would start 
antibiotic therapy pre-operatively on the ward or in clinic, with 40.9% starting therapy at 
induction of anaesthesia. The antibiotic of choice was metronidazole (77.9%), followed by co-
amoxiclav (35.1%) and ciprofloxacin (20.1%). Few respondents would always ask for pre-
operative imaging in the acute setting (7.1%), but the majority would seek imaging frequently 
(37.0%) or occasionally (51.9%). Where imaging was used, magnetic resonance imaging (MRI) 
of the pelvis was the preferred modality (96.1%), with a small minority using endo-anal 
ultrasound (2.5%) or CT (1.9%) (table 20). 
 
Where the diagnosis of Crohn’s disease was suspected but not yet established, respondents 
were asked to report which investigations they would use to confirm or refute this. Faecal 
calprotectin was routinely used by 22.9%, colonoscopy always used by 57.1%, flexible 
sigmoidoscopy always used by 16.8% and MR small bowel by 9.7%. Conversely, 25% of 
respondents would never use faecal calprotectin to aid diagnosis, 3.2% would not use 
colonoscopy, 18% would not use flexible sigmoidoscopy, and 13.6% would not use MR of small 
bowel. No respondents routinely used video capsule endoscopy (VCE) to confirm diagnosis of 









 Response (%)  
In the acute setting: Always Frequently Occasionally Never Missing 
Would you use 
antibiotics? 





Post-operatively Other Missing 
When would you start 
them? 
65 (42.2%) 63 (40.9%) 10 (6.5%) 7 (4.5%) 9 (5.8%) 
List Ciprofloxacin Metronidazole Co-amoxiclav Gentamicin  
What antibiotics would 
you use? 
31 (20.1%) 121 (78.5%) 54 (35.1%) 22 (14.2%) - 
 Always Frequently Occasionally Never Missing 
Would you obtain pre-
operative imaging? 
11 (7.1%) 57 (37.0%) 80 (51.9%) 5 (3.2%) 1 (0.6%) 
















Always Frequently Occasioncally Never Missing
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11.4.4 Crohn’s fistula in acute setting 
Respondents were asked to identify which procedures they would routinely consider in an 
operation for an acutely symptomatic/emergency presentation of Crohn’s anal fistula; 32% 
would drain sepsis, 31.1% would consider placement of a draining seton if appropriate, and 
0.6% would consider excision of fistula track. The majority of respondents (89.6%) indicated 
that they would never consider a cutting seton in this setting (Table 21). 
 
Respondents reported on what advice they would give to a less experienced surgeon (a 
general surgical colleague or registrar) undertaking surgery in this setting. Responses tended 
to recommend a more conservative approach with 43.5% advocating drainage of sepsis 19.5% 
advocating placement of a draining seton, and 94.8% advising against a cutting seton. Free 
text comments from two respondents indicated a feeling that only an experienced colorectal 
surgeon should be undertaking these procedures. 
 
 
 Response (%)  
If you were doing the case, 
would you consider: 
Always Frequently Occasionally Never Missing 
Incision and drainage of 
abscess 
50 (32.4%) 48 (31.1%) 44 (28.6%) 8 (5.1%) 4 (2.5%) 
Insertion of draining seton 48 (31.1%) 61 (43.5%) 35 (22.7%) 1 (0.6%) 10 (6.4%) 
Insertion of cutting seton 0 0 13 (8.4%) 138 (89.6%) 4 (2.5%) 
Excision of track 1 (0.6%) 0 45 (29.2%) 104 (67.5%) 4 (2.5%) 
  
If you were advising a 
colleague or registrar, would 
you advise: 
Always Frequently Occasionally Never Missing 
Incision and drainage of 
abscess 67 (43.5%) 46 (29.8%) 31 (20.1%) 7 (4.5%) 3 (1.9%) 
Insertion of draining seton 30 (19.4%) 50 (32.4%) 60 (38.9%) 11 (7.1%) 3 (1.9%) 
Insertion of cutting seton 0 0 4 (2.5%) 146 (94.8%) 4 (2.5%) 
Excision of track 0 0 23 (14.9%) 125 (81.1%) 6 (3.8%) 





11.4.5 Subsequent elective surgery 
The survey elicited procedure preferences for the first subsequent elective examination under 
anaesthetic (EUA). As in the acute setting, draining seton was routinely considered (66.6%) 
and cutting seton was avoided (84.4%). Where preferences were indicated, Ethibond ® 
(Ethicon) was the preferred seton material for 41.5%, silastic slings for 24.6% and comfort 
drains ® (Agency for Medical Innovation) in 3.2%. Other procedures such as excision of track, 
fistulotomy and faecal diversion were not considered options in this context by 62.9%, 35.7% 
and 33.1% of surgeons respectively.  
 
If a fistula was found at EUA, 30.6% would routinely undertake post-operative MRI. If a fistula 
was not identified, but suspected, 63.9% would routinely undertake post-operative MRI. 
Routine repeat EUA would be performed by 16.5% of respondents, although 75.9% of 
respondents indicated that they would frequently or occasionally undertake repeated EUA, 
suggesting a ‘selected case’ approach. Post-operative antibiotics were routinely used by 
11.2% of respondents, and in selected cases (frequently/occasionally) by 75.0% (Table 22). 
 Response (%)  
At first planned EUA, would 
you consider 
Always Frequently Occasionally Never Missing 
Insertion of draining seton 48 (31.1%) 61 (43.5%) 35 (22.7%) 1 (0.6%) 10 (6.4%) 
Insertion of cutting seton 0 0 13 (8.4%) 138 (89.6%) 4 (2.5%) 
Excision of track 1 (0.6%) 0 45 (29.2%) 104 (67.5%) 4 (2.5%) 
Fistulotomy 0 5 (3.2%) 88 (57.1%) 55 (35.7%) 6 (3.8%) 
Faecal diversion 0 0 54 (35.0%) 53 (34.4%) 47 (30.5%) 
  
After first elective procedure, 
would you routinely plan for: Always Frequently Occasionally Never Missing 
Post-operative antibioticsϮ 15 (11.2%) 21 (15.7%) 79 (59.3%) 13 (9.7%) 5 (3.7%) 
Post-operative imaging if 
fistula foundϮ 48 (36.0%) 48 (36.0%) 32 (24.0%) 1 (0.7%) 4 (3.0%) 
Post-operative imaging if no-
fistula foundϮ 85 (63.9%) 33 (24.8%) 9 (6.7%) 2 (1.5%) 4 (3.0%) 
Repeat EUA Ϯ 22 (16.5%) 47 (35.3%) 54 (40.6%) 6 (4.5%) 4 (3.0%) 
Table 22 Summary of management around first planned examination under anaesthetic. 
ϮPercentage based on 133 respondents from full survey as no equivalent response 
options used in pilot. 
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11.4.6 Medical and multi-modal management of Crohn’s anal fistula. 
An inflammatory bowel disease multi-disciplinary team was available to 87.6% of 
respondents. Of these, 25.1% routinely discussed all cases of Crohn’s anal fistula in this setting 
and only 0.7% of respondents never discussed patients. A multi-modal approach utilising joint 
medical and surgical therapy was routinely used by 28.6% of respondents, with just 1.9% not 
using a combined approach (table 23). 
 
Gastroenterology follow-up was arranged for all patients by 71.4% of respondents. 
Immunosuppressant therapy was routinely used in treatment of this condition by 32.8% of 
respondents, with 58.8% indicating a selected-case approach. Eight responses were excluded 
from this analysis as their response from the pilot survey could not be mapped to the final 
questionnaire. 
 
Surgeons were asked to identify which drug(s) they would prefer a patient to receive as part 
of multi-modal care. Anti-TNF-α therapy was most frequently preferred (64.2%), followed by 
azathioprine (33.7%). Despite expressing preferences, the final decision on medical 
management was left with a gastroenterologist by 42.2% of surgeons (table 23). 
 
The decision on seton removal was made by surgeons in 64.2% of cases, the multidisciplinary 
team in 33.7% of cases and by gastroenterologists in 5.8% of cases. The patient made the 
decision for seton removal in 4.5% of responses. A free-text option was available to report 
timing of seton removal. Responses indicated that this was highly variable and tailored to the 
patient. In some cases, timings were related to surgery e.g. 3 months post-op, and in others 
related to biologic therapy e.g. after third dose. Respondents also indicated that it might be 




 Yes No Missing 
Do you have access 
to an IBD MDT? 135 (87.6%) 14 (9.1%) 5 (3.2%) 
  Always Frequently Occasionally Never Missing 
Do you routinely 
discuss CAF patients 
in an IBD MDT?Ϯ 
39 (25.1%) 58 (41.7%) 45 (32.3%) 1 (0.7%) 0 
Do you arrange 
follow up for 
patients with 
gastroenterology? 
110 (71.4%) 31 (22.3%) 9 (6.4%) 0 4 (2.6%) 
Do you use 
multimodal 
approach? 
44 (28.5%) 70 (45.5%) 19 (12.3%) 3 (1.9%) 18 (11.6%) 
Do you use 
immunosuppressant 
drugs?ϮϮ 
48 (32.8%) 58 (39.7%) 28 (19.1%) 8 (5.4%) 4 (2.7%) 
      
What drugs would you ask for to complement 
surgical therapy? 
 n % 
 Glucocorticoid 
steroids 34 22.0 
 Aminosalicylates 24 15.5 
 Azathioprine 52 33.7 
 6-Mercaptopurine 16 10.3 
 Methotrexate 23 14.9 
 Anti-TNF-α therapy 99 64.2 
 Gastroenterology 
decide 65 42.2 
Table 23 Summary responses and multimodal management approaches used. 
*Selected cases group was split into Frequently and Occasionally after pilot. 
ϮPercentage based on 143 respondents who replied ‘Yes’ to IBD MDT or missing 
responses (i.e. excludes those with no MDT). ϮϮ 8 patients excluded as option 
‘selected cases’ removed in full version. IBD=Inflammatory bowel disease, MDT = 









11.4.7 Definitive Surgical Management of Crohn’s anal fistula 
Eleven surgical procedures were considered as options by respondents as options to facilitate 
definitive closure of a fistula. The most frequently considered options were removal of seton 
only (70.7%), fistulotomy (57.1%), advancement flap (38.9%), fistula plug (36.4%) and ligation 
of intersphincteric track (LIFT) procedure (31.8%). Fistulectomy (27.9%), fibrin glue (12.9%) 
and local perineal flaps (7.8%) were used by fewer respondents. Early adopters of technology 
indicated use of over the scope clip (OTSC) (1.2%), video assisted fistula closure (VAAFT) (1.9%) 
and fistula-assisted laser closure (FiLaC™) (0.6%) (Table 24). 
 
Most respondents used diverting stoma and proctectomy on a selected case basis, with only 
12.3% of respondents never using a stoma and 12.9% never considering proctectomy. Free-
text responses defining indications for these were similar with the phrase ‘failed bottom’ used 
by many respondents. This was defined as recurrent or chronic perianal sepsis, incontinence, 
and symptoms or proctitis refractory to medical therapy. Dysplasia and malignancy were 
reported as specific indications for proctectomy. Patient choice was identified by several 
respondents as a factor in their decision to undertake these procedures. Where proctectomy 
was performed, a small perineal defect would be primarily closed, but respondents preferred 
flap-based perineal reconstruction if a large defect remained. 
 
A significant minority (41.5%) of respondents indicated that they would treat rectovaginal 
fistula. This group of respondents would use definitive procedures including advancement flap 
(21.5%), fistula plug (10.9%), Martius flap (9.3%), omental interposition (6.2%) and LIFT 
procedure (4.6%) to treat recto-vaginal fistula. A diverting stoma would be used by 6.2% of 
respondents. A summary of definitive options used in perianal and rectovaginal fistulae are 




Which of the following 
procedures would you offer 
in the treatment of Crohn’s 
anal fistula? 
Perianal Fistula (n=154) Rectovaginal fistula (n=64) 
Removal of Seton only 109 (70.7%) - 
Fistulotomy 88 (57.1%) - 
Fistulectomy 43 (27.9%) - 
Fistula Plug 56 (36.4%) 7 (10.9%) 
Advancement flap 60 (38.9%) 14 (21.5%) 
Fibrin Glue 20 (12.9%) - 
LIFT 46 (29.8%) 3 (4.6%) 
OTSC 2 (1.2%) - 
VAAFT 3 (1.9%) - 
FiLaC 1 (0.6%) - 
Local (Perineal) Flap 12 (7.8%) - 
Martius Flap - 6 (9.3%) 
Omental interposition - 4 (6.2%) 
Diverting stoma - 4 (6.2%) 
Table 24 Definitive surgical procedures and their use in perianal and rectovaginal fistula. 
LIFT=Ligation of intersphincteric tract, OTSC = over the scope clip, VAAFT=Video 
assisted anal fistula treatment, FiLAC = fistula laser assisted closure. 
 
11.4.8 Synthesis of pathway 










11.5 Discussion  
11.5.1 Summary 
This study has used a collaborative approach to assess current UK surgical practice in 
fistulating perianal Crohn’s disease. It has identified areas of common practice, including 
choice of imaging modality, antibiotics and avoidance of sphincter-disrupting treatments such 
as cutting seton. The survey has clearly exposed variation in practice including choice of 
operative intervention, timing of seton removal and optimal use of multimodal therapy. 
11.5.2 Strengths and limitations 
There are limitations associated with survey-based research including responder bias. We 
attempted to address these in the study design by using personal contacts and trainee-
consultant relationships with the opportunity for case-based discussions over impersonal 
electronic surveys with attendant poor response rates. Mitigation against survey fatigue due 
to length of questionnaire was also evident in engagement of local collaborators to deliver 
and complete the questionnaire. Anonymous participation in the survey may also have helped 
improve response rates, as there was no concern about identification or challenge related to 
practice. The high response rate was achieved with the support of the trainee collaborative 
networks. 
Management of a condition with variable presentations and degrees of severity such as 
fistulating perianal Crohn’s disease, will inevitably lead to some difficulties in achieving clear 
agreement around routine practice as management is rightly tailored to each case. This is 





11.5.3 Findings in context 
There is little evidence on the use of antibiotics alone in the treatment of perianal Crohn’s 
disease, with meta-analyses on the use of ciprofloxacin suggesting a marginal effect in 
remission of Crohn’s anal fistula 287 288. In combination with Adalimumab, it may offer 
additional benefit in healing 289. Recent American guidelines suggest that antibiotics in 
perianal sepsis might be of benefit only in the immunosuppressed, or where there is systemic 
upset or cellulitis 290. 
 
Magnetic resonance imaging is well established as the imaging modality of choice in perianal 
Crohn’s disease, and has been used to guide therapy in one study 86.  Endo-anal ultrasound is 
not yet a widely used technology. It has a niche role here as a diagnostic adjunct in specialist 
hands 291,but has limitations depending on the type of fistula present 292.   
 
Surgeons used a variety of investigations for establishing the diagnosis of Crohn’s disease. 
Faecal calprotectin is a sensitive marker of mucosal inflammation, so may be raised in a 
number of non-Crohn’s related scenarios 293 294.  Endoscopic assessment allows visual and 
histologic assessment of the colon. The split between colonoscopy and flexible sigmoidoscopy 
may be associated with surgeons ruling out proctitis only rather than assessing the whole 
colon, as proctitis is a prognostic factor in mucosal healing 176 and also in persistence of fistula.  
 
The roles of anti-TNF-α therapy and azathioprine are well established in this setting, so their 
positions as drugs of choice are merited 74 86 289. Previous work has demonstrated that steroids 
should not be used for Crohn’s anal fistula alone, and their use in this setting runs counter to 
current guidelines 176 273.  The use of steroids to treat associated luminal disease may be 
appropriate, and it is possible that this factor was considered when responding to questions 




In both acute and initial elective settings, the survey shows a tendency towards conservative 
and sphincter-preserving procedures, in the form of drainage of sepsis and use of draining 
seton. Respondents widely rejected the use of cutting setons in this group of patients. Patients 
with Crohn’s anal fistula tend to follow a chronic and recurrent disease course necessitating 
multiple interventions, and therefore efforts should be made to preserve continence where 
possible 295. The conservative advice given to less experienced surgeons suggests UK practice 
is aimed at avoiding iatrogenic exacerbation of fistulating disease and tends to favour 
management by experienced colorectal surgeons. 
 
The removal of seton timing varied with treatment intent, although in free text comments, 
respondents indicated that they tended to follow one of two published UK practices 86 296. The 
perceived advantage of early removal of a seton is the removal of a ‘splint’ maintaining 
patency of a fistula and allowing it to heal. The trade off is that removal too early in the 
treatment process might promote recurrent perianal sepsis. 
 
There is a wide range of procedures offered as definitive surgical options for patients with 
Crohn’s anal fistula. Draining seton alone, fistulotomy, fistula plug and LIFT have been 
described in the literature, with varying outcomes, although this is mostly observational and 
not trial based data98 102 295. The variety of choice in definitive surgery may reflect in part a lack 
of consensus and limited evidence for the surgical management of Crohn’s anal fistula but 
may also be influenced by individual surgeon expertise. Many of the respondents will refer on 
to specialists. This study did not record the subspecialisation of the respondent, so it is 




Much of the recent literature has focussed on a multimodal approach to Crohn’s anal fistula, 
with emphasis on sepsis control and institution of medical therapy (e.g. biologics) to aid fistula 
closure showing benefit over surgery alone 112 281. Current trials are investigating various 
permutations of this approach 94. It is encouraging that most respondents have access to an 
IBD MDT and utilise immunosuppressant drugs as part of their therapy, although only 28% 
routinely employ this approach. This study did not explore make-up of the IBD MDT or 
whether it was supported at a local or regional level. 
11.5.4 Specialist practice 
There is a group of surgeons who do not undertake proctectomy or stoma formation, or 
manage Crohn’s rectovaginal fistula. In light of the varied definitive options described, it is 
possible that a number of surgeons will simply place a seton and not offer any surgical options 
beyond that, perhaps preferring to refer on to specialist colleagues. Single centre experience 
with rectovaginal fistula, even in tertiary or quaternary centres comes from small cohorts 297 
298. As volume is associated with outcome in some aspects of colorectal surgery 299, perhaps 
centralisation of definitive surgery for Crohn’s anal fistula should be considered. This might 
offer better outcomes, but risks losing local expertise in peripheral hospitals 300. Those who 
do undertake proctectomy or stoma formation broadly agreed on indications for these 
procedures. It is of note that patient preference or request was a recognised indication, as 
quality of life in patients with Crohn’s anal fistula has been found to be improved in patients 








This study provides a current understanding of individual surgical approaches to Crohn’s anal 
fistula in the context of trends in national practice. Variation in practice will have implications 
for design of and implementation of future research interventions in Crohn’s anal fistula. 
Further work is required to reach consensus on standardisation of the Crohn’s anal fistula 
management pathway. In the interim, early and efficient control of sepsis, multimodal Crohn’s 
anal fistula management, and an emphasis on sphincter-preserving surgical techniques are 
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12.1.1 Local factors related to treatment 
Whilst a patient and clinician may be responsible for making decisions about investigations 
and treatment, the ability to implement these decisions is reliant upon a number of factors. 
Firstly, there is the recognition or suspicion of a diagnosis which leads to a decision to 
investigate or treat. The time interval from requesting an investigation to completion of the 
investigation will be dependent upon the available resource for the test, both in terms of 
number of appointments available for the resource, and the number of competing referrals 
for the resource. This is similar for the institution of a treatment strategy, although there may 
be additional safety tests such as blood tests or pre-operative assessment. This suggests that 
treatment strategies may also be ‘supply sensitive’. 
12.1.2 Patient pathway 
A patient pathway is a process or sequence of events where a patient is taken from referral 
or first related clinical activity, through to treatment301. These have been used in settings such 
as laparoscopic cholecystectomy302, complex biliary disease303, and oesophageal cancer304, 
and achieve more efficient use of resources with lower costs of care.  
 
Pathways are typically time bound. In the assessment of suspected cancer, a ‘31/62’ limit is 
used – 31 days to diagnosis, 62 days to first treatment305. Due to the tight time bounds on this 
pathway, there is a push to complete their treatment pathway as soon as possible. This may 
lead to prioritization of this group of patients over groups competing for the same resource. 
There is no pathway equivalent to this in the management of inflammatory bowel disease. 
This may be associated with variation in the investigation and treatment of Crohn’s anal 
fistula. Delays within this pathway may affect quality of life and may also influence the efficacy 
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of therapy. The pathway may be subject to variation due to individual clinician practice as 
demonstrated in chapters 10 and 11. 
12.1.3 Complexity in healthcare 
As outlined in previous chapters, the management of Crohn’s anal fistula is a complex 
intervention. This process requires input from multiple clinical teams, offering several 
different interventions according to different disease states of the patient. The Medical 
Research Council (MRC) has identified characteristics related to complexity in healthcare 
interventions306. These include number and type of interventions, the interaction of multiple 
groups and variability in outcomes and intervention types. A summary of these characteristics 
is shown in table 25.
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Component of complexity Explanation 
Number of interacting components within 
experimental and control interventions 
Decisions about treatment made by a common team 
Number and difficulty of behaviours required 
by those delivering or receiving the 
intervention 
Behaviour of staff within assessment may affect outcome. For example where behaviours related to 
health promotion behavior are required at each clinical contact, this may reflect excessive number 
of new behaviours for an intervention to be consistent. 
Number of groups or organisational levels 
targeted by the intervention 
Where only one group e.g. surgeons require behavior or practice modification for an intervention, 
this is more likely to be achievable than modifying practice or behaviours of several groups. 
Number and variability of outcomes Assessment of an outcome is difficult where outcomes are non-binary and associated with multilple 
health states. This makes measurement more challenging. 
Degree of flexibility or tailoring of the 
intervention permitted 
A complex intervention may be more than administration of a single intervention or drug. It may 
require tailoring of the intervention to patient factors including disease states. 
Table 25 Summary of components of complexity as defined in the Medical Research Council 2008 framework. 
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These contributors to complexity arise from an evaluation perspective and are thought to 
exert direct and indirect influences on outcomes307. The MRC recognises that for these 
interventions, causation cannot always be definitively proven in standard randomised trials306. 
The MRC proposes that alternate methods of evaluation should be considered.  
 
A related system for assessing outcomes lies in ‘realist evaluation’; a branch of social science 
research concerned with complex evaluations which asks ‘what works, for whom and in what 
setting?’. It is based upon the assumption that each intervention has a context and mechanism 
arrangement that explains outcomes (Figure 29)308. Context refers to the setting of the 
intervention and includes resource and behavioural factors associated with the intervention. 
This may explain why rates of MRI imaging may be high in a centre with easy access to an MRI 
scanner compared to lower rates in a centre with limited access to this modality. Resource 
availability may modify behaviours meaning that use declines in a centre with limited access.  
Mechanism refers to how an intervention works. For example, an intervention where patients 
had to undergo drainage of perianal sepsis within 24 hours of presentation may be achieved 
differently in different units. One hospital might place all patients on the emergency list to 
undergo sepsis drainage by a junior surgeon with limited experience, others may provide 
access to a consultant theatre list for expert management. It is possible to imagine how this 
might affect outcomes; those undergoing procedures by less experienced surgeons might 






Figure 29 Summary of context-mechanism-outcome model and example of intervention 




Both of these methods for evaluation are designed to be used in prospective evaluation of a 
complex intervention. That is not possible within the context of this study, although principles 




The primary aim of the study was to explore the pathway from presentation with symptomatic 
Crohn’s anal fistula to treatment with anti-TNF therapy in specialist hospitals with the 






12.3.1 Pathway start and end point 
The start-point of the patient pathway was selected as the point of presentation with a 
symptomatic fistula, in any clinical setting. Guidelines state that initial treatment should be 
control of sepsis and use of anti-TNF-α therapy111. As outlined in the previous chapters, 
patients would often undergo multiple assessments and interventions along this pathway, 
and there is relative agreement on how an initial presentation should be managed. Given this, 
and the variation in treatment options, it was determined that the end of the patient pathway 
should be first treatment with anti-TNF-α therapy. Patient pathways may diverge at this point 
to include other medical therapies or operations, but all should pass through this treatment 
node. 
12.3.2 Pathway nodes of interest 
A patient pathway includes key steps. Working with a group of gastroenterologists and 
surgeons, it was expected that a patient pathway might reasonably include one or more of: 
• Surgical outpatient appointment 
• Gastroenterology outpatient appointment 
• Inflammatory Bowel Disease Clinical Nurse Specialist outpatient appointment 
• Magnetic resonance imaging scan of the pelvis 
• Examination under anaesthesia or other planned surgical procedure 
• Emergency surgical procedure to assess or treat perianal sepsis or pain 
12.3.3 Retrospective design 
A prospective cohort design was not feasible for this study. There is a lack of data on the UK 
incidence of Crohn’s anal fistula, and have no benchmark upon which to base estimates of 
pathway length. This means that estimation of sample sizes, and costing of a research project 
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to pathway completion was not possible. This study has been reported in line with the 
‘strengthening reporting in observational studies’ (STROBE) guideline309. 
 
Whilst surgical research is derided for use of retrospective data178, it serves an important 
purpose here: it allows exploration of readily available data to inform any prospective study 
design. As this study uses primarily administrative data, there should be low levels of missing 
data in the study design. A further consideration is that a prospective study with active 
observation might introduce observer bias. 
12.3.3.1 Approvals 
The data collected for this study is routinely collected, and forms part of an assessment of 
practice. As such, it falls under the remit of service evaluation. This means that authorisation 
to conduct this work is given by local clinical governance teams, rather than the NHS research 
and ethics committee. Local approvals were secured for each participating site. The approval 
documents for the Sheffield site are shown in appendix L. Outside governance approvals, each 
site was required to have approval of a gastroenterologist and surgeon as data related to both 
departments would be under review. 
12.3.3.2 Participating sites 
Three centres were selected to participate in this study. These centres are recognised as 
having well developed IBD services, with access to all relevant investigative and therapeutic 
options. The participating centres were Sheffield Teaching Hospitals NHS Foundation Trust, 
Cambridge University Hospitals NHS Foundation Trust, St Mark’s Hospital, London Northwest 
Healthcare NHS Trust. These sites were selected as they provide a comparable context308 for 




12.3.4 Case identification 
Cases were identified using a convenience strategy with no formal power calculation. Cases 
were identified through administrative clinical coding. The International Classification of 
Diseases (ICD) published by the World Health Organisation provides a standardized method 
for reporting diseases and comorbidity by disease system. This system identifies Crohn’s 
disease using the reference K60.x and perianal diagnoses as K61.x . At the time of writing, the 
10th revision of this document was in use310.  Hospital administrative databases were searched 
using ICD-10 clinical codes K50.x (Crohn’s disease) AND K60.x OR K61.x (anal fistula), for 
events between 2010 and 2015. Identified cases were cross-checked against local biologic 
therapy databases to confirm which patients had received anti-TNF treatment. Patient 
records were retrieved for identified cases. 
12.3.5 Inclusion Criteria 
Adults with newly symptomatic Crohn’s anal fistula not on anti-TNF therapy at the start of the 
study period, and who had received anti-TNF therapy by the end of the study period, were 
included. Those with non-fistulating perianal manifestations of disease, those who declined 
anti-TNF therapy, and those who transferred care from one hospital to another during the 
study, were excluded. 
 
Demographic and clinical data extracted from clinical records included: time since diagnosis 
of Crohn’s disease at beginning of pathway, and prior anti-TNFα, thiopurine or methotrexate 






12.3.6 Data extraction 
Data extraction was performed by a collaborator at each site. Pathway data extracted 
included: date of first presentation with symptomatic fistula within the study period, date of 
first anti-TNFα dose, date, location and specialty of all IBD-related documented clinical 
interactions (outpatient/inpatient), timing of MRI scans, and visits to operating theatre 
(planned and unplanned). All data were anonymised prior to transfer to the lead side through 
a secure email system (nhs.net). 
12.3.7 Analysis 
Overall pathway length was calculated as time from first presentation to time of first dose of 
anti-TNF in days. Clinical events identified included attendance at surgical and medical 
outpatient clinics, MRI scans, admissions, and surgical procedures. Time to transition from 
each care event (i.e. medical outpatients, surgical outpatients, medical admissions, radiology 
(MRI), elective theatre) was for each event in days. Mean number of events per pathway was 
calculated, as was the rate of care events and unplanned readmission per 30 days of pathway 
(care events/(pathway length/30). These values were plotted following log transformation to 
normalise the distribution. 
 
Comparison of medians between groups was performed using Mann-Whitney U-test. Other 
statistical tests used are indicated in parenthesis. A p value of <0.05 was set as the threshold 
for statistical significance a priori. This study was registered as a service evaluation with audit 



















12.4.1 Summary of included cases 
Clinical coding identified a total of 311 cases across all sites. Following removal of duplicates 
and excluded cases, a total of 79 (25.4%) of patients were eligible for the study. These were 

















12.4.2 Clinical characteristics 
54 patients (68%) had a pre-existing diagnosis of Crohn’s disease (CD). The date of diagnosis 
was confirmed from clinical records. In these patients, the mean time from diagnosis of CD to 
presentation in this study was 9.5 years (S.D.+/-7.2). Patient phenotype is presented in table 
1. Of the 54 patients with a prior diagnosis of CD, 14 (25.9%) had previously received anti-
TNFα therapy, 27 (50.0%) had previously received thiopurine agents, and 1 (1.8%) 
methotrexate. The Montreal classification of included patients is presented in table 26. 
 
 
 A1 A2 A3 
 L1 L2 L3 L1 L2 L3 L1 L2 L3 
B1 1 1 2 5 14 13 1 2 2 
B2 0 2 0 1 0 4 0 0 0 
B3 0 1 4 2 11 10 0 1 2 
Table 26 Montreal Classification of Included Patients. 
This defines phenotype of disease by age at diagnosis (A1= less than 16 years old, A2 
= between 17 and 40 years old, A3 = more than 40 years old), location of disease (L1 = 
ileal, L2 = colonic, L3 = ileocolonic) and behavior of disease (B1 = non-stricturing, non-
penetrating B2 = structuring, B3 = penetrating (all would have prefix of ‘p’ for perianal 





12.4.3 Interval between presentation and anti-TNF treatment 
The median time from presentation of a symptomatic Crohn’s fistula to receiving the first dose 
of anti-TNF therapy was 204 days (almost seven months)(IQR 113-453 days) (Figure 31) across 
the whole cohort. The median interval for patients with existing CD was 174 days compared 
to 365 days for those with a new diagnosis of CD (p=0.019).  There was no significant 
difference in the median length of the pathway in those patients with a pre-existing diagnosis 
of CD according to whether they had or had not received anti-TNF in the past (136 vs 199 days, 
p=0.29). 
 
Figure 31 Kaplan Meier chart showing time from entry into pathway to receiving anti-TNF. 




Number of care events per 30 days underwent log transformation. Longer pathways showed 
a negative correlation with the number of clinical events per 30 days of the pathway 
(Spearman r = -0.87, ((-0.91 to -0.79) p<0.01) and with unplanned readmissions Spearman r = 
-0.95 ((-0.97 to -0.91) p<0.01) (figure 32). This suggests that longer pathways are not 
associated with increased clinical activity, which might suggest underlying difficult to treat 
disease. Similarly, the longer pathways are not associated with increased rates of emergency 




Figure 32 Log transformation of rates per 30 days of pathway for any clinical event, 
and unplanned admission by  length of pathway (days). 
Both show significant negative correlation of rates with pathway length. (Clinical 
event Spearman r = -0.87, (-0.91 to -0.79) p<0.01; Unplanned readmission Spearman 
r = -0.95 (-0.97 to -0.91) p<0.01. 
 
12.4.4 Route of access and outpatient use 
Overall, 29(36.7%) of 79 patients initially presented via an acute surgical route, 5(6.3%) 
presented via a medical admissions unit, 21(26.6%) and 22(27.8%) via surgical outpatients and 
medical outpatients respectively, and 2(2.5%) presented through contact with an IBD 
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specialist nurse. For those 25 patients with no prior diagnosis of CD, 9(36.0%) presented via 
surgical outpatients and 9(36.0%) as an acute surgical admission. 7 (28.0%) patients presented 
through medical outpatients. The distribution of point of access by diagnosis is detailed in 
Table 27. The mean number of surgical outpatient events per patient was 1.10, and the mean 
number of medical outpatient events per patient was 1.49.  
 





7 (28%) 15 (27.8%) 22 (27.8%) 
Acute medical 
admission 
0 5 (9.3%) 5 (6.3%) 
Surgical 
Outpatients 
9 (36.0%) 12 (22.9%) 21  (26.6%) 
Acute surgical 
admission 
9 (36.0%) 20 (37.0%) 29 (36.7%) 
IBD Specialist 
Nurse 
0 2 (3.7%) 2 (2.5%) 
Table 27 Point of access to pathway split by whether patient had new or existing diagnosis of 
Crohn’s disease. 
Numbers denote number of patient accessing through each route, with percentage of 
study population in brackets 
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12.4.5 Frequency of MRI scanning 
An MRI was performed in 59 (74.6%) of patients during the pathway. Of those undergoing 
MRI, 42 (71.1%) underwent one scan, 15 (25.4%) patients underwent two MRI scans. One 
patient each (1.69%) underwent three and six MRI scans. The mean number of MRI was 1.03 
per patient. 
 
12.4.6 Frequency of surgical interventions 
Of the 79 patients, 72 (91.0%) underwent a total of 140 surgical procedures, including 
examination under anaesthetic, seton insertion, drainage of sepsis, or other fistula procedures 
(see Table 28 for breakdown). Of these, 36 (50.0%) had a single procedure, 17 (23.6%) had 
two procedures, 6 (8.3%) had three procedures, 13 (18.0%) had four procedures. The mean 
number of operations was 1.9 per patient.  
 
Procedure performed Number (percentage of all procedures) 
Examination under anaesthetic 14 (10.0%) 
Drainage of abscess 39 (27.8%) 
Insertion of seton 67 (47.8%) 
Lay open of fistula 10 (7.1%) 
Anal fistula plug 1 (0.7%) 
Video assisted anal fistula treatment (VAAFT) 1 (0.7%) 
Seton removal 5 (3.5%) 
Stoma formation 2 (1.4%) 
Proctectomy 1 (0.7%) 




12.4.7 Time to transition 
Time to and from each point of care (medical or surgical outpatients, medical or surgical 
admission, nurse specialist appointments, MRI scans and elective theatres) was calculated. 
Transition from medical outpatients or admission to surgical outpatients tended to be shorter 
than transition from surgical admission or outpatients to medical outpatients (32.0 vs 56.5 
days; p = 0.08) (Table 29). The median time to commencement of anti-TNF from last clinic 
appointment was 77 days (IQR 27.5-225.5 days). 
 
         
            To 
From MRI SOPD MOPD MAU SAU CNS Elective Theatre 
MRI - 42 29 - 19 - - 
SOPD 24 51.5 56 - 59 - 22 
MOPD 34 35 89.5 16 70 43 35 
MAU 24 11 26 - 18 - - 
SAU 29.5 45 75 60 61 - 0 
CNS 16 40 39 18 - - - 
Elective 
Theatre - 59 48.5 55.5 38 25 73.5 
Table 29 Table showing median time to move from one part of the pathway to the 
next. 
Point of origin is in the left column, and destination is in the horizontal column. ‘–‘ 
indicates no data available. MRI = Magnetic Resonance Imaging, SOPD = Surgical 
Outpatient Department, MOPD = Medical Outpatient Department, MAU = Medical 





12.4.8 Establishing Current Pathways 
Based upon this data, there are 3 potential clinical pathways from presentation of perianal 
Crohn’s disease to anti-TNF therapy.  The pathways are essentially determined by mode of 
presentation.  
 
Surgical outpatient presentation 
Patients presenting to surgical outpatients tend to undergo elective surgery (median wait 22 
days), followed by attendance at medical outpatients (median wait 48.5 days). Most then 
undergo an MRI (median wait of 34 days) then return to medical outpatients (median wait 29 
days). After this, they will be started on anti-TNF therapy (median wait 77 days).   
 
Emergency surgery presentation 
Patients entering the pathway via acute surgical admission will undergo MRI (median wait 
29.5 days), before attending for surgical follow up (median wait 42 days) and undergoing 
elective surgery (median wait 22 days), and then attending medical outpatients (median wait 
48.5 days) and accessing anti-TNF therapy (median wait 77 days).  
Medical outpatient presentation 
Finally, patients may present to medical outpatients and be referred for an MRI (median wait 
34 days), before referral for a surgical opinion (median wait 42 days) and undergoing elective 
surgery (median wait 22 days). They may then proceed to anti-TNF therapy (median wait 77 
days) (see figure 33).  
 
It is important to note that these reflect frequently represented pathways for the whole 
cohort. As suggested by above findings, some patients will have multiple clinic appointments 
and multiple MRI scans. Patients presenting to the surgeons as an emergency typically 
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underwent outpatient MRI scan, although a small number underwent emergency 






Figure 33 Typical pathways of patients from presentation with Crohn’s anal fistula to commencement of anti-TNF therapy 
a) for patients presenting to surgical outpatients, b) for patients presented acutely to the surgical team and c) for patients presenting initially 
to the medical outpatient team. Curved arrows are labelled with median waiting times (in days) between sequential steps in the pathways 




This is the first study to assess the delays between presentation of perianal Crohn’s disease 
and initiation of biological treatment. It has shown that the median pathway length is 
substantial, even in centres with an established IBD service.  There is median delay of 204 
days.  In one case, the delay extended to over five years.  This study identifies two particular 
barriers to a shorter patient pathway: establishing the initial diagnosis of Crohn’s disease in a 
patient with newly diagnosed fistula, and referral or access to medical services by surgeons.  
 
12.5.1 Barriers to diagnosis 
Perianal fistula may be the first presentation of Crohn’s disease in 15% of patients32. Some 
presentations of perianal disease may be immediately apparent as Crohn’s disease.  There 
may be clinical features typical of Crohn’s disease such as florid oedematous skin tags, 
multiple fistulae and proctitis.  In others without these pathognomic features, patients may 
be treated initially as having cryptoglandular disease. There is currently no other diagnostic 
tool allowing early identification of disease Crohn’s disease. In addition, acute perianal 
abscesses, presenting as an emergency, may be treated by a less experienced junior surgeon, 
possibly with limited senior input and sometimes minimal follow up again contributing to 
appropriate management delay 
 
12.5.2 Complexity in the patient pathway 
Patients with suspected Crohn’s disease do not qualify for enhanced pathways available to 
patients with suspected cancer, and yet the unrelenting disease process may mean that by 
the time of clinical review, disease progression may necessitate a return to an earlier point in 
the pathway. For example, further urgent surgery to drain recurrent infection, or repeat MRI 
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scan to assess newly arising fistula tracks. Even if the patient has an uncomplicated disease 
pathway, the wait for medical, radiological and surgical review or intervention lead to 
substantial delay in treatment with a consequent impact on quality of life and potentially on 
long-term outcomes and likelihood of successful treatment.   
 
Options to reduce the delays at each of these steps should be considered, and could include 
agreed fast track referral pathways between medical and surgical arms of the IBD service – 
including directly into surgical admissions units and back to receive anti-TNF-α infusions. 
Combined in-patient rounds and out-patient clinics are likely to help the rapidity of diagnostic 
clarity and appropriate decision-making with respect to appropriate treatment. Even more 
than this may be required – an open door policy with the multidisciplinary team interacting 
on a daily basis rather than just meeting periodically may facilitate the interdisciplinary clinical 
conversations that potentially smooth a patient’s journey with a difficult and complex 
condition.  
12.5.3 Basis for time driven pathway 
This work is driven by the view that earlier anti-TNFα is better than later anti-TNFα for both 
clinical outcome and quality of life benefits. No trial has tested this hypothesis. Evidence 
suggests that duration of fistula presence is a poor prognostic factor indirectly suggests 
benefit of a time-based approach311 312. However, given the impact of fistula symptoms on 
quality of life and the common situation where disease deteriorates whilst waiting for the 
next step in the pathway, a streamlined pathway would seem sensible. 
 
12.5.4 Limitations 
There are limitations to this study, particularly its retrospective nature.  We have only 
captured the timing of events, not the intention that lead to the event (e.g. routine vs urgent 
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follow-up), nor have we captured factors related to patient choice.  We have also defined the 
pathway as terminating only when anti-TNF therapy has been commenced.  Nevertheless we 
feel that focusing on this element of the treatment pathway is relevant as both a surrogate 
for i) the experience of these patients in terms of symptomatic debility43 313, and ii) because of 
the perception that delays in treatment may be associated with a poorer outcome – a finding 
replicated in other aspects of Crohn’s disease314 315.  
 
There is a high level of variation in pathways to anti-TNF therapy for patients with perianal 
Crohn’s fistula disease.  In most cases the delay to treatment is substantial.  It is very likely 
that such delays affect both quality of life and overall outcome.  These findings could be used 
to test strategies to reduce delay, or to understand barriers to implementation of effective 
treatments from randomised trials into clinical practice. 
 
12.6 Conclusion 
There is delay in many of the elements of the pathway in patients with Crohn’s anal fistula. 
In particular, commencement of anti-TNF therapy is often delayed with new diagnoses of 
Crohn’s disease waiting 365 days and patients with established CD waiting 174 days. 
Diagnosis is a challenge in patients with first presentation of Crohn’s disease.  Resolving 
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13.1.1 Variation in management 
Crohn’s disease has been associated with perianal fistulation since the condition was first 
described, with around 33% of Crohn’s patients affected 316. Management of Crohn’s anal 
fistula presents particular challenges related to heterogeneity in presentation and disease 
course, and the need for long-term immunosuppressive medical therapy and multiple surgical 
interventions138 174. As outlined in previous chapters, there are a several different surgical 
treatments available for Crohn’s anal fistula and in outcomes following surgery.  
 
The previously reported survey of surgical management of Crohn’s anal fistula indicated that 
some areas of practice showed variation, including antibiotic choice, imaging modalities and 
use of draining setons. There was also variation in other aspects of management such as 
optimisation of multimodal care and selection of definitive surgical procedures317. 
 
13.1.2 Guidelines to inform practice 
A guideline provides recommendations on a set of clinical actions or processes, summarising 
best practice for a given condition. There are broadly speaking three types of guideline – 
evidence based, evidence-based consensus, consensus without evidence base. Evidence 
based guidelines are considered the most robust and reliable form of guideline, although they 
require significant time and resource to develop318. An evidence-based consensus guideline is 
‘a public statement on a particular aspect of medical knowledge that is generally agreed upon 
as an evidence-based, state of the art knowledge by a representative group of experts in that 
area’319. Where evidence is lacking, it might be appropriate to undertake a non-evidence 




13.2 Delphi methodology 
 
 
13.2.1 Background to the Delphi Process 
 
The Delphi process was conceived by the RAND corporation in the 1950s320. It was originally 
used as a forecasting method for the likelihood of Russian bombing attacks on the USA. It was 
subsequently policy makers, and recognised for its role in facilitating group communication 
around complex situations321. In recent years, it has been adopted as a method to achieve 
consensus in health-related matters. It broadly uses method of item generation, followed by 
prioritisation through iterative voting, with a final consensus (figure 34). Those participants 
informing the consensus are typically invited experts or other stakeholders. The use of experts 
in this process gives rise to the name of the process, referring to the Oracle at Delphi in Greek 
history322. 
 
13.2.3 Method of Delphi consensus 
 
Study design 
Prior to beginning the study, it is important to define the aim of the exercise. A short, open 
question may be posed to address the question, or a set of statements may be proposed, 
with the facility for participants to add their own statements for discussion321. 
 
Panel selection 
It is important that a panel includes a broad selection of participants representing a range of 
views, not just those the organiser wishes to endorse. Some methodologists consider a Delphi 
consensus to be a jury of peers323, therefore the jury should be representative. This can be 




Round 1: Item generation 
In the first round, items for inclusion are drawn from different sources. These include those 
identified through systematic review of the literature, through supporting qualitative or 
quantitative work, or those identified by an expert panel as being of relevance. Participants in 
this round can add additional items for voting321 324. The process of voting is summarised in 
figure 34. 
 
Subsequent rounds: Iterative voting and ranking of items 
During subsequent rounds, each item undergoes further votes. Responses from previous 
rounds are presented to participants to allow interpretation of the group consensus. The 
number of items may be reduced where agreement cannot be reached after rounds of 
voting321 324. Voting is anonymous and ensures that all participants voices are valued equally. 
 
Final round: Agreement of consensus 
The final round of voting may occur as early as round two322. Where consensus is reached, 
participants should be willing to commit to and support the resulting statements324. 
 
 
Figure 34 Summary of Delphi methodology 
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Modifications of Delphi methodology 
The key principles of Delphi are anonymous and iterative voting. This means that rather than 
being held remotely, a consensus exercise can be held in one location providing anonymity 
can be achieved. Similarly, it is possible to use a quasi mixed-method approach to 
predetermine statements for voting324. Both strategies may be employed to reduce the time 
taken to achieve consensus. 
 
13.2.2 Strengths and limitations of the Delphi process 
Unlike other methods of prioritisation such as nominal group or Q sort, Delphi is designed to 
achieve consensus324. Iterative voting and discussion allows experts on the panel to 
understand point of view of others to achieve consensus. It also fosters collaboration amongst 
the group of experts; this is the same group likely to be responsible for implementing any 
findings321 324. 
 
These strengths can also be considered a weakness, as the desire to achieve consensus can 
lead to a central tendency, avoiding extreme statements. This may lead to the group agreeing 
a position that does not provide new information324. This is a particular problem when expert 
groups provide generic statements to avoid areas of disagreement, meaning that statements 
have no significant influence upon practice323. The method can also require a significant period 
of time to complete and reach consensus322. Improper selection of the panel can also lead to 
bias due to inadequately representation of belief or opinion. 
 
13.3 Aim 
The aim of this exercise was to establish UK evidence-based consensus on surgical 




13.4.1 Justification of consensus methodology 
To establish consensus amongst UK colorectal surgeons, a pragmatic approach to consensus 
methodology had to be taken. An electronic Delphi approach would be conducted over a long 
period of time and may lead to attrition from an already small pool of participants. Alternative 
methods such as nominal group technique would require long periods of time with intense 
negotiation, limiting the number of items that could be addressed in available time.  
 
With these considerations, it was decided that generation of evidence-based items prior to 
voting, voting without discussion, time for discussion, and a second vote, would be the 
appropriate approach. This means that the methodology used took the form of a modified 
Delphi Technique. This method has been used as an accepted variant324. 
 
13.4.2 Item generation 
Potential statements for inclusion in the consensus were developed by an expert group of 
colorectal surgeons and gastroenterologists with specialist interest in managing inflammatory 
bowel disease (IBD).  All statements were based on systematic literature review, and current 
practice based on responses to the survey of surgical practice described in previous chapters.  
 
Statements were prepared in five principal areas of practice: i) context, ii) assessment and 
management of an acute presentation of Crohn’s anal fistula, iii) operative and perioperative 






Participants in the consensus were invited as they had indicated interest in contributing 
through completion of the questionnaire, or following advertisement of the exercise by the 
Association of Coloproctology of Great Britain and Ireland (ACPGBI), the UK colorectal 
specialty association  
 
13.4.2 Voting 
Each statement was presented to the group of experts, and an initial vote undertaken 
electronically using ResponseCard® (Turning Technologies, UK), allowing contemporaneous 
and anonymous recording of votes, with responses visible to participants.  
 
The initial vote was followed by debate amongst experts and refinement of the wording of 
the consensus statement prior to a reiterative second vote. Voting was undertaken using a 
five-point Likert scale, ranging from ‘strongly disagree’ to ‘strongly agree’. 
 
Consensus was defined a priori as ≥80% of respondents voting in agreement (either agree or 
strongly agree). Participants could change their final vote until closing of that vote, once all 
votes were cast.  
 
Weighting was attached to each statement based on the available evidence and strength of 
recommendation. This classification was based upon modified GRADE criteria, as used in other 
consensus documents 176 325. In summary, this method ranks recommendations as ‘1’ (strong) 
or ‘2’ (weak). These are modified with a letter to indicate the level of evidence supporting this. 
‘A’ denotes high quality evidence such as a well-conducted randomised controlled trial or 
meta-analysis. ‘B’ identifies moderate quality evidence such as a non-randomised trial or 
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prospective study. ‘C’ identifies low quality evidence such as retrospective studies or case 
series. ‘D’ is used where expert opinion supports the recommendation. Grading was carried 
out by the steering group. The consensus process is summarised in Figure 35. This exercise 










The consensus group consisted of 17 Consultant Colorectal surgeons and two patient 
representatives. The colorectal surgeons all had a declared interest in inflammatory bowel 
disease. The patient representatives had engaged with the ACPGBI Delphi process and 
regularly shared experiences of patients treated for aspects of inflammatory bowel disease, 
including Crohn’s anal fistula. A total of 51 statements were considered. Responses to 
accepted statements are presented below, along with the results of the final vote (SA – 
Strongly Agree, A – Agree, N – Neutral, D – Disagree, SD – Strongly Disagree). Rejected 
statements are summarised after each section, along with reasons for rejection. 
13.3.1 Context – Accepted Statements 
Fistulating perianal Crohn’s disease is frequently a chronic condition. 1A 
It is recognised that patients with fistulating perianal Crohn’s disease may heal, although the 
majority of patients will have recurrent or non-healing fistulating disease174. This typically 
requires long-term medical therapy and repeated surgical procedures138. 
Management of fistulating Crohn’s anal fistula should take a patient-centred approach. 1C 
The preferences of surgeons and patients in surgical treatments have been shown not to align 
in some aspects of Crohn’s disease 326. Due to the chronic nature of the disease, treatments 
should be tailored to the needs and goals of each patient. Some patients may prefer symptom 
palliation while others may aim for definitive management aimed at fistula eradication. These 








Prognostic factors for successful healing include: 
Absence of proctitis. 1A.  
Short duration of fistulating disease. 1C.  
Non-Smoking status. 1C.  
‘Simple’ fistula. 1C.  
Prognostic factors for failure of healing include: 
Proctitis. 1A.  
Active Smoking status. 1C 
‘Complex’ fistula. 1C. 
Prognostic factors for healing and failure of healing have been identified in studies ranging 
from retrospective cohorts to prospective trials. Proctitis is a predictor for proctectomy in a 
number of retrospective studies 248 327. Complex fistulae (i.e. those which are not short, low 
tracks as per the American Gastroenterology Association classification) 216 are associated with 
poor healing rates. Smoking status has an impact on the overall activity of Crohn’s disease, 
increasing the rate of relapse 328. The duration of fistulating disease reflects the perception 
that it may be easier to manage a ‘fresh’ fistula rather than a well-established, fully 
epithelialized fistula.  This has been identified as a significant prognostic factor in an open 
label study, where it was treated as a continuous variable with no predictive cut-off 
reported329. Despite the importance of these factors in response to treatment, randomised 
controlled trials have not undertaken adequate stratification to mitigate effects across 
treatment arms 76 93. It is worth noting that the ongoing PISA trial has specifically included 
early seton removal in both interventional arms94again suggesting that clinicians place 
importance on likelihood of successful treatment if fistulae are of relatively recent onset. 























13.3.2 Acute Management – Accepted Statements 
Perioperative metronidazole should be used in selected cases in the acute setting. 1B 
The majority of the literature assesses both ciprofloxacin and metronidazole 287. The 
consensus group preferred to use metronidazole, in line with survey results177. This may 
reflect UK antibiotic practice and avoidance of ciprofloxacin due to its causative link with 
Clostridium difficile infection330, although this is thought to be lower in CD populations than 
other populations 331. Ciprofloxacin has been used in the longer term as an adjunct to anti-
TNF therapy in Crohn’s anal fistula, although this has had varied results 88 289. The consensus 
group did not advocate antibiotics in all patients presenting acutely with Crohn’s anal fistula. 
The specific circumstances where the consensus group would recommend antibiotics were in 
the presence of local cellulitis or induration, systemic sepsis, immunosuppression, or where 
there might be a delay before drainage of sepsis. 
 
Acute operative management should involve drainage of any abscess. 1B 
 
An experienced colorectal surgeon should consider placing draining seton(s) in readily 
identifiable fistulae. 1B 
 
Sepsis control is the principal aim of surgical drainage in the acute setting, and therefore 
drainage of any abscess is advised. If fistulae are readily identifiable, then a seton should be 
placed acutely at the time of abscess drainage332. In this setting, tissue is potentially friable 
and oedematous and there is an increased risk of creating false tracks  333. Given this, the 
expert agreement was that only those with appropriate experience should place a seton in 
this setting.  
Cutting setons should not be used in perianal Crohn’s disease. 1D 
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Historically prevalent, and occasionally still used in fistula surgery, the cutting seton was 
rejected for use in Crohn’s anal fistula by the consensus group. This corresponds with current 
UK practice;90% of surgeons would never consider a cutting seton in this setting 177. Due to 
the nature of the disease and recurrent procedures, cutting setons were felt to carry 
unacceptably high risk of future incontinence334.  Voting results for accepted acute 
management statements are presented in figure 37. 
 
 
Figure 37 Voting results for accepted acute management statements 
 
13.3.3 Acute Management - Rejected statements 
Selected patients should undergo an MRI scan preoperatively 
SA: 0% A: 63% N: 19% D: 13% SD: 6% 
The seton material of choice is a silastic sling 
SA: 13% A: 13% N: 31% D: 38% SD: 6% 
The consensus group felt that whilst a ‘road-map’ MRI might be useful, the primary aim in this 
setting was control of sepsis and that this should not be delayed. Responses to seton choice 
in the survey were heterogenous. Participants in the consensus indicated use of Ethibond®, 
silastic slings and Comfort drains™ (CJ Medical, Truro, UK)177.  
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13.3.4 Initial Elective management – Accepted Statements 
Draining setons should be placed in fistula tracks at first elective Examination Under 
Anaesthesia. 1A 
The use of draining setons in this setting is well described. This allows ongoing drainage of a 
track as a bridge to immunomodulatory therapy 281. It may not be technically possible to insert 
a seton in every case.  
Selected patients will require MRI of the perineum. 1C 
MRI of the perineum is the most commonly used imaging modality in UK Crohn’s anal fistula 
practice 177. Precise indications for MRI did not emerge from discussions but it was apparent 
that not all surgeons would request MRI in all patients. Some surgeons would prefer to have 
imaging before undertaking an elective examination under anaesthetic, to aid localisation of 
fistula openings and any residual sepsis. Other surgeons indicated that they would use MRI 
post-operatively to assess resolution of fistula-related sepsis after placement of setons 86. 
 
Selected patients will require repeat examination of rectum under anaesthetic. 1D 
A second examination may be of benefit in a patient with on-going symptoms, or those where 
it was not possible to place draining setons at first operation. An experienced colorectal 
surgeon is usually able to define fistulae and control sepsis, a pre-requisite to biologic therapy 
335 336. 
 
Presence or absence of proctitis should be established with diagnosis of perianal Crohn’s 
fistula. 1B 
 
Proctitis is felt to be a prognostic indicator for successful management of Crohn’s anal fistula 
and presence of proctitis requires focus of attention on disease control with 
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immunomodulation 337-339. As such, presence or absence of proctitis should be confirmed at 
the first opportunity following diagnosis. 
 
If Crohn’s disease is suspected, then diagnostic confirmation should be sought with 
colonoscopy and/or imaging 1B 
 
Colonoscopy can be used to assess for proctitis, and also the terminal ileum for evidence of 
Crohn’s disease. This may be useful in cases where perianal fistula is the first presentation of 
IBD. Choices for cross-sectional imaging typically include CT to assess for terminal ileal 
pathology, or MRI small bowel series to confirm the phenotype of disease 340. Despite the 
reported performance of faecal calprotectin 61, variation in levels based on location of disease 
341 and the reported sensitivity to other causes of inflammation in the gut meant that it was 
not recommended in this setting. Voting results for accepted initial elective management 
statements are presented in figure 38. 
 






13.3.5 Multidisciplinary management 
All patients with perianal Crohn’s disease should be discussed in a multidisciplinary setting. 1D 
 
All surgeons managing perianal Crohn’s disease should use a multidisciplinary approach. 1A 
 
Current best practice in Crohn’s anal fistula management uses both medicine and surgery to 
achieve fistula closure 95 112 281. In order to achieve this, it requires surgeon and physician to 
work together, along with the wider multidisciplinary team (MDT) including clinical nurse 
specialists, pathologists and gastrointestinal radiologists. Although there is evidence for 
multimodal (multidisciplinary) management, there is, at present, no evidence for a formal 
MDT meeting in the management of these patients 112. However, it is recommended as an IBD 
service standard by the Royal College of Physicians342. 
 
Medical therapy is best directed by a gastroenterologist. 1D 
 
Surgical opinion is important in decisions about medical therapy. 1D 
 
In keeping with the multidisciplinary approach, medical therapy should be directed by a 
gastroenterologist. The surgeon may be able to offer insight on operative findings that could 
influence multimodal management. These should be taken into account when considering 
modification of therapy 112. 
Steroids should not be used in isolated perianal Crohn’s disease. 1B 
 
There is no evidence for the use of systemic steroid therapy in the treatment of Crohn’s anal 





Multidisciplinary discussion about anti-tumour necrosis factor-α therapy should occur 
promptly after sepsis control. 1B 
 
Whilst there is no body of evidence on timing of biologic therapy, use of biological agents 
including anti-TNF-α agents, is considered to be an important aspect of successful symptom 
control in Crohn’s anal fistula 75 77 79. This is already recognised by the majority of surgeons 
managing this condition 177. Biological therapy should be addressed soon after control of 
sepsis and may avoid unnecessary delay in healing.  
 
Timing of removal of a seton should be a multidisciplinary decision involving the patient. 1D 
Optimal timing of seton removal after induction with anti-TNF-α therapy has not yet been 
established. 1A 
 
A number of factors may influence seton use including the anatomy of the track, patient 
symptoms and therapeutic intent (palliation of symptoms vs. closure of fistula tracks). At 
present, the evidence base has not defined the optimum time for seton removal. Previous 
work has discussed the timing of seton removal in relation to induction with biologic therapy 
86 344. Typically reported management in the surgical survey177 preferred the previously 
reported strategy of seton removal around the second dose of anti-TNF therapy296. Given the 
degree of uncertainty, decision-making should be guided by clinicians, but shared with the 
patient. Voting results for accepted multidisciplinary management statements are presented 





Figure 39 Voting results for accepted multidisciplinary management statements 
 
13.3.6 Multidisciplinary Management - Rejected statements 
Further surgical management should be undertaken by a core member of the IBD 
multidisciplinary team.  
SA: 13% A: 38% N: 6% D: 25% SD: 19% 
 
The definition of an IBD MDT was felt to be inadequately established, such that defining a 
‘core member’ would be problematic. 
13.3.7 Definitive Surgical Management – accepted statements 
Sphincter preserving techniques should be used in a stepwise fashion based on functional risk. 
1C 
SA: 61% A: 39% N: 0% D: 0% SD: 0% 
With repeated surgical procedures and metachronous fistulae, options for surgical 
management should be considered in light of their likelihood of success and impact on 
immediate and future continence. Selection of initial procedures aimed at healing should 
weigh up success rate against risk of incontinence in the context of patient preference, with 
individual patient trade-off preferences guiding therapy, rather than clinician selection 326. 
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In many patients, long-term management with a seton may be an acceptable option 281. This 
provides symptomatic relief and carries little risk to continence. It may avoid repeated surgery 
in up to 90% of patients 345. 
 
Secondary tracks should be successfully treated before definitive surgical management of 
primary tracks. 1D. 
 
For the purposes of this consensus, the following definitions were used: a primary track has 
an internal opening in anorectum and an external opening on the perineum; a secondary track 
has an external opening on the perineum but does not have an opening into the anorectum 
but rather communicates indirectly via a primary track; a secondary tract is the blind sinus or 
sideways branch off either. Closure of a primary track may impede drainage of a secondary 
tract, leading to further abscess formation and recurrent symptoms. Secondary tracks should 
be addressed prior to closure of the primary or ‘feeding’ track. This will ensure clearance of 
residual sepsis and diminish chances of failure in treating the primary track346. In some cases, 
treatment of the secondary track may be as simple as seton removal in a patient on biological 
therapy. It was also emphasised that surgery for the secondary track could be carried out 
immediately prior (ie under the same anaesthetic) to surgery on the primary track, and may 
include procedures such as drainage, laying open, seton removal or insertion of anal fistula 
plug.  
 
Fistula plug is a continence preserving option in perianal Crohn’s disease. 1B 
 
Fistula plug (AFP) for Crohn’s anal fistula has been described in several papers. A recent meta-
analysis reported complete closure in 58.3% of patients, with little change in continence 347. 
A subsequent RCT was performed using this therapy in Crohn’s anal fistula and achieved 
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closure in 31.5% of patients at 12 weeks93. In this study 54 Crohn’s patients underwent an anal 
fistula plug, with fistula closure at 12 weeks achieved in 31.5%.  The closure rate was similar 
to that achieved with seton removal alone (RR 1.31 95% CI 0.59-4.02; p=0.19).  This study 
excluded patients with proctitis but included both complex and simple fistula treated. 
Complexity of fistula was not associated with outcome. In review of source material, abscess 
formation occurred in 3.7-53.8% of patients208 213 214 348. Additional complications included one 
wound dehiscence214, five plug extrusions and two episodes of significant perianal pain348. 
 
There is a conflict between the meta-analysis and RCT data, that is reflected in the acceptance 
of the consensus agreement that the anal fistula plug may still have a role. The meta-analysis 
included both prospective non-randomised cohorts and retrospective cohort data. It is likely 
that these patients were entered based on clinician preference and reflect ‘real world’ data, 
although results may be affected by the relatively small sample sizes, and bias towards 
reporting favourable results. There is also limited data on the co-incident medical therapy in 
these studies. The RCT was selective in certain aspects (absence of rectal disease) and less 
prescriptive in others (fistula anatomy not standard). This could mean that patients were 
entered into the study who may not have received a fistula plug based on clinician preference. 
It is plausible that fistula plug offers benefit in some anatomical configurations, but not others 
(e.g. simple vs complex, long vs short track). Whilst the evidence for this intervention is not 
overwhelming, there are relatively few reports of complications. Coupled with the minimal 
invasiveness, a fistula plug may be considered an acceptable option for the treatment of this 
condition. 
 
Permacol ™ paste (Covidien, Mansfield, MA), Over the scope clip (OTSC ®, Ovesco Endoscopy 
AG, Germany), FiLaC® (Fistula Laser assisted Closure Biolitec AG, Jena, Germany) and 
autologous stem cells may have potential as continence preserving techniques. 2C 
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These therapies have been used in Crohn’s disease in small numbers, with success rates of 
54%, 83%, 71% and 57% respectively, and little in the way of adverse outcomes 104 349 350. As 
yet, no large randomised controlled trials have reported on their use in Crohn’s anal fistula. 
Only a small number of UK surgeons regularly use these emerging technologies in clinical 
practice 177.  
The results of a randomised controlled trial of autologous stem cells versus a control of 
physiological saline, both with sutured closure of the internal fistulous opening in patients 
maintained on biological therapy, has been published since the consensus, with results 
significantly favouring the use of autologous stem cells, even in the context of a high rate of 
fistula closure in the control arm246. 
 
Advancement flap is a treatment option in perianal Crohn’s disease. 1C 
 
Eight retrospective185 198 217-222 and two prospective observational studies223 224 reported the 
outcome of mucosal advancement flaps in both Crohn’s and idiopathic perianal fistulous 
disease. Of the 624 reported procedures, 240 of these were performed for Crohn’s fistula. 
Success in short term healing was seen in 50.0%-85.0% of patients. Where reported, 
recurrence at >1 year was 30.0%-50.0%198 223. Complications were reported in only one study, 
with occurrence of haemorrhage and flap retraction occurring in 6.6%218. The experience of 
endoanal advancement flap in CD was summarised by Soltani et al in 2010 99. They found a 
success rate of 64%, with incontinence rates at 9.4% in Crohn’s anal fistula.  
Selection criteria for these procedures typically avoided proctitis, but there was no consistent 
reporting on medical therapy required to induce favourable local conditions, nor was there 
reporting on the medical therapies required to maintain favourable conditions and support 
healing post-operatively. Therefore, consideration of this procedure should be tempered by 
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the potential impact of concomitant medical therapy and disease activity, as well as potential 
for impaired continence in a patient group who prioritise preservation of continence. 
 
Further (high-quality) information may be gained from the current PISA trial, which 
incorporates endoanal advancement flap as one of the intervention arms 94. On current 
evidence an advancement flap might be considered in the absence of proctitis, significant 
fibrosis or stricturing disease.  
 
Ano/recto-vaginal fistulae will rarely heal on anti-TNF-α therapy alone. 1A 
 
Definitive treatment of ano/recto-vaginal fistulae should be by specialist surgeons in specialist 
centres. 1D 
 
Ano/Recto-vaginal fistula represents a unique challenge in Crohn’s anal fistula. Genital fistulae 
in Crohn’s will rarely heal with biologic therapy alone 76 351. Not all UK surgeons will manage 
this condition, and consequently it is managed in fewer centres with expertise in a range of 
operative techniques 177 297 298. Treatment of ano/rectovaginal fistulae should be under 
combined surgical and luminal gastroenterological care. 
 
 
Diverting stoma may improve quality of life for patients with perianal Crohn’s disease. 1B 
Faecal diversion is indicated in uncontrollable sepsis. 1C 
Faecal diversion may be considered for symptom control. 1C 




Use of a stoma is often considered a ‘failure’ by clinicians. Evidence highlights that patients 
affected by perianal Crohn’s disease see improvement in some quality of life domains 
following formation of a stoma 50, and some patients have indicated that they would like to 
discuss this early in their treatment313. Therefore, quality of life as reported by the patient 
may be an indication for stoma. Both colostomy and ileostomy have been used for this 
indication. Selection of stoma location should take into account distribution of disease (i.e. 
rectal, colonic) and previous surgery107. Uncontrollable or recurrent sepsis, incontinence, or 
ongoing discharge are indications for faecal diversion, although up to two thirds of patients 
may subsequently require further surgery including proctectomy 107 352. 
 
Proctectomy provides improved symptom control and quality of life in selected patients. 1D 
 
This statement highlights the importance of patient priorities and their role in decision-
making. As such, it might be considered early in the treatment process. Current UK practice 
would consider proctectomy in the face of recurrent or refractory perianal sepsis, rectal 
disease refractory to medical therapy, to improve quality of life or at patient request177. As 
well as the indications highlighted for stoma formation, proctectomy might also be considered 
in patients with strictures, and cancers forming in fistula tracks 353 354. This is not an absolute 
panacea as a number of patients may still have perineal morbidity and altered pelvic function, 
including dyspareunia in 10%110 355. 
 
There may be a role for myo-cutaneous flap-based perineal reconstruction after proctectomy 
for perianal Crohn’s disease. 2C 
 
Proctectomy in the setting of severe Crohn’s anal fistula is often associated with poor perineal 
healing, with delayed healing at or beyond 12 months in 58% of patients355 356. A retrospective 
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study of a cohort of 145 patients who had undergone proctectomy for Crohn’s disease found 
persistent perianal sinus in 23% of patients, and was associated with rectal involvement and 
faecal contamination of the surgical field.  Despite numerous interventions, closure was 
achieved in only 9 patients357. While a sinus may result in an occasional perineal discharge, in 
some the non-healing perineal wound may re-establish considerable discharge and sepsis. For 
this reason reconstruction with a rectus abdominis, gluteal or gracilis based myocutaneous 
flap should be considered 358 359.  Voting results for accepted definitive surgical treatment 
statements are presented in figure 40. 
 
 










13.3.8 Definitive Surgical Management - Rejected statements: 
Fistulotomy has a role in perianal Crohn’s disease where there is minimal sphincter division.  
SA: 17% A: 44% N: 17% D: 17% SD: 6% 
Fibrin glue may be effective in long or complex tracks.  
SA: 0% A: 0% N: 0% D: 56% SD: 44% 
LIFT procedure is a continence preserving option in perianal Crohn’s disease. 
SA: 5% A: 42% N: 42% D: 11% SD: 0% 
 
It should be noted that there is evidence to suggest laying open of a superficial fistula is not 
associated with problems of healing in the large majority of patients360, although one third of 
patients may have long term incontinence 361.Various permutations of this statement were 
discussed including ‘no’ and ‘minimal’ sphincter division. The consensus group expressed 
concern that without clear indications and limits to what might be laid open, patients might 
come to harm from repeated fistulotomy. 
 
The evidence for fibrin glue in Crohn’s anal fistula arises from two small trials of patients with 
perianal Crohn’s disease. One found that fistulae closed in 38% of those treated vs 16% of 
controls.  The second study assessed outcomes in refractory Crohn’s anal fistula (n=14) and 
achieved clinical improvement in 75% of patient at 3 months, with complete healing in 57% 
at two years. Poor results from studies in cryptoglandular disease have tempered the 
enthusiasm of the consensus group for this treatment 362. 
 
The Ligation of the Inter-Sphincteric tract (LIFT) procedure was rejected as the evidence for 
its’ use arises from a small single centre study, where 9/15 patients treated were healed at 
two months 102. The consensus group felt that this was insufficient to recommend use in 
Crohn’s anal fistula. Concerns were expressed around the conversion of anatomy to 
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intersphincteric fistula, precipitating subsequent fistulotomy. There was also concern that 
sphincter disruption and long-term incontinence with this procedure. Despite the fact that no 
sphincter is divided in this procedure, there is disruption of the intersphincteric space and 





This paper reports on a consensus exercise, describing agreed practice in the treatment of 
fistulating perianal Crohn’s disease. Due to the likelihood of repeated procedures, 
conservative or continence sparing procedures are preferred in the first instance. The role of 
the multidisciplinary team is reinforced and the need for adjuvant medical therapy 
highlighted.  In contrast to other guidelines on the topic, this consensus has provided practical 
advice for surgeons managing this condition in the UK considering prevailing management 
trends. A summary of the recommended steps in management is shown in figure 41.  
 
 




13.4.2 Comparison with other guidelines 
There are several contrasts and similarities with the two recent publications from the World 
Gastroenterology Organisation (WGO) and European Crohn’s and Colitis Organisation (ECCO) 
175 176. All papers agree on ‘staging’ the disease by assessment of the rectum for proctitis. The 
WGO publication further advocates assessment of the small bowel to complete staging. The 
ECCO paper was published in 2010, prior to a number of relevant publications on operative 
approaches to Crohn’s anal fistula. Consequently, non-cutting fistulae and/or fistulotomy are 
recommended for simple fistulae. Surgical therapy is advocated for complex fistulating 
disease, but no specific procedures are mentioned. Ano/rectovaginal fistulae are discussed, 
and a combined medical and surgical approach (including stoma formation) is advocated 175. 
The WGO consensus advocates the use of fistulotomy as a surgical procedure and suggests a 
number of treatments which may be considered in definitive surgical management including 
mucosal advancement flap, fistula plugs, LIFT and mesenchymal stem cells, and proposes a 
structured algorithmic approach176. In contrast, the UK-based consensus presented here 
advises that procedures are selected with patient aims in mind. 
 
13.4.3 Strengths and limitations 
The recommendations from this exercise have two key limitations or sources of bias: the 
participants and the information they used. The consensus group was by its nature self-
selected and included surgeons with an interest in the condition. This has potential to skew 
results away from more nationally generalised recommendations. Despite this, none of the 
agreed statements show major conflict with the results of previous national survey of current 
practice 177. Some recommendations were undoubtedly limited by the quality of available 
evidence. While large trials of medical therapy have been reported, there are fewer quality 
trials of surgical or multimodal therapies for this condition. Consequently recommendations 
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are based on either small trials or retrospective studies with inherent bias. These challenges 
have been identified in a recent review of guidelines for the management of anal fistula 363. 
An ongoing trial aimed at improving outcomes for patients with perianal Crohn’s disease has 
utilised best available evidence and guidelines to optimise the intervention arms, but also 
acknowledges the relatively poor evidence base for the selected components of each 
pathway94. 
 
In making recommendations, the consensus group considered both clinical outcomes and 
qualitative patient-reported outcomes. The body of literature on this condition reports widely 
on healing rates following use of setons and biologics 281, but limited focus on qualitative data 
following surgery. Quality of life data comparing Crohn’s anal fistula patients with and without 
faecal diversion show that diverted patients have better quality of life 50.  There is a need to 
explore these aspects of care further to identify the patient benefits conferred by the various 
surgical options, and even consideration and discussion of diversion earlier in the patient 
journey than is currently offered. As highlighted following each recommendation, there is a 
limited evidence base from which we can draw strong recommendations and virtually no head 
to head comparisons of surgical therapies. It would not be appropriate to report economic 
data on these therapies as existent economic analyses consider ‘mixed’ fistula cohorts364, 
ignoring the highly recurrent nature of these fistula. Surgical studies also fail to consistently 
report medical therapies associated with treatment, which are the main cost drivers in the 
treatment of perianal Crohn’s disease138. 
 
One of the strengths of this exercise is that it recognises uncertainty and the need to involve 
patients in decisions about their care. Shared decision making has been investigated for 
patients undergoing surgery for breast and rectal cancer 365 366. Following sepsis control, it 
would be appropriate to discuss the possible surgical options and relevant information to 
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patients to support decision making 367. The management of Crohn’s anal fistula should 
involve a multidisciplinary approach combining the knowledge of a gastroenterologist and 
colorectal surgeon who have appropriate experience.  The use of best evidence should involve 
patients at the centre of their own care, with management of expectations considering the 
potential for chronicity and relapsing nature of the disease 368. 
 
13.4.4 Implications for practice 
This exercise has identified areas for further research, including work around optimum timing 
of seton removal and, by extension, timing of biologic therapy. The wide range of surgical 
procedures available reflects lack of evidence of their efficacy but may also reflect 
heterogeneity within the disease.  There is a lack of data to enable robust judgements on the 
cost effectiveness of surgical options. Further work to understand this could take the form of 
clinical trials and should include assessment of patient preferences and choices in decision-
making, quality of life and functional outcome at several time-points, as well as objective and 
subjective healing outcomes. This consensus exercise should be repeated at a future date 
when stronger prognostic data maybe available, as well as further information on the short 
and longer-term outcomes of novel therapies such as over the scope clip and stem cells, and 



























14.1 What is mixed method research 
Mixed method research is research that ‘focuses on collecting, analysing, and mixing both quantitative 
and qualitative data in a single study or a series of studies.’369 370 It has been used in health research, 
and is becoming part of surgical research strategies371.  
 
As mixed method approaches have developed, there has been debate on the theoretical grounding of 
this research type372. Original proponents were described as either constructivist or positivist. 
Constructivism is an approach where no one source or method gives an answer, and that reflection 
on several methods or results can provide a reflection of reality. Positivism recognises only that which 
can be scientifically verified, or which is capable of logical or mathematical proof. Simplified, one group 
would prioritise qualitative data over quantitative data, and the other, the reverse. It is recognised 
that mixed methods have a tendency to favour certain forms of qualitative data (semi-structured 
interviews) and quantitative data (closed-question surveys), and this approach does not necessarily 
satisfy both philosophical groups373.  
 
As with most efforts to dichotomise complicated ideas, this left room between the two approaches 
for the emergence of the pragmatic paradigm. This  asks ‘what works?’ for a specific research question, 
allowing adaptability of design, and for data types to be weighted in different ways369 374. This is 









14.1.1 Benefits of mixed-method approaches 
This mixing of data types provides several benefits369 376. These include: 
• Complementarity: Data from one set of results can be used to illustrate points from another 
e.g. interview quotes may be used to explain or support discussion of a survey finding. 
• Initiation: This is when the results of the two methods demonstrate divergence or 
incongruence and generate new hypotheses e.g. e.g. a survey of surgeons indicates their 
patients undergo frequent wound changes, but interviews with nurses reveal that these 
changes are infrequent and highlights potential barriers to frequent dressing changes. 
• Expansion: This is where the methods are appropriately used to explore different aspects of a 
research question e.g. a clinical study to assess how many people attend a follow-up clinic 
appointment, and interviews with those who do not attend appointments to explore reasons 
for this. 
• Triangulation: This involves the use of both studies to corroborate findings. The same (or 
similar) questions are asked using two different methodologies, with the findings from the 
two compared to assess where the ‘real’ answer lies. When triangulation is being undertaken, 
it is important to determine a priori which dataset will take priority when there is 
disagreement between the two377 378. 
 
The main disadvantage of a mixed method approach is that the study requires more time to design, 




14.2 Design of a mixed methods study 
There are five major designs of mixed method research. These are convergent, explanatory sequential, 
exploratory sequential, embedded, and mixed methods systematic review376. These use different data 
sources at difference stages in the study and apply different weighting to data according to the 
research question. The approach to survey-based research has already been outlined, and the 
approach to qualitative interviewing is described in the next chapter. Types of mixed-method design 
are presented in figure 42. 
 
Convergent: Both qualitative and quantitative methods are used concurrently, and results are mixed 
at interpretation stage. Study design is suited to mapping process changes through capture of 
clinical data, mixed with interviews or focus groups of service users. 
 
Explanatory sequential: This study design begins with a quantitative component which generates 
further questions. Qualitative methods are then employed to explore this. 
 
Exploratory sequential: This study design uses qualitative data to generate research questions, 
which are then tested using quantitative methods such as a survey. This may be through exploration 
of experiences of a sample of patients, followed by a survey of a wider patient population. 
 
Embedded: In this design, qualitative methods are embedded within a larger clinical study. This may 
be interviews or focus groups with study participants to explore outcomes or explore feasibility and 
acceptability of interventions. 
 
Mixed methods systematic review: This is a form of systematic review which includes both 
quantitative and qualitative data in the synthesis of findings. 
Figure 42 Types of mixed method study design 
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14.3 Selection of mixed method approach 
 
The mixed method approach selected for this study was an exploratory sequential design. As there 
was no relevant data in the literature upon which to base a survey for this condition, it was decided 
to undertake a qualitative interview-based study to generate hypotheses to test in a quantitative 
survey. Themes emerging from the studies would undergo triangulation to identify areas of agreement 
and dissonance, validating or refuting findings378. This is particularly helpful where a population for 
research is potentially limited. The flow of data in this study is presented in figure 43. This study has 
taken a pragmatic approach. 
 

























15 Mixed Method I: Semi Structured Interviews - Patient experiences and 





I was involved in study design, data collection and analysis. I prepared the manuscript with input from 
co-authors. Jack Marshall conducted interviews and supported analysis of data. 
Oversight was provided by Georgina Jones, Alan Lobo and Steven Brown. 
 







The systematic review of surgical interventions did not identify a clear front running technique for the 
cure of Crohn’s anal fistula. With the equivalence of outcomes, and subtle differences between 
interventions, selection of a procedure might be adjusted to account for patient preferences or values. 
This means that selection of a surgical procedure is a ‘preference sensitive’ decision379. 
 
The surveys of clinician preferences have given an indication of the treatments that tend to be offered 
to patients. The complementary data on patient information needs and preferences for this condition 
is not yet available. There are several ways to collect data from patients; qualitative interviewing is an 




15.2 Interview based research 
Qualitative research is an exploratory or hypothesis generating approach380. It assesses words and 
behaviours and the meaning behind them. In healthcare research, this commonly relates to the 
conduct of interviews and assessment of their content381. 
 
Interviews may be conducted in person or by telephone256 321. They may be designed to follow a strict 
protocol with no additional questions permitted (structured). Alternatively, they may provide a set of 
questions, but allow the interviewer scope to further investigate strands of interest arising during the 
investigation (semi-structured).  
 
The content of interviews is typically transcribed and analysed. The approach to analysis can take 
several different forms382 383. It can focus upon language and how it is used (discourse analysis), 
interpretation to understand feelings and perceptions of events (phenomenological analysis). It can 
also be based more deeply in psychology research, with the interpretation of interviews within the 
context of existing theoretical models for example those describing grief processes or change models 
(grounded theory). Each of these has a setting in which it can be deployed.  
 
15.3 Framework analysis 
Framework analysis is a form of thematic analysis. In thematic analysis, transcripts of interviews or 
speech are analysed to identify themes. Themes may be proposed at the outset of the research 
project, or identified emergently during analysis. These themes can then be organised into over-
arching or subthemes. Grouping of content is based upon themes only. 
 
The same process is largely followed in Framework analysis, but data is coded on both a theme and 
case basis384.  This allows generation of a coding matrix, permitting researchers to view content 
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according to both themes (what was said) and cases (who said what). This analytic approach was 
initially proposed for policy-based research, although has been used across healthcare. 
 
15.4 Framework methodology 
In brief, the framework methodology follows seven steps383: 
1) Transcription of the interview. Verbatim transcription of the audio recording of an interview 
is standard practice. This transcription may be undertaken by the investigator who conducted 
the interview or by a researcher from their team. This allows familiarisation with the interview 
content. In some cases, this may be contracted to an outside service. 
2) Familiarisation with the interview. Review of the interview transcript along with the audio 
recording and field notes allows the researcher to immerse themselves in the content of the 
interview, and to understand contextual content. 
3) Coding. The research assesses the transcript line by line and codes any content within a phrase 
which might be important to any aspects of the research question. 
4) Developing a working analytical framework. After coding 3-5 transcripts, the research team 
meets to discuss and agree a framework structure. This involves identification of over-arching 
(superordinate) themes, and sub- (subordinate) themes which address specific aspects of a 
theme. 
5) Application of analytic framework. The refined analytic framework is then applied to the 
already coded transcripts, and to the remaining transcripts in a study. 
6) Populating the framework matrix. The framework matrix is a summary table where each row 
represents a case, and each column represents a theme. The matrix is populated with 




7) Interpreting data. The research team reviews the matrix to provide a narrative of the 
phenomenon under investigation.  
15.5 Strengths and limitations of Framework Analysis 
The main strength of framework analysis comes from the development of the analysis matrix383. The 
extraction of data into the framework facilitates the assessment of content presented in the 
participants own words and construction of a richer narrative than might be constructed from isolated 
themes. The systematic approach means that it can be used across teams with reproducible results385. 
 
The main limitation of framework analysis is the significant amount of time required to complete the 
analysis, especially where several different researchers are involved in coding. There is also the delay 
associated with the requisite training of researchers in the methodology383 386. 
 
15.6 Aim 















This study received ethical approval from the Greater Manchester (South) NHS Research Ethics 
Committee (16/NW/0640) (Appendix N), and is reported in line with the Consolidated criteria for 
reporting qualitative research (COREQ) guidelines387. 
 
15.7.1 Research team and reflexivity 
Interviews were carried out by JM or ML. JM was a male undergraduate medical student who 
undertook interviews as part of his Intercalated BMedSci studies. ML was a male clinical research 
fellow who undertook interviews as part of his PhD studies. ML has prior experience of conducting 
semi-structured research interviews. Both JM and ML undertook further interview training and 
feedback with GJ, a professor of health psychology. Interviewers were debriefed after initial interviews 
to ensure conduct of interviews was appropriate. Researchers established their relationship with 
participants at the point of recruitment, typically following a clinic appointment with another health 
professional. Where ML had reviewed the participant in a clinic appointment as part of routine care, 
JM undertook the interview. Participants were made aware of the clinical background of the 
interviewer, and of their interests in the topic. Reflexivity (the inherent bias carried by the conduct of 
the researcher in interviews or interpretation of transcripts) was addressed in two ways; interview 
training included efforts to avoid emotional reactions to responses and transcripts underwent dual 
review and coding by the investigators to address reflexivity related to interpretation. Transcripts 
were revisited later in the study to reassess findings in light of emerging themes.  
15.7.2 Methodological Framework 
A qualitative methodology was adopted using semi-structured interviews. Semi-structured interviews 
use a common framework or structure, but allow the researcher to explore ideas and concepts that 
arise through further prompts or questioning. A structured interview would allow only the questions 
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presented on the interview schedule. Qualitative methods were chosen to allow detailed exploration 
of patient experiences and preferences.  
15.7.3 Participant Selection 
The participant sample was selected through purposive sampling i.e sampling of the population to 
ensure variation amongst those interviewed by ensuring a mix of active and inactive fistula, and 
experience of different surgical procedures. Recruitment was targeted at biologic infusion clinics 
(nurse-led unit for ambulatory attendees receiving infusions of biologic therapy for Crohn’s disease), 
and surgical-IBD clinics. Participants were eligible if they had undergone previous surgery for Crohn’s 
anal fistula. Additional targeted recruitment was carried out during the study to balance the number 
of patients with a stoma against the number of patients treated with other surgical procedures as this 
group was under represented. Participants were identified through clinic attendance at one of two UK 
hospitals and approached following outpatient attendance. The approach included an introduction 
from one of the research team, and provision of an information leaflet with a tearable ‘opt in’ slip for 
return (Appendix O). When the patient indicated that they wished to participate, contact was made 
and a time for interview was agreed. 
 
Participants were eligible to participate if they had undergone any surgical treatment for a Crohn’s 
anal fistula at any point. If a potential participant did not have a conversational standard of English 
then they could not participate as the study was not funded to cover translator fees. Recruitment to 








Research interviews were conducted in the education centre at Sheffield Teaching Hospitals, and the 
Clinical Research Facility at Blackpool Teaching Hospitals. The rooms selected were intended to be 
quiet and away from clinical areas.  
 
As the interview might address sensitive issues, only the participant and interviewer were present 
during the interview. If a participant became distressed, the researcher would offer to suspend or 
terminate the interview and arrange for access to local IBD nurse specialists. Descriptors of 
participant age, sex, duration of Crohn’s disease, prior fistula operations, and current fistula status 
were recorded. 
15.6.5 Data Collection 
An interview guide was prepared by ML and GJ based upon the previous reviews of the literature and 
with input from the research team (Appendix P). No pilot interviews were undertaken, although input 
from a patient representative was sought during the drafting of the interview guide. Each participant 
undertook a single interview, which was audio recorded. Supporting field notes were taken by the 
interviewer where appropriate. There is no consensus on the minimum number of interviews for 
adequate sampling in qualitative research388. As data saturation can occur with as few as twelve 
interviews389, saturation was first assessed at this point, and then after each subsequent interview. 
Saturation was reached when five subsequent interviews did not reveal any new themes. Transcripts 
were not returned to participants for comment. 
15.6.6 Data Analysis & Coding 
Interviews were transcribed by their respective interviewer. Coding was undertaken independently by 
JM and ML using NVivo 11 Computer-Assisted Qualitative Data Analysis Software (QSR International, 
Australia). A screenshot of the NVivo coding interface is presented in appendix Q. Data analysis was 
undertaken using the framework methodology as described by Richie384. After five interviews, codes 
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were compared and discussed with the research team, and a coding framework was agreed. This 






A total of 17 people completed interviews, by which point saturation of themes was achieved. Of 
these, nine were male, 8 female and with a median age of 27 (range 19-71). Treatment experience 
included setons (thirteen cases), fistula plug (three patients), and stoma formation for fistula (four 
cases). Ten participants had an active fistula i.e. fistula with ongoing discharge requiring further 
treatment. Participants reported treatment experiences from four different hospitals, and ten 
different surgeons were named during interviews, showing a range of treatment experience.  A 
summary of participant characteristics is shown in Table 30. Of those approached, 28 patients declined 

























Previous operations Fistula 
status 
I.1 M 19 15 years Seton Inactive 
I.2 F 60 6 years Seton Active 




I.4 M 23 9 years Seton Inactive 
I.5 F 60 40 years Seton, End Ileostomy Active 
I.6 M 25 7 years Drainage of abscess Active 
I.7 F 26 7 years Seton Active 
I.8 F 27 5 years 
Seton, fistula plug, 
advancement flap 
Active 
I.9 M 56 20 years Seton, fistula plug Inactive 
I.10 M 25 9 years Seton, fistula plug,  Active 
I.11 F 22 7 years End Ileostomy Inactive 
I.12 M 31 1 year Seton Active 
I.13 M 71 6 months Seton, proctectomy Inactive 
I.14 M 22 6 months 
Drainage of abscess, loop 
ileostomy 
Inactive 
I.15 F 24 3 years 
EUA, seton, Loop 
colostomy 
Active 
I.16 M 67 15 years EUA, seton Active 




EUA, drainage of abscess, 
seton 
Active 






15.7.1 Coding hierarchy 
The initial coding hierarchy contained four over-arching themes and 10 subthemes. These are 
summarised in table 31. Following discussion between the research team and following iterative 
review of all manuscripts, these were restructured into five over-arching themes: Experience of 
Crohn’s disease, experience of receiving information, procedure specific comments, decision making 
and desired information. The final coding hierarchy,  summary of themes and number of participants 
referencing them is shown in table 32. Saturation was assessed for following interview 12 and 
confirmed following interview 17. A graphic representation of themes and sub-themes is shown in 
figure 44. 
 
Overarching theme Sub-theme 
Information What the patient wants to know 
Information giving 
Information received 
Living with a fistula Impact on quality of life 
Fistula symptoms 
Decision making What factors affect decision making 
Patient involvement 
Shared decision making 
Online health information Patient use of internet 
Clinician views of online health information 
















Over-arching theme Sub theme Number of participants 
referencing subtheme (%) 
Experience of Crohn’s 
disease 
Impact of disease 15 (88.2%) 
Quality of life 9 (52.9%) 
Effect of operation 12 (70.6%) 
Aftercare 10 (58.8%) 
Fistula expectations 9 (52.9%) 
Relationship with healthcare professionals 10 (58.8%) 
Experience of receiving 
information 
Delivery of information 8 (47.1%) 
Information from clinicians 15 (88.2%) 
The internet as an information source 15 (88.2%) 
Peer support 10 (58.8%) 
Written information 8 (47.1%) 
Conflicting information 4 (23.5%) 
Procedure specific Seton 12 (70.6%) 
Stoma 15 (88.2%) 
Decision making Trade-offs 14 (82.4%) 
Decision making preferences 15 (88.2%) 
Desired information Procedural information 9 (52.9%) 
Treatment goals 12 (70.6%) 
Sex and reproductive health 3 (17.6%) 
Aftercare 9 (52.9%) 
Delivery of information 8 (47.1%) 











Figure 44 Concept map showing relationship of themes, sub-themes and third tier themes. 
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15.7.2 Experience of Crohn’s disease 
Six sub-themes were identified including impact of disease, quality of life, relationship with healthcare 
professionals, fistula expectations, effect of operation, and aftercare. 
15.7.2.1 Impact of disease  
All participants discussed their experience of Crohn’s disease in general, and also specifically about 
their experience of fistulating disease. The experience was described in universally negative terms. 
This was often linked to aspects such as pain and the inability to undertake routine tasks. 
 
‘… some of the nights I’ve had, when my bottom was bad, it was …honestly the pain was… it was 
terrible. Sitting on the toilet crying. And you shouldn’t have to live your life like that should you?’ 





15.7.2.2 Quality of life 
The relationship between fistula and quality of life was explicitly mentioned by several participants. 
Both the condition and the drawn out investigative process were felt to have a negative impact on 
quality of life.  Several participants discussed the odour related to discharge as having a significant 
negative impact on their quality of life as it affected their ability to go out in public and interact 
normally with others. 
 
 ‘…it started to smell so it was like if I can smell it can other people smell it, I didn't wanna be near 
anyone in case it did.’ 
I.1., M, Inactive fistula 
 
‘I’ll suffer for another three months, but you just get used to living in this reduced state.’ 
I.6., M, Active fistula 
 
 
‘Well, if I was in a queue in a shops or something, now and again I thought ‘I can smell myself’, and I’d 
walk away from the queue.’ 




15.7.2.3 Effect of operation 
Participants discussed their experiences of life after surgery. They reported experiences of pain which 
were worse than expected, and long recovery times, even after minor surgery. 
 
‘I didn’t necessarily know it would maybe debilitate me that much for the period of time for recovery.’ 
I.10, M, Active fistula 
‘the first two weeks after it I thought I was dying. I’ve never been in so much pain’ 





Aftercare was central to the experience of many participants. One aspect of this was what patients 
described as poor provision of information immediately following a procedure. 
 
‘When I came out of theatre, all I know that I got these setons in and I didn’t know exactly, particularly 
what they were um you know I just, I were just sent home with them in and it was a bit frightening to 
be honest.’ 
I.2, F, Active fistula 
 
‘No.  I wasn’t told anything when I was discharged. And, I was like…it was a cutting seton as well. So 
when I took the dressing off and looked in the mirror, I was like ‘Oh my god, there is a massive hole in 
my bum cheek’. 





15.7.2.5 Fistula expectations 
Several participants discussed their expectations of fistula outcomes at the start of their experience.  
Across those interviewed, there was a tendency to desire a cure for fistula when it first appeared. Over 
time, many people accepted that as part of Crohn’s disease, it was not a condition that could be cured, 
but could be managed.  
 
‘I thought there was a cure at first, so I was like ‘ah so this is fine I don’t care’ and then they... explained 
more about it and I was like ‘this is more serious than I thought’ 
I.1., M, Inactive fistula 
 
‘I think that that is there focus when they come in, I want a cure, but you don’t always cure, you can 
help you know and help it through life and living through life with it but you’ve got it and Crohns is a 
disease that isn’t going to go away, not at this moment in time.’ 




15.7.2.6 Relationship with healthcare professionals  
Both positive and negative relationships with healthcare professionals were described, and were often 
central to the patient experience of treatment and of receiving information. A number of patients 
reported dissatisfaction with aspects of their relationships with their surgeon. The varied opinions 
around clinician relationships seem to be related to patient opinions of treatment, whether they felt 
listened to by their clinician, and whether the clinician was able to offer advice or treatments which 
benefitted the patient. 
 
‘In the end, um, I felt like I was being fobbed off to be honest…he washed his hands of me, he just  said 
he was going to discharge me.’ 
I.2, F, Active fistula 
 
‘The general care I got was kind of high and it maybe uh puts your trust more in what they're saying 
rather than being more critical of it.’ 
I.4, M, Inactive fistula 
 
'The team of people who I can get hold of, who know me, who can explain things to me, who’ve looked 
after me with continuity, is the reason I don’t go anywhere else’ 




15.7.3 Experience of receiving information 
Six subordinate themes were identified related to receiving information. These were information from 
clinicians, delivery of information, conflicting information, the internet as a source of information, 
peer support and written information. 
15.7.3.1 Delivery of information 
Many participants felt that the quality of counselling prior to surgery was poor, and could be 
delivered at a slower pace. 
‘It just seems like everything is really rushed and they haven’t got time to really talk to you. They 
don’t actually sit down half of the time and it’s like duh, duh, duh, and they go into their offices, and 
it’s like…are we done?’ 
I.5, F, Active fistula 
 
‘It was quite rushed, and she sort of just gave me [leaflets] or whatever. I think I would have 
preferred someone to just sit down with me properly.’ 





















15.7.3.2 Information from clinicians 
Information from clinicians typically focussed on short risks and outcomes of procedures and long-
term outcomes of the condition. 
‘At the time, that was sort of the thing that was most worrying to me…obviously I know it’s a small 
risk, of cutting your sphincter muscle…’ 
I.6, M, Active fistula 
 
‘Mr X said that he wants to take my seton out because it’s not working anymore, and was on about 
putting either a plug or a clip in. Try one of those he says, but there’s only a 50% chance that it 
works’ 
I.7, F, Active fistula 
 
‘I was always told it’s unlikely, well not unlikely, it’s never certain that a fistula is going to heal, and 
likewise, if someone has had fistulas from something like Crohn’s, it’s also likely that it recurs.’ 
I.10, M, Active fistula 
 
Two participants specifically mentioned a discussion of risk of incontinence prior to surgery, but 









15.7.3.3 The internet as a source of information 
The internet was used by most participants to seek information on their condition and treatment 
options. Other information sources included discussion forums, written leaflets, and charity sources. 
Participants typically fell into those who found the internet useful, and those who did not. 
‘I looked on Google, and that made me even more scared.’ 
I.1, M, Inactive fistula 
 
 ‘I remember sitting in hospital, researching myself because I didn’t get enough information….I 
would have liked to know more about the treatment itself.’ 
I.11, F, Inactive fistula 
 
‘On the stoma sites, a lot of people do Vlogs, so I’ve watched them before. There’s some good ones 
that are helpful.’ 





15.7.3.4 Peer support 
Peer support was often discussed as a way of finding out information which clinicians did not routinely 
offer. Internet peer support e.g. internet forums were typically considered to provide useful content. 
They also provided social support for participants as they reported feeling better after talking to others 
with similar problems. 
 
‘You feel as if you’re not on your own, because other people are writing things.’ 
I.2, F, Active fistula 
 
‘Obviously, there’s forums and bits like that which you always seem to go to. People were great. 
Some people go…you get the odd horror story in here and there but you sort of expect [that].’ 
I.6, M, Active fistula 
‘I used the Crohn’s forum and there’s different sections for stuff. You can literally just click on one 
that’s about fistulas, and it will tell you loads of stuff. You can type in and message that I’d had one 
done, and can anyone offer some advices – loads of people come back and tell you stuff, it’s great.’ 
I.7, F, Active fistula 
‘I’m on so many support groups on Facebook…there’s so many people going through what I’m going 
through – it’s crazy.’ 











15.7.3.5 Written information. 
Written information, in the form of leaflets, was not seen as being a preferred format for delivery of 
information for many participants. It was felt to have a supporting role in the delivery of information. 
 
‘[It’s] secondary, supportive, rather than primary, because you can’t ask questions of a piece of paper.’ 
I.17, F, Active 
 
15.7.3.6 Conflicting information 
Participants reported receiving conflicting information from different sources. The areas where 
conflicting advice had been given around major implications of treatment decisions. 
‘I’ve seen different consultants, all lovely, but I felt like each person was telling me something 
different.’ 
I.11, F, Inactive fistula 
 
‘Mr X tells me that it won’t affect my fertility if I had the proctectomy. And when I went to [other 
hospital], they said it would massively affect me having children in the future.’ 




15.7.4 Procedure specific comments 









15.7.4.1 Seton insertion 
The majority of participants specifically reported experiences of setons. These showed that setons 
generally improved symptoms, although participants did not like the experience. 
 ‘I’ve got this seton in and I feel fine, whereas before I hadn’t got a seton in, but I felt horrific.’ 
I.4, M, Inactive fistula 
 
‘Just having one with a seton in permanently is bearable’ 
I.10, M, Active fistula 
 
‘I came out once and had a whole network of the things, and I couldn’t figure out what was going 
where when and why. I was just desperate to get them out – they were horrid’ 
I.17, F, Active fistula 
 
Participants also expressed discomfort with the uncertainty related to the duration of seton 
placement.  
‘I had those setons in for about two years, and I remember thinking ‘when are they coming out?’ 
I.4, M, Inactive fistula 
 
‘I was told that they’d only need to be in there for a certain period of time, a certain number of weeks, 
then they could come out. I had some that were in for much longer!’ 





15.7.4.2 Stoma formation 
The demographics table shows that not all participants have direct experience of a stoma. Those who 
had discussed it with their surgeon had done so with it being considered an option of last resort. 
Opinions on stoma formation were both positive and negative.  Both I.4 and I.17 had previously 
undergone temporary stoma formation and subsequent reversal for indications other than Crohn’s 
disease in the past. Both expressed strong views on avoiding a stoma. 
 
 
‘I would see that as a last resort, I wouldn't want to have one'. 
I.1, M, Inactive fistula 
 
‘I was reasonably happy to have it ….I was going through a ‘no-life’ situations, and I thought ‘stoma 
bag can’t be any worse than this is’….which as it’s proving, it’s not.’ 




15.7.5 Decision making 
Two subthemes were identified: ‘trade off’ and ‘who makes the decision’. 
15.7.5.1 Trade off 
Several participants alluded to trading off different aspects of treatment for different outcomes, 
referencing symptoms, quality of life, or repeated procedures as factors in their choices. Participants 
were typically willing to accept a procedure which limited disruption to their lives and achieved some 
symptomatic relief from the fistula compared to those which were intended to be curative but 
disruptive to life or associated with increased risks. Two participants had experienced medically 
refractory Crohn’s disease and undergone stoma proctectomy or formation. Both indicated that 
trading-off a stoma for improved quality of life was worthwhile, despite the temporary impact on 
quality of life. 
 ‘I suppose I’d weigh up that against your success percentage and look at what suited me best. I 
obviously want the most successful treatment, but if it’s going to be six months of to and fro between 
the hospital….’ 
I.6, M, Active fistula 
 
‘If…my quality of life was worse and that was a permanent state, then I would say yeah, the quality of 
life improvement would maybe be worth just having a stoma’ 
I.10, M, Active fistula 
 
‘I would guess I would probably opt for a less invasive procedure to start with and see how it goes. If 
it became really troublesome, we could do something more aggressive’. 




15.7.5.2 Who makes the decision? 
The process of decision-making was discussed by several participants. Several people indicated that 
they preferred a clinician-centred or clinician guided decision model. Others felt that they wanted a 
more active and decisive role in the process. Participants recognised the uncertainty associated with 
decisions, and this is perhaps why they willing to rely on clinician input.  
 ‘I’d take a professional opinion on that, I think. Take whatever the medical advice would say would 
be the best option for you’. 
I.5, F, Active fistula 
 
‘I prefer for the doctor to be telling me what’s best for me.’ 
I.16, M, Active fistula 
 
‘I like to be led by somebody who knows what they’re on about. I like to make my own decision, but I 
like to be led in the right direction….as long as they’re honest with me and lay all the information out, 
and not concentrating too much on worst and best. [Talk] about the middle ground where most people 
end up. I think I can make a pretty informed decision.’ 
I.9, M, Inactive fistula 
 
‘It’s also been my choice as well – I’d say I’ve been quite involved in that’. 
I.10, M, Inactive fistula 
 
It was notable that many participants felt that they had not been offered a choice in the treatment of 
their fistula. They indicated that they felt that the surgical procedure on offer was the only option 
available to them. Some were aware of alternative options, but these were presented as an option if 
the proposed treatment failed. 
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‘They didn’t give me an option of what they were going to do. They were going to do this…but they 
didn’t go ‘there’s A,B,C and D’.’ 
I.6, M, Active fistula 
 
‘They said they’d do whatever they felt was best if I was ok with that…’ 
I.7, F, Active fistula 
 
‘They just give me one thing and say ‘We’ll try this’, so I’ve gone for that, not knowing there’s other 
possibilities.’ 




15.7.6 Desired information 
Interviews explored the kind of information participants would like in order to make decisions about 
their care. This identified five sub themes; procedural information, treatment goals, sexual and 
reproductive health, aftercare, and delivery of information. 
15.7.6.1 Procedural information  
Participants broadly wanted to know about success and failure rates of fistula closure, and likelihood 
of fistula recurrence for specific procedures. They also wanted to know how likely it was that a 
treatment would improve their symptoms. There was a recognition that fistula can recur in the future, 
hence the focus on symptom control. Participants indicated that procedural information was widely 
covered by surgeons. 
 ‘It was useful knowing the percentages because I suppose you don’t get your hopes as much then.’ 
I.7, F, Active fistula 
 
‘Success rate is number one…what sort of percentage chance my surgery would succeed.’ 
‘Because [recurrence] is sort of one thing you imagine…I don’t have to worry about it, and then a few 
years down the line, you’ve got another one….is it worth actually going off and closing it at all?’ 




15.7.6.2 Treatment goals 
Participants discussed treatment objectives beyond fistula closure, including symptom improvement, 
and aspects related to daily activities and quality of life. 
‘I think pain has to be number one. And the lack of itching or soreness.’ 
I.5, F, Active fistula 
 
‘The success rate, probably followed by how invasive that procedure is….You don’t want to keep 
coming all the time. I’d rather go in and go ‘right, it should sort itself out now after a period of time’.  
I.6, M, Active fistula 
 
‘Recovery time. I want to know about aftercare and exactly what’s going to happen…..Speed and 
effectiveness really.’ 
I.14, M, Active fistula 
 
‘I’d need to know that I can carry on doing the things that I do. I basically want to be able to sit on a 
bike seat for a start.’ 

















15.7.6.3 Sexual and reproductive health 
Three participants (all female), raised concerns about the impact of treatments on sexual and 
reproductive health, and felt that this should be part of any discussion. During interviews with these 
participants, it was clear that information about fertility or sexual function had only been discussed 
because they had raised the topic. 
‘They started mentioning fertility thing and I was like, oh, wow, wow, wow, what’s going on here?’ 
I.11, F, Inactive fistula 
 
‘It obviously affects my sex life ‘cause it’s all closely linked isn’t it?’ 
‘Some people have said you can have children, some people have said you can’t so…’ 
I.15, F, Active fistula 
 
‘I’m a female of child bearing age – is it going to have implications for that?’ 





Participants discussed the need for information about aftercare following treatment of their fistula. 
‘The fact that they would always be draining and you would have to be wearing the pads.’ 
I.5, F, Active fistula 
‘If I was ever going for anything then [I’d ask] ‘What is your aftercare procedure?’ 
I.6, M, Active fistula 
 
15.7.6.5 Delivery of information 
Several participants offered thoughts on the modality of sharing information. Many preferred a face 
to face discussion with a health care professional, typically a surgeon. They indicated that written 
information could be provided to take away and reinforce details from the consultation. 
 ‘It’s just sitting down and taking the time….it would be helpful to give a leaflet…maybe even some 
pictures of stuff.’ 
I.7, F, Active fistula 
 
'Face to face, verbal. I like to ask a lot of questions, so to be able to have a dialogue has always been 
really useful.’ 
















This study has explored patient experiences around receiving information and making decisions about 
surgery whilst being treated for Crohn’s anal fistula. It suggests that information currently used to 
counsel patients before surgery on a fistula is not adequate in terms of format, delivery or content. It 
also demonstrates the significant negative effect of Crohn’s anal fistula on quality of life across many 
domains, although the focus of the study is on how information was received. 
 
15.8.1 Where do patients get information about treatment decisions? 
Participants felt strongly that information about surgical treatments should be given verbally by their 
surgeon. They felt that the surgeon had the most appropriate knowledge to discuss treatments. Many 
patients also stated that satisfaction in their relationship with their surgeon was important when this 
information was being shared. The association between satisfaction and clinician relationship has 
previously been demonstrated in IBD390.  
The clinical encounter was not the only source of information for patients. In this study, participants 
accessed multiple sources for information about surgical treatments for Crohn’s anal fistula. This is in 
keeping with the literature where patients use many different sources253 390. The use of internet forum 
is not a new finding, and, the reasons given for use of these websites are congruent with the 
literature253. Our review of internet based resources for patients undergoing surgery for Crohn’s anal 
fistula found a limited number of resources, each of which discussed just one treatment. All sources 
achieved low scores using tools to assess decision support characteristics125. 
15.8.2 When should we give information? 
In Elwyn’s three talk model, the time to present options would be during the second phase124. Many 
participants felt uncomfortable with a discussion about a stoma at a point early in the disease process. 
Others felt that there was always a chance of a stoma when diagnosed with Crohn’s disease and it was 
appropriate to have it as an option at any stage. Given that a shared decision paradigm requires 
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presentation of plausible options and elicitation of values, it should be appropriate to discuss all 
options prior to any planned procedure. 
15.8.3 What should pre-operative information include? 
Study participants expressed a list of informational items they would like to know when discussing a 
surgical treatment. These include items related to procedural conduct and high level outcomes of 
success and failure, impact of the procedure on quality of life and other functions, time needed to 
recover and aftercare considerations. These are summarised in figure 45. It is interesting that many 
patients were unable to recall the information shared with them during their consultations beyond 
the likelihood of success or failure of a treatment, and many expressed dissatisfaction with the amount 
of information given on non-technical features of procedures, including time to recover, impact on 
normal function, and in some cases sexual function. These experiences match with those reported in 
surveys of patients with IBD390. A study which included audio recordings of consultations about surgery 
for oesophago-gastric cancers found similar trends – surgeons focussed on technical factors and 
overall success (or mortality), whereas patients were more interested in time to recovery and impact 






Figure 45 What do patients want to know when discussing fistula surgery? 
 
15.8.4 Decision making 
The interviews have clearly shown that patients can make trade-off decisions. Items which participants 
commonly valued included chance of procedure success, avoidance of repeat surgery, rapid return to 
normal function, avoidance of stoma formation. These were traded against costs including risk of 
procedure failure, risk of fistula recurrence, risk of stoma formation. Patients all reported that function 
or quality of life at the time of making a treatment decision could affect the balance of their decision. 
When discussing hypothetical choices, participants typically stated they would favour the least 
invasive and least disruptive intervention. This fits with the broader patterns seen in shared decision 
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making, where deployment of this approach tends to reduce the number of invasive tests or 
procedures392.  
 
Two previous studies have assessed trade-offs between treatment options in Crohn’s disease and 
ulcerative colitis326 393. In order to understand the trade-off exercises, two key concepts are required: 
willingness to gamble, and willingness to trade. Willingness to gamble refers to the proportion of 
population who would risk a reduction of remaining life expectancy to avoid an alternate treatment. 
Willingness to trade describes the proportion of remaining life expectancy someone would risk to 
avoid an alternate treatment strategy326 393. In the study of preferences in Crohn’s disease, patients 
were keen to avoid major surgery including proctectomy and permanent stoma formation326. There 
was a trend towards differing preferences in patients who had been managed surgically vs those who 
had been managed medically; for example 47% of patients treated medically would gamble to avoid 
a laparoscopic ileocolic resection compared to 29% of surgically managed patients. The same study 
found that surgeons and patients placed similar values on the options, but gastroenterologists had 
widely differing opinions.  In a comparable study in ulcerative colitis, the same willingness to trade to 
avoid major surgery was seen, and trading preferences of gastroenterologists differed from the rest 
of the population393. Given the number of options available for treatment of Crohn’s anal fistula, this 
exercise should be repeated in this setting. 
 
15.8.5 Strengths and limitations 
The main limitation of this study is that it was undertaken across just two NHS hospitals. This means 
that experiences reported reflect only those from these sites, and may not be directly extrapolated to 
those outside of these centres. As participants were recruited at different points in their treatment 
pathway, there is a risk of recall bias affecting the experience. There is also the risk of responder bias; 
this means that only those with strong positive or negative experiences of disease or treatment 
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participated, leading to reporting of only extreme experiences. The sample size was sufficient to reach 
saturation. This relatively low number may reflect the frequent use of prompts to seek relevant 
information394. 
 
This study benefits from broad participation demographics, including male and female participants of 
varying age, with a mix of active and inactive fistula, and a broad range of procedural experience, 
including stoma formation. This means that the expressed desires of information delivery and content 
might be extrapolated more broadly. This study has also been conducted with appropriate 
methodological oversight, dual review of interviews, and reported to meet existing guidelines387. 
 
15.8.6 Implications for practice 
These interviews raise questions with direct relevance to clinical practice. One of these is: ‘How do we 
discuss surgical treatments with patients?’ The recent Montgomery ruling has implications around 
consent, specifically on discussion of options and recommendation of treatments taking into account 
patient values and preferences117. Study participants have indicated a range of factors of relevance to 
their decisions, the need for time to discuss with their surgeon, and the need for supporting literature 
or sources to use away from the clinical setting, prior to a major treatment decision being made. 
Current barriers to this approach include time, and the availability of relevant tools122. There is also a 
need to standardise the content of information, and this might be achieved through a core information 
set395. 
15.6 Conclusion 
This study shows that information and counselling about surgical treatment options for Crohn’s anal 

























16 Mixed Method II: Survey of patient experiences and preferences in receiving 





Findings from a limited number of semi-structured interviews cannot be generalised to the wider 
population, although they might provide a framework to guide quantitative research. To test the 
findings of the interviews in a wider population, a survey of patients is an appropriate next study. This 
permits the quantification of reported findings and measurement of variables using validated tool. It 
is also possible to undertake statistical assessment of data to investigate underlying factors using 
methods such as principal component analysis. 
 
16.2 Principal component analysis. 
Principal component analysis (PCA) is a form of factor analysis and is often used in complex datasets 
with multiple variables396. The objective of PCA is to reduce the number of factors accounting for 
variation within a sample: a process of dimension reduction397. This means that a small number of 
factors associated with the highest amount of variability in a model can be used to predict behaviour. 
Principal component analysis does not mean that factors are discarded to reduce variables. Instead, 
new variables (components) are calculated as combinations of the measured factors. These new 
factors may represent unobserved or indirectly measured (latent) variables or constructs396 398. Each 
of these new components are independent of each other. Each of the components should have 
significant contribution from a handful of factors, and each factor should only account for significant 
variation in one component. 
 
This is achieved by assessing the correlation of factors within a dataset. Correlation can be easily 
considered with a pair of data points, X and Y.  It is possible that several factors will move in in the 
same direction with similar magnitude as they measure items that are similar or related. Each of these 
clusters of correlating factors could form a principal component.  By including the Z axis, correlation 




The variation between clusters can be further explored by changing the position of the axes in order 
to change the relationship of clusters in 3D space. This analysis may allow the same component to 
account significantly for variability across several factors. It is possible to adjust for this by undertaking 
rotation of the axis. Varimax is a rotational approach in which the axes are rotated in many dimensions 
to identify maximum differences in the weighting of components. This means that components have 
either large or small weighted values for each factor, and each component identifies with one variable 
only397 398. Several methods can be used to determine the number of factors to be extracted and which 
components are considered to contribute to each factor397-399.  
 
The underlying relationship is identified by the research team by identifying factors with higher 
weighting in each component. If these can be combined into a plausible single idea, this might explain 
the underlying concept. This degree of interpretation is a strength and a weakness of PCA398. 
 
Principal component analysis is an appropriate analysis to use in this study as it can be used to assess 
information which is considered important for patients to make a decision about surgical treatment. 
A reduction in items would be helpful for the development of a decision aid where space is limited, 
and excessive information is not helpful. 
16.3 Aim 
To survey of patients who have undergone recent surgery for Crohn’s anal fistula to assess 







16.4.1 Item generation 
Item generation was undertaken with reference to three sources: 1) semi-structured interviews, 2) 
expert patient panel, 3) Clinician panel and 4) summary review of relevant literature. A summary of 
included domains and themes is presented in table 34. 
16.4.2 Semi-structured interviews 
Themes identified from semi-structured interviews were reviewed by the research team and 
considered for relevance to the research question. 
16.4.3 Expert patient panel 
Patient input on the questionnaire design was solicited from members of the standing ‘patient 
engagement’ panel for the ENiGMA collaboration. This is panel involves patients who have been 
treated for Crohn’s anal fistula. A representative from this group was asked to provide feedback on 
proposed areas of questioning, as well as phrasing of questions. 
16.4.3 Clinician panel 
The clinician panel included a colorectal surgeon and gastroenterologist with an interest in 
inflammatory bowel disease. 
 










Domain Theme Source 
Demographics Age/Sex 
Ethnicity 





Information source Clinician 
Supportive information/other source 





Items relevant to decision making 
Enough information received 
Interviews 
Patient panel401 
Decision making  Experienced decision-making style 
Preferred decision-making style 
Interviews 
Literature390 










Table 33 Domains and themes identified for inclusion in the questionnaire. 
 








• Time since Crohn’s disease was diagnosed 
• Last operation for fistula 
Information used before surgical treatment 
• Sources used (aside from hospital team) 
• Important items when discussing surgery 
Decision making about surgery 
• Was a choice offered 
• How was the decision made 
• Preferred decision-making style 
Context about decision 
• Was sufficient information provided 
• Preferred people to discuss treatment with 
• Regret about treatment decision 
Preferred information format 
• How should information be delivered? 
• Do you have internet access? 







16.4.4 Identification of validated measures 
Review of the literature identified two relevant measures; Control Preferences Scale (CPS) and 
Decisional Regret Score (DRS). 
16.4.4.1 Control Preferences Scale 
The control preference scale was developed in 1997 as a way of assessing the locus of control in 
treatment decision making402. This is a five-point scale which moves from decisions undertaken 
entirely by the patient to decisions taken entirely by the doctor, with varying degrees of input from 
each party along the scale (figure 46). It has been used and validated across several healthcare 
settings403-405. Whilst CPS is a broadly accepted tool, it is important to consider that it is based upon 
qualitative data from the 1970s. The surrounding context has changed significantly since that time406.  
There is now a cultural shift away from decisions being taken by the treating physician122. Patients 
have access to information through the internet, changing the balance of knowledge/insight around 
decision-making400. There are also many more treatment options available for fistula compared to the 
1970s, and this may also affect decision making. The key advantages of the CPS are that it is short, 
reliable, and is widely used and understood by researchers.  
 
I made the final selection about which treatment I had 
I made the final selection of my treatment after I had seriously considered my doctor/nurse’s 
opinion 
My doctor/nurse and I shared the responsibility for deciding which treatment was best for me. 
My doctor/nurse made the final decision about which treatment was used, but seriously considered 
my opinion. 
My doctor/nurse made all the decisions regarding my treatment. 




16.4.4.2 Decisional Regret Score 
Decisional regret score was first presented in 2003407. This is a five-item score has statements 
addressing regret about a decision. Each item is rated using a five-point Likert scale ranging from 
strongly disagree to strongly agree (figure 47).  Each point on the is attached to a score ranging from 
1-5. Items 1,3 & 5 frame the decision in a positive light, and items 2&4 address potential harm from 
the decision. Scoring of items 2&4 are reversed. The score for each component is calculated by 
subtracting one from the score attached to the Likert scale, and multiplying the result by 25. The score 
is averaged across the five items. A score of 0 means no decision regret, and 100 means high decision 
regret.  For a valid score to be calculated, each item must have a response408. Decision regret has been 
measured in many healthcare settings409, and the tool has been shown to be reliable408. 
 
It was the right decision 
 
I regret the choice that I made 
 
I would go for the same choice if I had to do it over again 
 
The choice did me a lot of harm 
 
The choice was a wise one 
 





16.4.4.3 Selection of other measures 
As no other validated measures could be found, measures were developed for this questionnaire. 
Respondent sex was presented using a tick box of male/female/other/prefer not to answer. Age and 
time since diagnosis of Crohn’s disease were left as free text responses to allow continuous data to be 
entered. Ethnicity was defined using headline descriptors recommended by the Office for National 
Statistics410. Highest level of education was presented as a select one tick-box response. 
 
Information sources used was populated using data from interviews, and respondents asked to tick 
each item used. Desired information was populated from interviews, and respondents asked to rate 
the importance of each item using a nine-point Likert scale. A nine point scale was selected as this 
offers a balance of reliability, ability to discriminate, and ease of use for respondents411.  
 
A three-item tick box (yes, no, not sure) was used to assess whether the respondent was offered a 
choice of operations. A similar three item tick box was used to assess whether the respondent felt 
they had enough information. 
 
A list of potential sources for verbal sharing of information was populated from interview items, and 
a tick all that apply option presented. A similar list was presented for the list of potential sources for 
information, and presentation of information. Five-point scales were used for access to internet and 








16.4.5 Questionnaire pre-pilot 
The questionnaire was subjected to iterative review by the research team and supporting panels. The 
group ensured revision of questions to be neutral in form, and that all pertinent response items were 
presented.  
16.4.6 Considerations within Total Survey Error framework 
















Sample size Appropriate sample size estimated with 
reference to Surgical Workload and 
Outcomes Reporting Database. Trade-off in 
power for attainable sample size made. 
Sample coverage Geographic spread of participating centres 
identified, including teaching hospital and 
district general hospitals, and those in the 
north and south of England. 
Non-response at unit level Questionnaires could be distributed by 
post, or when a potential participant was 










Non-response at item level Clear rubric developed through pilot phase 
and anonymity in response to encourage 
responses which may not match practice 
norms. Limited length of questionnaire to 
avoid fatigue. 
Measurement error due to respondents Anonymity in response to encourage 
responses which may not match practice 
norms. Limited length of questionnaire to 
avoid fatigue. 












Post-survey error Administrative plans for handling data 
made. Included recording of first response 
only if multiple responses given to single 
response question. 
Mode error Anonymous paper-based survey selected as 
considered more likely to be completed 
than web survey. 
Comparison error No comparisons planned. 




16.4.7 Ethical approval 
Ethical approval was secured from the London-Westminster REC (reference 17/LO/1446) (appendix 
S). Health Research Authority approval was secured prior to commencement of the study.  
16.4.8 Eligibility criteria 
Eligibility criteria for participation in the study was set as a patient who had undergone any surgery 
for Crohn’s anal fistula at the participating institution within the preceding 12 months. 
16.4.9 Setting 
Participating hospitals were identified through the ENiGMA network, and through regional research 
networks. The sites identified through the ENiGMA network were primarily teaching hospitals, and 
those through research networks were all   
16.4.10 Questionnaire validation  
Face validity was assessed by in a focus group. Potential participants were those who had undergone 
surgery for Crohn’s anal fistula at Sheffield Teaching Hospitals within the preceding six months. 
Participants were approached through clinic appointments and further information provided if 
requested. The focus group was held in a non-clinical area of the Royal Hallamshire Hospital at a 
mutually convenient time for participants and was planned to last for 1 hour. 
 
Five people agreed to participate in the focus group at clinic and at follow-up telephone call. Shortly 
before the focus group, two participants withdrew for work-related reasons. This left three 







ID Sex Age Last operation 
FG01 F 58 Loop colostomy 
FG02 M 27 Seton 
FG03 M 25 Seton 
Table 35 Focus group characteristics 
 
The focus group was presented with the questionnaire and asked to complete it in silence, annotating 
questions as they went. All participants completed the questionnaire within 10 minutes. Each question 
was discussed in order, with participants invited to offer comment and feedback on wording of 
question or response items, as well as presentation of items. The focus group indicated that they felt 
the questions asked had face validity. Participants did not identify any questions as irrelevant to the 
scenarios under discussion, providing a form of content validity. Minor amendments were suggested 
and agreed by the focus group and incorporated as shown in figure 48. The revised questionnaire was 
reviewed by the research team. The final version of the participant invitation letter and questionnaire 
is presented in appendix T and U respectively. 
 
Participants were also asked to comment on any questions which were not relevant to the scenarios 
under discussion, providing a form of content validity. Written and verbal feedback was collated and 
presented to the research team. Criterion validity was not assessed as there were no related validated 
questionnaires. Construct validity was not assessed as the questionnaire did not assess abstract 






• No change 
 
Section 2: 
• Add column to table of sources used to allow patients to rate how useful a source was. Use nine-
point Likert scale used elsewhere. 
• Include Wikipedia as an information source 
• Change wording of question on information items to be hypothetical. 
• Add items on ‘impact on sitting’ and ‘impact on sexual activity’ (both identified from interviews) 
 
Section 3: 
• Change the word ‘about’ to ‘of’ in the first question in this section 
• Change the order of the control preference questions to record ‘what happened’ first, followed 
by ‘desired outcome’. 
• Addition of support group as option for information source. 
 
Section 4: 
• Add ‘not applicable’ to question one. 
• Include rubric of ‘tick all that are relevant’ in second question. 
 
Section 5: 
• Add support group as an information source 
• Change smiley face image to stick people 
• Labels on bar chart should be exchanged for accuracy. 









Type of validity How assessed in this study Reason 
Face validity Verbal feedback from  
steering group and feedback 
from focus group. 
 
Content validity Informally assessed by 
steering group which included 
experts in the field. 
 
Construct validity Not assessed. No relevant validated 
questionnaires identified. 
Criterion validity Not assessed. No abstract concepts assessed. 
Table 36 Summary of validity assessment in questionnaire 
 
16.4.11 Questionnaire reliability  
Test- retest reliability was considered as an option for this study. The research team were concerned 
that there was a limited pool of potential participants with the condition and achieving a sufficient 
number for retesting might be a significant challenge. The reliability of measures such as CPS and DRS 
are already known. Intra-class correlation was assessed for the 9-point scales related to importance 





Type of reliability How assessed in this study Reason 
Test-retest (stability) Not assessed Access to participant pool 
limited, and patients may 
undergo multiple procedures in 
a short period of time.  
Alternate form (equivalence) Not assessed Rewording of questions and 
scales would require 
generation of a significant 
question bank, outwith 
resource of the study. 
Internal consistency  Assessed for 9-point scales of 
preferred information only. 
Validated tools used have well 
documented consistency and 
reliability. 
Table 37 Summary of reliability assessment in questionnaire 
 
16.4.12 Data capture 
Potential participants were identified by the participating hospital and according to the eligibility 
criteria. Participants were sent a copy of the questionnaire, along with a cover letter explaining the 
study, and a prepaid envelope for return of questionnaire. Questionnaires were returned to the 
research team and entered into a REDCap database286. Decision regret was only entered where 
responses to all five items were available. If a respondent ticked multiple boxes where only one was 






16.4.13 Sample size calculation 
The surgical workload and outcomes database estimates that approximately 1000 operations are 
performed each year for Crohn’s anal fistula. The research team estimated that approximately 200 of 
these were likely to be repeat procedures. This means that 86 responses are required to achieve a 
10% margin of error with a 95% confidence interval. To facilitate PCA, a minimum of 5 responses per 
information item was required, meaning a minimum of 75 responses was need. The response rate was 
potentially as low as 39%412 therefore a minimum of 225 questionnaires had to be distributed to 
potential participants. 
 
16.4.14 Statistical analysis 
Descriptive statistics were reported for frequencies with median or mean and either standard 
deviation or interquartile range presented as appropriate. Correlation between continuous variables 
was assessed using Spearman’s correlation. Comparisons across groups were performed using analysis 
of variation (ANOVA) or Kruskal-Wallis tests as appropriate.  
Principal component analysis of importance of factors to decision making was conducted using SPSS 
version 24 (IBM, Armonk, NY). The dataset was first checked for adequacy of sampling using the Kaiser-
Meyer-Olkin test. The dataset was checked for sphericity (i.e. whether it contains sufficient variation 
to permit PCA) using Bartlett’s test. Following initial tests, a correlation matrix was constructed. 
Communalities of factors were assessed to identify and remove any factors with values of <0.6.  PCA 
was conducted using a varimax orthogonal rotation matrix. Factor reduction was undertaken using 
the Eigenvalue method, where factors with Eigenvalue <1 were removed. The loading of remaining 
factors was assessed. A loading value cut-off of 0.45 was selected as it is associated with ‘good’ 
discrimination between trivial and non-trivial factors399.  The resulting factors and components were 
assessed by the research team for face validity of the construct. Where there was cross loading of a 
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factor across two components, each component was reviewed to identify the best fit for the factor. 
Internal consistency of each factor was assessed using Cronbach’s alpha. 
16.5 Results 
16.5.1 Centre level responses 
Ten sites participated in the study and distributed 220 questionnaires. A total of 92 responses were 
received giving a response rate of 41.8%. A summary of number of responses by participating site 
are presented in table 38. 
 Sent Returned Response rate 
Nottingham 26 7 26.9% 
Cambridge 31 12 38.7% 
Sheffield 19 12 63.2% 
Doncaster 17 5 29.4% 
Guys & St Thomas’ 45 18 40% 
Manchester 22 7 31.2% 
Blackpool 7 4 57.1% 
Oxford 20 7 35.0% 
Birmingham 24 18 75.0% 
Royal Devon & Exeter 9 2 22.2% 
Overall 220 92 41.8% 
Table 38 Questionnaire response by site. 
 
16.5.2 Respondent demographics 
The characteristics of respondents are shown in table 39. A broad demographic was captured with an 
approximately even split by sex, a wide age range and duration of Crohn’s disease. There was also a 
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range of respondents according to educational level, ethnicity, and most recent operation on their 
fistula. 
16.5.3 Reliability 





 Frequency Percentage 
Sex   
Male 44 47.8 
Female 48 52.2 
   
Ethnicity   
Asian (British, Indian or Pakistani) 8 8.7 
Black (British, African or Caribbean) 5 5.4 
White British 68 73.9 
Mixed or multiple heritage 5 5.4 
Other 4 4.3 
Prefer not to say 1 1.1 
   
Level of highest qualification   
None 7 7.6 
GCSE 23 25.0 
A-level 22 23.9 
Bachelor’s degree 23 25.0 
Higher degree e.g. MSc/PhD 12 13.0 
Other 3 3.3 
   
Last operation for fistula   
Examination under anaesthesia only 13 14.1 
Seton insertion 54 58.7 
Advancement flap 2 2.2 
Fistula plug 6 6.5 
Proctectomy 3 3.3 
Diverting stoma 5 5.4 
Not sure 4 4.3 
Other 5 5.4 
   
 Median Range 
Age (years) 42 19-87 
Duration of disease (years) 8 0.08-37 










16.5.4 Sources of information used 
Respondents were asked to report whether they were helped to make decisions by talking to 
surgeons, gastroenterologists or nurse specialists in clinic settings. Surgeons were helpful to 74 
(80.4%) respondents, gastroenterologists to 58 (63.0%) respondents, and Nurse specialists to 46 
(50.0%) respondents. The most frequent sources used to gather information aside from clinicians were 
leaflets from the treating hospital (43.5%) and the patient’s GP (41.3%) (table 40). Friends and family 
had the highest median reported helpfulness score of 8, although GP, online video, NHS choices and 
hospital leaflets all achieved a score of 7. The range of these ratings was wide (figure 49). 
 
 Number who used source Percentage who used source 
GP 38 41.3 
Internet forum/chatroom 
36 39.1 
Social media 17 18.5 
Wikipedia 18 19.6 
Online videos 19 20.7 
Charity Websites 17 18.5 
NHS Choices 29 31.5 
Leaflets from hospital 40 43.5 
Friends or family 16 17.4 






Figure 49 Respondent rating of helpfulness of different information sources. 
Box and whisker plot showing median and range of values 
 
16.5.5 Desired information 
 
Respondents indicated the importance of items using a 9-point Likert scale. All items were felt to be 










How long will I stay in hospital? 86 8 6-9 
Will the treatment close the fistula? 85 9 8-9 
The risks of the operation 88 9 8-9 
How painful is the operation? 86 8 5-9 
How invasive is the operation? 87 8 6-9 
Will I need wound care when I go home? 88 8 6-9 
Will I need to attend my GP after my operation? 85 7 5-9 
Will I need to attend hospital frequently after 
my operation? 
86 8 6-9 
Will I need further surgery? 89 9 7-9 
Will the treatment stop discharge? 87 9 8-9 
Will the treatment affect my continence? 88 9 9-9 
Will the treatment affect my ability to work? 88 9 7-9 
Will the treatment affect my ability to sit down? 87 9 8-9 
Will the treatment affect sexual activity? 88 8.5 7-9 
Will I still need to take medications for the 
fistula? 
86 8 6-9 
Table 41 Summary of importance of information items when discussion treatments. 
 
 
These values underwent factor analysis using Principal Component Analysis. Data was tested for 
appropriateness for this form of analysis. Kaiser-Meyer-Olkin (KMO) test for sampling of adequacy was 
0.811, showing good sampling. Kaiser-Meyer-Olkin (KMO) assesses the proportion of variance within 
the dataset that might be due to underlying factors or co-variance; the higher the number, the more 
likely it is that the data is appropriate for a factor analysis methodology. Bartlett’s test confirmed 
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sphericity of data i.e. that data and variables were summarised in such a way that variables can be 
summarised into fewer factors(p<0.001). On first assessment of communalities, 10 items had 
communality values <0.6. These were excluded from the analysis, and communalities were 
recalculated. In this second round of extractions, Kaiser-Meyer-Olkin value was 0.781 showing 
adequate sampling and Bartlett’s test for sphericity remained significant (p<0.001) (Table 42) 




Length of stay 1.000 .490 - 
Will treatment close fistula 1.000 .442 - 
Risks of procedure 1.000 .663 0.750 
How painful procedure is 1.000 .782 0.787 
How invasive procedure is 1.000 .753 0.779 
Need help with wound at home 1.000 .638 0.734 
Need to attend GP after surgery 1.000 .781 0.840 
Need to attend hospital after surgery 1.000 .741 0.768 
Need for further surgery 1.000 .542 - 
Will treatment stop discharge 1.000 .710 0.750 
Effect on continence 1.000 .772 0.817 
Effect on work 1.000 .575 - 
Effect on sitting 1.000 .697 0.705 
Effect on sexual activity 1.000 .451 - 
Need for future medications 1.000 .524 - 
Table 42 Communalities of factors included in principal component analysis. 
 
Assessment of Eigenvalues identified three components with values >1 (figure 50), accounting for 
76.9% of variability (Table 44. Eigenvalues denote the spread of data across an imaginary line of 
correlation for data pairs. The more spread out the datapoints are along this line, the better the 




Total Variance Explained 
Component 
Initial Eigenvalues 
Extraction Sums of Squared 
Loadings 
Total % of Variance Cumulative % Total % of Variance 
1 4.158 46.198 46.198 4.158 46.198 
2 1.673 18.591 64.789 1.673 18.591 
3 1.099 12.207 76.996 1.099 12.207 
4 .537 5.965 82.961   
5 .430 4.776 87.737   
6 .356 3.956 91.693   
7 .304 3.383 95.076   
8 .277 3.079 98.155   
9 .166 1.845 100.000   




Figure 50 Scree plot of Eigenvalues.  






In component 1, wound care, including attendance at general practice and hospital following surgery 
were heavily weighted (Table 44). This fits with a theme of ‘Wound and aftercare’. Procedure related 
pain was weighted >0.450, but also cross-loaded with component three, where it was conceptually a 
better fit. 
 
For component 2, effect of treatment on discharge, continence and sitting were weighted >0.450. This 
may reflect the effect of treatment on perianal symptoms. 
 
For component 3, risks of procedure, procedure related pain, and invasiveness of procedure were 







1: Wound and 
immediate aftercare 
2: Effect on 
perianal region 
3: Severity of 
procedure 
Risks of procedure .078 .156 .848 
How painful procedure is .656 .033 .596 
How invasive procedure is .254 .050 .844 
Need help with wound at home .744 .370 .208 
Need to attend GP after surgery .905 .094 .106 
Need to attend hospital after surgery .839 .195 .160 
Will treatment stop discharge .125 .836 .190 
Effect on continence .083 .899 -.044 
Effect on sitting .301 .773 .128 
Table 44 Weighted factors associated with components in PCA.  
Highlighted components are those exceeding cut off of 0.450. 
 
 
Reliability was calculated for each of these components. Corrected item correlation was >0.5 for all 
scale items. Cronbach’s alpha showed good correlation of items in all components (Table 45). 
 




Need help with wound at home .707 
0.859 
Need to attend GP after surgery .801 





Will treatment stop discharge .575 
0.793 Effect on continence .729 
Effect on sitting .649 
Severity of 
procedure 
Risks of procedure .569 
0.788 How painful procedure is .640 
How invasive procedure is .701 




16.5.6 Choice and CPS profile 
Respondents stated that 34 (40.2%) had been offered a choice of operation, 46 (50.0%) were not 
offered a choice of operation, and 9 (9.8%) were not sure if they were offered a choice.  Sixty-four 
(69.6%) respondents felt they had enough information to support decision making; 22 (23.9%) did not 
feel they had enough information and 6 (6.5%) respondents responded ‘not applicable’ as they did 
not feel they made a decision. 
 
Respondents reported that decisions were made by doctors entirely in 22.8% cases, or with patient 
input in 13.0% cases. The decision was shared in 32.6% cases. In contrast, the preferred locus of 
control for respondents was closer to the patient with 45.7% desiring shared responsibility for 
decisions, 17.4% wanting the doctor to make the decision with their wishes in mind, and 29.3% 
wanting to make the decision with the doctor’s input. The difference between actual and preferred 






Figure 51 Differences between experienced and preferred decision making about last operation 
reported using control preference scale categories.  













16.5.7 Decisional regret 
Decisional regret was assessed across the group 74 complete responses were received. The median 
decision regret score was 17.2 (range 5.6-33.3). There was no significant difference in the reported 
decision regret by operation (ANOVA, p=0.54) (table 46 & figure 52), or who made the decision for 
surgery (Kruskall-Wallis, p=0.14). Both increasing age and increasing duration of disease were 
associated with increased levels of decisional regret (Spearman r 0.935, p<0.001 and 0.790, p<0.001 
respectively). Spearman correlation between last treatment decision according to control preference 
scale showed that decision regret decreased as the decision moved closer to the clinician (Spearman 
r = -0.241, p=0.025) (figure 53). This association was the same as that with decision maker and age, 









Examination under anaesthesia 
only 
12 16.5 5.6-31.3 
Seton insertion 43 13.7 7.0-31.3 
Advancement flap 2 20.4 19.3-21.5 
Fistula plug 5 19.4 9.6-29.0 
Proctectomy 1 20.7 - 
Diverting stoma 3 24 21.3-24 
Not sure 3 16.3 10.6-27.5 
Other 5 11 8.3-17 
Table 46 Decisional regret according to last operation.  





Figure 52 Decisional regret according to last operation 
 
Figure 53 Decision regret according to decision making process. 




16.5.8 Preferred information format 
The preferred format for sharing of information to support decision making was from the surgeon 
80/92 (87.0%), and booklet 58/92 (63.0%). Nurse specialists may also have a role to play for 43/92 
(46.7%). Other resources scored much lower in terms of preference (table 47). 
 
 
Number who would like 
resource 
Percentage of respondents 
Booklet 58 63.0% 
DVD 21 22.8% 
Patients 32 34.8% 
Interactive website 29 31.5% 
Webpage 34 37.0% 
Surgeon 80 87.0% 
Nurse 43 46.7% 
Don’t want 0 - 
Support group 8 8.7% 
Not sure 4 4.3% 






This study has two main findings. Firstly, patients use a range of information sources when considering 
surgery for Crohn’s anal fistula. Secondly, there are specific items of information that will help patients 
to make treatment decisions. The study suggests that patients would prefer to make decisions in a 
more shared manner than occurs at present, although this was not statistically significant. 
16.6.1 Findings in context of literature 
The finding that a range of information sources are used is not novel253 400. This study does provide an 
estimate of how useful patients consider the different sources, although this is limited by the sample 
size. In context, this study tells us that patients are likely to prefer information being shared directly 
by the surgeon and supported by a written information leaflet. 
 
In keeping with the wider cultural shift, respondents tended to favour control preferences that 
involved a sharing of decision responsibility between patient and clinician123. This was in contrast to 
the experienced decision-making style, which tended towards clinician centred in many cases. 
 
Decision regret has been recorded in one previous study in Crohn’s disease in a small cohort 
undergoing a single procedure: Video Assisted Anal Fistula Treatment, (VAAFT)413. Unfortunately this 
has not been calculated as described by the user manual408, and instead proportion of patients 
indicating each response item have been reported. Decisional regret has been used across other 
surgical conditions414 415 and should be investigated further in Crohn’s disease. In a condition where 
healing is rare, more patient focussed measures may be of greater help to distinguish ‘good’ 
treatments. 
16.6.2 Strengths and limitations 
The main strength of this study arises from its wide geographical sampling of respondents. This has 
ensured a mix of age, sex and ethnicity that would have been challenging to achieve in a single centre. 
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Findings of the PCA can be considered robust as tests have confirmed adequacy of data sampling. 
There are also recognisable limitations. Survey based research is affected by responder bias251 252. 
Whilst efforts were made to facilitate easy return of the questionnaire, respondents may have been 
drawn from the extremes of positive and negative experience. There was limited response from some 
hospitals, and this may reflect the local demographic or patient experience at the unit. Visual 
inspection of data and statistical analysis shows that the sample is balanced and suggests a range of 
experiences are represented here. Recall bias may also be an issue, as the survey was administered at 
various times following surgery251 252. These strengths and limitations are considered within the total 
survey error framework in table 48. 
 
 











Sample size Sample size reached.  
Sample coverage Broad spread across England. Mix of age, 
sex and ethnicity achieved. 
Non-response at unit level Moderate non-response, with rates lower 
at some hospitals. May reflect care 









y Non-response at item level Missing responses in decision regret 
scoring. Standard rubric used. 
Measurement error due to respondents Some responses missing, may reflect 
fatigue. Risk of recall bias. 











n Post-survey error Plans for handling of data adhered to. 
Mode error Paper survey likely most effective mode. 
Some attrition at end of questionnaire. 
Comparison error N/A 




16.6.3 Policy impact 
The findings of this study should affect clinical practice. The consensus guidance described in chapter 
13 advocates a shared decision-making approach to treatment options. This statement should be 
strengthened in future iterations to make it a key principal of management. Guidelines and quality 
markers have been developed by several stakeholder groups. These largely focus upon clinical 
outcome measures such as clinical recurrence, mortality and use of diverting stoma416. Patient 
reported outcomes such as the ‘friends and family’ test are now routinely collected as part of NHS 
practice417. It should be possible to integrate an assessment of a patient reported outcome measure 
of decision making, such as the control preference scale, into routine clinical practice and use this as 
a quality metric. The use of a wide number of sources including websites and booklets also presents a 
challenge to policymakers. These sources have been shown to be difficult to read and have limited  
function in support of treatment decisions125 418 419. Policymakers should recognise this and develop 
appropriate material to fulfil this role. 
16.6.4 Impact for researchers 
The study suggests variation between desired and perceived experiences of decision making, and 
identifies key items required to support patients to make treatment decisions. These items have 
shown great reliability and could be used to develop a tool to assess condition-specific preparedness 
for decision making. This may support engagement of patients in decision making. The study has also 
shown that decision regret can be collected in this patient group. Decision regret is difficult to 
interpret in isolation of outcomes and clinical factors. A prospective study using changes in quality of 
life might aid estimation of clinically important differences in decision regret for different treatments. 
Characterisation of patients with high and low decision regret might facilitate a stratification method 




Patients use a range of information items to retrieve information about surgery and require 






























The previous chapters explore the experience s of those treated for Crohn’s anal fistula using different 
research methods. The interpretation of these findings can be strengthened through use of mixed 
methods analysis. The benefits of this approach have been discussed in chapter 14. This chapter 
describes triangulation and comparison of the two data sources used. 
 
 
17.2 Justification of triangulation methodology  
As outlined in Chapter 14, quantitative and qualitative data can be combined in several different 
ways, each of which is able to demonstrate convergence or dissonance of findings.  
 
17.3 Aim 
The aim of this study was to triangulate findings from the qualitative and quantitative interviews. 
 
17.4 Method 
Data was combined using a ‘merged’ approach, where preliminary analysis of each study is completed 
prior to combination of each dataset. The relationship is shown in figure 54. Integration of  data was 
achieved through triangulation of methods following the triangulation protocol378. Findings from the 




Figure 54 Flow of information in merged study. 
 
17.4.1 Sorting of findings  
The findings of the two studies were reviewed by a single researcher to identify key categories or 
themes in each dataset. The themes from each component study were combined into one unified list. 
This formed the basis of the subsequent assessments.  
 
17.4.2 Assessments of extent of agreement 
For each theme identified on the unified list, the data was compared to identify whether the two 
sources showed agreement. This can be described as complete agreement, partial agreement, 
silence, or dissonance. 
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17.4.3 Assessment of overall convergence 
Convergence was assessed by assessing both meaning expressed in each theme. If a range of opinions 
were expressed in one study, and this range was reflected in the other study, the sources would be 
considered convergent. The datasets were also assessed for prominence of data i.e. the frequency 
with which a theme is mentioned or reported. Convergence could be defined as: 
• Agreement: Full agreement in meaning and prominence of themes 
• Partial agreement: Agreement on one but not both components 
• Silence: One source does not report or discuss a theme identified in the other 
• Dissonance: Disagreement between both sources on meaning and prominence of findings 
 
17.4.4 Completeness of data  
Completeness was assessed by comparing questions asked around each theme in each study, and 
identifying where the datasets overlap allowing complete assessment of the sources. It is also used 








The unified list of themes contained six items: clinicians as an information source, other sources of 
information, the information needed to make treatment decisions, decision making experiences and 
preferences, and satisfaction with treatment choice. Themes, prevalence in the two studies, and 

























Clinicians as a source of 
information 15 92 
‘It’s just sitting down and taking the 
time….it would be helpful to give a 
leaflet…maybe even some pictures of 
stuff.’ 
Available information sources 
aside from clinicians 
15 92 
‘I used the Crohn’s forum and there’s 
different sections for stuff. You can 
literally just click on one that’s about 
fistulas, and it will tell you loads of stuff. 
You can type in and message that I’d had 
one done, and can anyone offer some 
advices – loads of people come back and 
tell you stuff, it’s great.’ 
Satisfaction with information 
received 
15 92 
‘It just seems like everything is really 
rushed and they haven’t got time to 
really talk to you. They don’t actually sit 
down half of the time and it’s like duh, 
duh, duh, and they go into their offices, 
and it’s like…are we done?’ 
Information needed to make 
treatment decisions 18 89 
‘Recovery time. I want to know about 
aftercare and exactly what’s going to 
happen…..Speed and effectiveness 
really.’ 
Decision making experience 
and preferences 
18 92 
‘I like to be led by somebody who knows 
what they’re on about. I like to make my 
own decision, but I like to be led in the 
right direction….as long as they’re honest 
with me and lay all the information out, 
and not concentrating too much on worst 
and best. [Talk] about the middle ground 
where most people end up. I think I can 
make a pretty informed decision.’ 
Satisfaction with treatment 
5 72 
‘I was reasonably happy to have it ….I was 
going through a ‘no-life’ situations, and I 
thought ‘stoma bag can’t be any worse 
than this is’….which as it’s proving, it’s 
not.’ 











17.5.2 Assessment of agreement 
Sources were assessed for agreement according to prevalence and meaning of themes. 
17.5.3 Full agreement 
Decision making experiences and preferences was the only theme with consistent spread of findings 
across both sources. Both sources showed equally high prevalence of this theme. The style of decision 
making experienced was typically felt to be clinician led with minimal input from the patient. Sources 
also agreed that patients wanted to be more involved in decision making; a shared decision model, or 
one skewed slightly towards either participant was consistently preferred.  
17.5.4 Partial agreement 
 
17.5.4.1 Clinicians as a source of information 
Partial agreement of meaning was identified for the theme ‘clinicians as a source of information’. This 
theme centred upon how useful different clinician groups were at providing treatment information. 
Both sources agreed that surgeons were good sources for information. Nurse specialists were 
accessed as sources of information about surgery in both groups, although there were differing 
opinions on how helpful they were, with some very negative opinions expressed in interviews.  A 
similar pattern was seen with respect to gastroenterologists. 
 
17.5.4.2 Information sources other than clinicians 
Partial agreement was also identified in for the theme Information sources other than clinicians. 
Whilst highly prevalent, there were differences in findings between the two sources. The survey 
indicated that when used, other sources of information were very useful. Interview participants did 
find many different sources useful such as leaflets provided by the hospital. The interview participants 
expressed concern over some online information sources such as online forums. There was some 
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scepticism expressed over the accuracy or reliability of the information provided in these settings. The 
ability of online information to support decision making has been assessed , and was not of adequate 
quality to support decision making125. 
17.5.4.3 Information needed to make decisions 
This was rated as partial agreement as the prevalence of the theme was not consistent across the 
sources, nor were the findings, although they showed some common trends. Items related to decision 
making addressed in the quantitative study (questionnaire) were identified from the patient 
questionnaire. All items presented in the questionnaire were rated as highly important, with a median 
score of 8. This matched the emphasis placed on many items in the interviews as being ‘key’ to making 
treatment decisions. Although items such as impact on sexual function were not as prevalent in the 
interviews, they were rated highly in the questionnaire.  
17.5.4.4 Satisfaction with treatment decisions 
Satisfaction with treatment decisions was mixed, including extremes of opinions about their 
treatment. Decisional regret scores had a relatively consistent median. Whilst there were extremes of 
scores, there was no statistically significant difference across groups by procedure. This may reflect 
under sampling of specific procedures in both the interviews and the questionnaire. 
17.5.5 Convergence assessment 
Overall assessment showed full agreement for 1/5 themes and partial agreement for 4/5 themes. No 
examples of dissonance or silence were identified. This shows a moderate level of agreement across 
the two studies. A convergence matrix is presented in table 50.  
17.5.6 Completeness comparison 
Comparison of the data sources for completeness. The questionnaire was based upon the interviews 
therefore it did not identify any new areas for assessment. The interviews provide additional content 
describing reasons why specific opinions may be given (e.g. bad previous experience with a clinician). 
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The datasets support the identification of these themes and provide potential reasons for variation in 











Clinicians as a source of 
information 
 X   
Available information sources 
aside from clinicians 
 X   
Information needed to make 
treatment decisions 
 X   
Decision making experience 
and preferences 
X    
Satisfaction with treatment 
decisions 
 X   






Mixed methods assessment of the two sources has demonstrated complementarity of sources 
discussing informational and decisional preferences in Crohn’s anal fistula. Findings show 
convergence with no evidence of dissonance. 
17.6.1 Findings in context 
Complete agreement was achieved for the theme on decision making experiences and 
preferences. This was consistent across the two sources and showed the imbalance between 
experienced and preferred models. This is in keeping with the literature where a shared approach 
is preferred by both patients and clinicians122 390. 
 
There were varying levels of satisfaction with treatment outcomes. Moderate levels of decisional 
regret related to surgery have been identified in other complex settings related to biologic use401 
and following surgery420. A single centre study assessing patients undergoing planned major 
procedures, the majority of which were for cancer, found low levels of regret421. This may reflect 
that operations associated with cure or treatment of cancer are easily considered a good idea as 
outcomes may be framed in terms of survival from cancer, whereas surgery for Crohn’s anal fistula 
is typically considered in terms of quality of life. 
 
The role of clinicians in giving information and the role of alternative information sources has 




17.6.2 Strengths and limitations 
This study has been conducted in line with the published triangulation protocol378, ensuring a 
robust approach has been employed. For pragmatic reasons the assessment has been carried out 
by a single researcher. This means that while triangulation was completed across themes and 
sources, it was not completed across researchers. 
 
17.6.3 Impact for policy makers & researchers 
These sources show partial to full agreement across all themes, and findings should be considered 
reliable. Stakeholders such as inflammatory bowel disease charities, clinical professional 
associations, and patient advocacy groups should consider how this study can impact patient care. 
Addressing the standards of information provided in a clinical setting, both in terms of content 
and format, could address some of the issues raised by patients. Implementation of an 
assessment of shared decision-making following clinic appointments might help to shift the 
decisional model. 
 
Researchers should investigate the characteristics of patients associated with their preferred 
decision-making model, to ensure resources for shared decision making can be deployed 
appropriately. Studies eliciting patient treatment goals and matching these with different 
procedure types and outcomes would assist in tailoring treatments appropriately. This could be 




Mixed method assessment of informational and decisional preferences shows the importance of 
information from multiple sources, the imbalance between preferred and experienced decision-




























• There is no clear front running surgical intervention. The available literature is severely 
limited by study design bias and outcome definitions. 
• Pooling of all patients with fistulating Crohn’s disease demonstrated a benefit from anti-
TNF-α agents in the induction and maintenance of fistula response. Stem cells show 
benefit and may be used as a second or third line treatment. 
 Variation of clinical practice: 
• There is variation in medical practice,  including the initial medical management of fistula. 
The timing of reassessment, and the strategies for escalation or de-escalation of medical 
therapy also show wide divergence in practice. 
• There is wide variation in surgical practice, and the range of definitive procedures offered. 
• Clinical pathways show wide variation in the time taken to access definitive therapy. 
There are potential barriers in the form of diagnosis and interface between specialties. 
• A consensus exercise on the surgical management of Crohn’s anal fistula among UK 
surgeons has identified a strategy preferring sphincter-sparing procedures. It also 
proposes criteria for consideration of faecal diversion. 
Mixed method research: 
• Patients are not satisfied with the content or delivery of information from clinicians. They 
seek information from other sources including peers. 
• Patients would like to be involved in making treatment decisions.  
• Wound care, effect on perianal region, and severity of operation are key information 
domains for patients to make decisions about their treatment. These items could form a 
preparedness for decision making tool. 
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18.1 Impact for policy makers 
This thesis has identified variation in the treatment of Crohn’s anal fistula. This variation could be 
linked to worse care experiences for some patients. There is a major policy drive to reduce 
variation across general surgery in emergency and elective settings422 423. It is important to extend 
this to the care of patients with inflammatory bowel disease who are cared for by both surgeons 
and physicians, increasing the opportunity for variation. As previously highlighted, variation can 
be due to limited information and limited resources284. Policy makers should consider factors 
outlined below (Figure 55). 
18.1.1 Addressing the information gap 
Whilst this thesis highlights many of the unknowns in the management of Crohn’s anal fistula, it 
does identify aspects of evidence-based practice, such as the use of anti-TNF-α drugs for induction 
and remission of fistula. There are many unknowns, and specific areas of need include the 
optimum timing, delivery, dosage of drugs, and role of surgery. Policy makers should work with 
funding bodies to commission work to address these knowledge gaps.  
 
Policy makers should use available information to synthesise evidence-based treatment 
guidelines. Given the level of variability in patient disease patterns, it is unlikely that a one-size 
fits all pathway will be appropriate. Current key performance indicators for Crohn’s anal fistula 
are based around outcomes such as abscess recurrence, stoma, and proctectomy rate416 These 
indicators are clinical outcomes based, and consideration should be given to patient-centred 
performance indicators. The evaluation of any evidence-based pathway should focus on the 




18.1.2 Addressing the resource gap 
Pathway work highlighted the challenge of moving a patient through a treatment pathway, even 
in centres with a large IBD practice. This may partly reflect capacity within the service to deliver 
the treatment pathway, including radiology and surgical services. Arguments have been made for 
the centralisation of pouch surgery424, and patients are willing to accept longer travel times to 
reduce the risks of complications of treatment425. Policy makers should consider whether this is a 
strategy that should be pursued in the context of Crohn’s anal fistula. 
 



































18.2 Impact for researchers 
This thesis suggests aspects of Crohn’s anal fistula treatment that require further investigation; 
decision making and regret, timing of treatment, and stratification & classification. 
 
18.2.1 Decision making & regret 
This thesis has explored practices around decision making. Patients have demonstrated a desire 
to be involved in decision making. Given the important of patient preferences in this condition, 
methods to improve patient participation in decisions should be investigated. The development 
of a patient decision aid would be a useful next step to address this. This thesis addresses the 
requisite early steps for the development of a patient decision aid128, and could be used to support 
the pilot and validation of such a tool. Mixed method work has supported the generation of a tool 
that might be used for procedure specific preparedness for decision making. Provision of 
information about surgical interventions might provide sufficient information to avoid decisional 
conflict and regret. This tool should undergo iterative development and assessment of validity 
using a generic preparedness for decision-making questionnaire as a reference anchor, and 
testing of reliability. The effect of this on decisional regret and other decision measurement 
indices could be tested in a randomised controlled trial.  
 
Decision regret has also been recorded following different procedures at various time points. This 
could be a useful outcome measure when counselling patients. This tool could be embedded in a 
cohort study of patients undergoing surgical treatment of Crohn’s anal fistula. This might give 
helpful information on its own, or coupled with an appropriate clinical outcome measure. 
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18.2.2 Timing of interventions and effect on outcomes 
There is variation in the time to complete the initial treatment pathway. It is not clear whether 
this affects outcomes. Whilst it would be logistically easier to conduct a cohort study to assess 
this relationship, this would be subject to significant confounding. Therefore, a randomised trial 
of a rapid initial treatment pathway should be considered. The proposed PICO is shown in figure 
56. 
 
Population: Presentation of new symptomatic Crohn’s fistula in TNF naïve patient 
Intervention: Rapid treatment pathway starting anti-TNF in 30 days. Includes preparation of 
fistula for healing by EUA with curettage of track as per Panes246. 
Control: Pragmatic control (standard care). 
Outcome: Fistula drainage index 6 months after starting treatment. Secondary outcomes as per 
core outcome set173. 



















There are several different classification systems in use for Crohn’s anal fistula53 54 247, none of 
which are truly satisfactory in terms of describing and predicting disease behaviour. Prognostic 
factors identified are typically those which are clinically apparent315. To ensure appropriate 
comparisons and to stratify patients by likely clinical outcomes, a new classification system is 
needed. This could be achieved through a prospective cohort study, with profiling of 
demographics and baseline physiology (including tissue sampling for potential biomarkers), and 
collection of treatment parameters. Outcome measures should include fistula drainage at 6 
months, fistula recurrence, complications of fistulating disease, and a quality of life measure173. 
Decision regret could be included in this study to ensure efficient conduct and not to exhaust the 






In Crohn’s anal fistula, anti-TNF-α drugs and azathioprine can be used for induction treatment, 
and the former for maintenance of treatment response. There is no front running surgical 
treatment for this condition. The limited evidence base is reflected in the variation reported in 
clinical practice by surgeons and gastroenterologists, and in the initial treatment pathway. 
Patients would like to be involved in decisions about their treatment, and have identified key 
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Appendix A: Search Strategy Medical Systematic Review 
 
COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS (CENTRAL)  
 
#1 MeSH descriptor: [Crohn Disease] explode all trees  
#2 Crohn 
#3 #1 or #2 
#4 MeSH descriptor: [Rectal Fistula] explode all trees 
#5 fistula 
#6 fistul* 
#7#4 or #5 or #6  




1  random$.tw. 
2 factorial$.tw. 
3 (crossover$ or cross over$ or cross-over$).tw. 
4  placebo$.tw. 
5  single blind.mp. 
6 double blind.mp. 
7 triple blind.mp. 
8 (singl$ adj blind$).tw. 
9 (double$ adj blind$).tw. 
10 (tripl$ adj blind$).tw. 
11 assign$.tw. 
12 allocat$.tw. 
13 crossover procedure/ 
14 double blind procedure/ 
15 single blind procedure/ 
16 triple blind procedure/ 
17 randomized controlled trial/ 
18 or/1-17 
19 Limit 18 to human 
20 Exp Crohn disease/ 
21 Crohn*.mp. 
22 20 or 21 












3 (crossover$ or cross over$ or cross-over$).tw. 
4  placebo$.tw. 
5  single blind.mp. 
6 double blind.mp. 
7 triple blind.mp. 
8 (singl$ adj blind$).tw. 
9 (double$ adj blind$).tw. 
10 (tripl$ adj blind$).tw. 
11 assign$.tw. 
12 allocat$.tw. 
13 crossover procedure/ 
14 double blind procedure/ 
15 single blind procedure/ 
16 triple blind procedure/ 
17 randomized controlled trial/ 
18 or/1-17 
19 Limit 18 to human 
20 Exp Crohn disease/ 
21 Crohn*.mp. 
22 20 or 21 
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Appendix B: GRADE PRO Medical Systematic Review 
 
Comparison 1: Drug therapy versus placebo 
 
Drug class  Outcome  Pooled RR  
(95% CI, p)  
 
Number of  
participants 
Quality* 
Antibiotics  Induction of fistula response 1.68 





Induction of fistula remission 1.20 















(1.22 to 5.23, p = 0.01) 
123 
(6 studies)  
⊕⊕⊝⊝3  
Low 




(0.85 to 7.21, p = 0.10)  
114 
(4 studies)  
⊕⊕⊝⊝4  
Low 




(0.03 to 4.19, p = 0.0006)  
2 


























(1.40 to 3.04, p = 0.0003) 
432  
(6 studies)  
⊕⊕⊕⊝7  
Moderate 




(1.34 to 2.89, p = 0.0006)  
253  
(2 studies)  
⊕⊕⊕⊝8  
Moderate 













(0.63 to 10.29, p = 0.19) (1 study)  Low 




































Mysenchymal stem cell 
therapy 




(1.02 to 1.59, p = 0.03)  
133  
(2 studies)  
⊕⊕⊕⊝15  
Moderate 









Comparison 2: Biologic versus biologic combined with antibiotic 
 
 Outcome  Pooled RR  
(95% CI, p)  
 





Induction of fistula response  
 
1.58 






Induction of fistula remission  
 
1.94 





Comparison 3: Methotrexate versus azathioprine  
 
 Outcome  Pooled RR  
(95% CI, p)  
 
Number of  
participants 
Quality 
 Induction of fistula remission  2.00  12 ⊕⊝⊝⊝18  
 
(0.56 to 7.09)  (1 study)  Very low 
 
*Studies were downgraded due to risk of bias; indirectness of evidence; unexplained heterogeneity; sparse data; and publication bias. In the case of very sparse 
data (< 35 events) and sparse data (< 300 events) the quality of evidence was downgraded by 2 levels and 1 level, respectively.  
 
1Downgraded 2 levels due to very sparse data (6 events) 
2Downgraded 2 levels due to very sparse data (4 events) 
3Downgraded 2 levels due to very sparse data (29 events) 
4Downgraded 2 levels due to very sparse data (17 events) 
5Downgraded 3 levels due to very sparse data (1 event) 
6Downgraded 1 level due to sparse data (172 events) 
7Downgraded 1 level due to sparse data (118 events) 
8Downgraded 1 level due to sparse data (81 events) 
9Downgraded 1 level due to sparse data (66 events) 
10Downgraded 2 levels due to very sparse data (13 events) 
11Downgraded 1 level due to sparse data (83 events) 
12Downgraded 1 level due to sparse data (47 events) 
13Downgraded 1 level due to sparse data (74 events) 
14Downgraded 1 level due to sparse data (38 events) 
15Downgraded 1 level due to sparse data (138 events) 
16Downgraded 1 level due to sparse data (109 events) 
17Downgraded 1 level due to sparse data (54 events) 
18Downgraded 2 levels due to very sparse data (34 events) 
19Downgraded 3 levels due to very sparse data (6 events) and high risk of bias for blinding of participants and selective reporting 
 
Appendix C: Sensitivity analysis results – including only studies that used fistula disease activity as the primary outcome 
 
 
Comparison 1: Drug therapy versus placebo 
 
Outcome Subgroup Pooled RR  
(95% CI, p) 
 
Adjusted Pooled RR  







(0.34 to 8.22, p = 0.52) 




(0.73 to 4.75, p = 0.20) 







(1.17 to 12.40, p = 0.03) 
5.36 




(1.09 to 1.90, p = 0.01) 
 
1.97  





(0.86 to 2.80, p = 0.14) 




(0.72 to 1.97, p = 0.50) 
 
1.19  




(1.02 to 1.59, p = 0.03) 
 
1.27  







(0.17 to 8.38, p = 0.85) 





(0.76 to 15.71, p = 0.11)  
 





(0.33 to 7.51, p = 0.57)  
1.19 




(1.40 to 3.04, p = 0.0003) 
 
3.57  











(0.93 to 3.37, p = 0.08) 




(0.79 to 2.66, p = 0.22) 
 
1.45  





(0.98 to 1.73, p = 0.06) 
1.31 








(0.03 to 4.19, p = 0.0006) 
Not estimable  
TNF-alpha antagonists 1.97 
(1.34 to 2.89, p = 0.0006) 
1.88 






(1.04 to 3.17, p = 0.04) 
Not estimable  
Maintenance of 
fistula remission 
TNF-alpha antagonists  1.94  
(1.25 to 3.02, p = 0.003) 
1.79 
(1.10 to 2.92, p = 0.02) 
 
 
Comparison 2: Biologic versus biologic combined with antibiotic for induction of remission 
 
Induction of 
fistula response  
 1.58  
(1.09 to 2.28, p = 0.01) 
 
1.58  





 1.94  
(1.14 to 3.29, p = 0.01) 
1.94  
























Appendix D: Sensitivity analysis results – including only studies that exclusively enrolled patients with peri-anal fistula 
 
Comparison 1: Drug therapy versus placebo 
 
Outcome Subgroup Pooled RR  
(95% CI, p) 
 
Adjusted Pooled RR  






(0.34 to 8.22, p = 0.52) 
1.68 





(0.73 to 4.75, p = 0.20) 





(1.17 to 12.40, p = 0.03) 
1.00 




(1.09 to 1.90, p = 0.01) 
 




(0.86 to 2.80, p = 0.14) 
1.55 




(0.72 to 1.97, p = 0.50) 
 
1.19  




(1.02 to 1.59, p = 0.03) 
 
1.27  







(0.17 to 8.38, p = 0.85) 
1.20 












(0.33 to 7.51, p = 0.57)  
3.00 




(1.40 to 3.04, p = 0.0003) 
 





(0.63 to 10.29, p = 0.19) 





(0.93 to 3.37, p = 0.08) 
1.77  




(0.79 to 2.66, p = 0.22) 
 
1.45  





(0.98 to 1.73, p = 0.06) 
1.31 








(0.03 to 4.19, p = 0.0006) 
 
 
Not estimable  
TNF-alpha antagonists 1.97 
(1.34 to 2.89, p = 0.0006) 
 





(1.04 to 3.17, p = 0.04) 
1.82  




TNF-alpha antagonists  1.94  
(1.25 to 3.02, p = 0.003) 
Not estimable  




fistula response  
 1.58  
(1.09 to 2.28, p = 0.01) 
 
1.58  





 1.94  
(1.14 to 3.29, p = 0.01) 
1.94  
(1.14 to 3.29, p = 0.01) 
 
 
Appendix E: Search strategy surgical systematic review 
 
1. *Crohn disease AND *rectal fistula AND *surgery 
2. *Crohn disease AND *rectal fistula AND seton.mp 
3. *Crohn disease AND *rectal fistula AND LIFT.mp 
4. *Crohn disease AND *rectal fistula AND fistula plug.mp 
5. *Crohn disease AND *rectal fistula AND advancement flap.mp 
6. *Crohn disease AND *rectal fistula AND VAAFT.mp 
7. *Crohn disease AND *rectal fistula AND OTSC.mp 
8. *Crohn disease AND *rectal fistula AND stoma.mp 





Appendix F: ROBINS-2 risk of bias assessment surgical systematic review 












Appendix G: Cochrane ROB for randomised studies surgical systematic review 






Appendix H: Gastroenterologist questionnaire 
Current management of 
fistulating perianal Crohn’s 
disease: Pilot Questionnaire 
The optimum management of fistulating perianal disease has been identified as a key topic for 
colorectal surgeons in the recent ACPGBI Delphi exercise. As fistulating perianal Crohn’s is a 
condition which requires multidisciplinary involvement, we are keen to understand current practice 
amongst gastroenterologists in this condition. Findings from this questionnaire will be used to 
inform the design of a future trial and/or consensus exercise. 
All these questions relate ONLY to FISTULATING PERIANAL CROHN’S DISEASE. Please answer with 
what you would most commonly do. It is accepted that clinicians may exercise judgement and tailor 
decision---making depending on clinical presentation. 
Thank you for taking the time to complete this questionnaire. Your support is appreciated! 
 
Questions or comments to m.j.lee@sheffield.ac.uk 
 
 
Section 1: Questions in this section relate to emergency presentations of perianal sepsis in 
established or clinically suspected Crohn’s disease. Please answer with what you would 
most commonly do. 
If you review a patient and you believe they have a perianal abscess related to Crohn’s, 
would you start antibiotics: 
Always Usually Occasionally Never 
 
 





Other (please specify)______________________________ 
 
 
Section 2: Questions in this section relate to presentations of perianal fistulae in established 
or clinically suspected Crohn’s disease. Please answer with what you would most 
commonly do. This assumes no fulminant sepsis requiring immediate drainage. 
In your experience, how does a patient with perianal fistula related to Crohn’s usually 
access treatment? 
Via surgical clinic Via acute surgical take Via IBD nurse 
 
Via medical clinic Via acute medical take Via gastroenterology Via GP 
 
If you saw a patient with a symptomatic fistula, would you refer directly to a surgeon or 
would you obtain imaging first? 
Usually obtain imaging first Usually refer direct to surgeon 
 
If referring to a surgeon, do you refer to a named surgeon or the acute surgical take? 
 
Usually a named surgeon Usually to acute take 
 
If you undertake imaging, which modality do you prefer? 
 
MRI perineum CT Endoanal Ultrasound 
 
 






What is the minimum set of investigations you would perform for a known Crohn’s patient 











If the diagnosis of Crohn’s is not yet established, but is suspected, which of the following 
investigations would you undertake? 
Faecal Calprotectin: 
 








Almost always Frequently Occasionally Never 
 
Video capsule endoscopy: 
 
Almost always Frequently Occasionally Never 
 
MRI small bowel: 
 
Almost always Frequently Occasionally Never 
 
Other (please specify):   
 
 
Section 2: Questions in this section are related to the postoperative management after sepsis 
control or first EUA. Please answer with what you would most commonly do. 




Are patients with fistulating Crohn’s disease discussed in your IBD MDT? 
 
Always Usually Sometimes Never N/A 
 
 
In your practice, are immunosuppressant drugs used to treat fistula in ano associated 
with Crohn’s? 
Almost always Frequently Occasionally Never 
 
 
In your practice, would you start with a single therapy or with multiple therapies? 
 
Single therapy 
Antibiotics and thiopurine 
Antibiotics and anti---TNF  Antibiotics, 
thiopurine and anti---TNF 
Other combination:______________   
 


















Generally speaking, what drug is your first-­‐line immunosuppressant in the 
management of fistulating perianal Crohn’s 
Steroid therapy 





Other (which?)    
 








What interval between sepsis drainage and commencement of 
immunosuppressant/add-­‐ in anti-­‐TNF therapy do you usually leave? 
 
1---2 weeks 3---4 weeks 5---6 weeks 7---8 weeks 9 weeks + 
 
Do you ask for evidence of sepsis resolution prior to immunosuppression? 
 
Almost always Frequently Occasionally Never 
 
 
If so, what evidence do you take into account (tick all that apply)? 
 





















In the context of fistula that is not responding to therapy based on clinical 
assessment, for how long do you typically continue first-­‐line immunosuppression 
before escalating therapy? 
up to 3 months up to 6 months  up to 12 months up to 24 months 
as per clinical symptoms other     
 
After a period of first-­‐line immunosuppression with improvement in symptoms, do 
you typically stop therapy, continue therapy or ‘step-­‐down’? 
Stop therapy Continue therapy Step down therapy 
 
If you answered ‘step down’ therapy, please indicate what drug(s) you would 
typically move to. 
Steroid therapy 






Other (which?) ________________________________________ 
 
 
After a period of first-­‐line immunosuppression without improvement in symptoms, 
what would you typically do next? 
Change medical therapy 
Re---image 
Obtain further surgical opinion 
 
If you would change medical therapy, what would you change it to? 
 
Steroid therapy 








Other (which?) ________________________________________ 
 
 
In a stable or improving patient, how would you monitor response? 
 
Repeat imaging Clinical response 
 
 
Do you use any strategies to optimise medical therapy (tick those which apply): 
 
Assessment of thiopurine levels and optimisation of dose 
Assessment of anti---TNF levels and optimisation of dose 
Assessment of anti---TNF antibodies 
 
What factors would make you consider referral to a surgeon for repeat EUA? 
 
Length of time on anti---TNF or immunomodulators Loss of response to drugs 
Quality of life Other:    
 
 





What aspects of your care does it affect (tick all that apply)? 
 
Surveillance – radiological/endoscopic Duration of immunosuppressant therapy 




Section 3: Definitive management aimed at fistula healing/control 
 
If your first line choice of immunosuppressant fails to resolve symptoms, what are your 
second and third line choices? 
Second line:  
Third line:  
 
 

















Optional: If you would like to sketch your management algorithm for perianal Crohn’s 
disease, please feel free to do so below. This has been undertaken on the corresponding 
colorectal surgeon questionnaire and has identified common decision points and 




Thank you for taking the time to complete this questionnaire. 
 
If you would like to be involved in a consensus exercise, please write your email address below. It is 
















Appendix J: Surgeon questionnaire 
Current management of 
fistulating perianal Crohn’s 
disease:  Questionnaire 
 
The optimum management of fistulating perianal disease has been identified as a key topic for 
colorectal surgeons in the recent ACPGBI Delphi exercise. This questionnaire is intended to 
provide a survey of current national practice and will help determine the intervention arm for a 
prospective randomised trial. 
All these questions relate ONLY to FISTULATING PERIANAL CROHN’S DISEASE. Please answer with 
what you would most commonly do. It is accepted that clinicians may exercise judgement and 
tailor decision-making depending on clinical presentation. 
Thank you for taking the time to complete this questionnaire. Your support is appreciated! 
 
Matthew Lee, Registrar in General Surgery 
Nick Heywood, Pelvic Floor Research Fellow 
Steven Brown, Consultant Colorectal Surgeon 
Peter Sagar, Consultant Colorectal Surgeon 



























Section 1: Questions in this section relate to emergency presentations of perianal sepsis in 
established or clinically suspected Crohn’s disease 
Do you use antibiotics peri-operatively if a patient with fistulating perianal disease presents as 
an emergency and needs an EUA? 
Always   Frequently  Occasionally  Never 
If yes, when do you start these? 
In clinic/on ward 
At induction of anaesthesia 
Post-operatively 
Other (please specify)______________________________ 
 





Other (please specify)______________________________ 
 
Do you obtain imaging pre-operatively? 
Always   Frequently  Occasionally  Never 
Which modality do you prefer? 































If the diagnosis of Crohn’s is not yet established, but is suspected, which of the following 
investigations would you undertake? 
Faecal Calprotectin: 
Almost always  Frequently  Occasionally  Never 
Colonoscopy: 
Almost always  Frequently  Occasionally  Never 
Flexible sigmoidoscopy: 
Almost always  Frequently  Occasionally  Never 
Video capsule endoscopy: 
Almost always  Frequently  Occasionally  Never 
MRI enteroclysis: 
Almost always  Frequently  Occasionally  Never 





























Section 2: Questions in this section are related to the initial surgical management of 
established or clinically suspected Crohn’s fistulae from clinic leading up to and then including 
first EUA 
 
How do you typically manage perianal sepsis associated with Crohn’s perianal fistula in the 
emergency setting? 





Almost always  Frequently  Occasionally  Never 
Placement of draining seton: 
Almost always  Frequently  Occasionally  Never 
Placement of a cutting seton: 
Almost always  Frequently  Occasionally  Never 
Excision of tract: 
Almost always  Frequently  Occasionally  Never 
Other (please specify): 
 
If called for advice by a colleague or registrar who is doing an EUA for perianal sepsis associated 
with Crohn’s perianal fistula in the emergency setting, what would you advise? 
Incision and drainage (I&D) alone:  
Almost always  Frequently  Occasionally  Never 
Placement of draining seton: 
Almost always  Frequently  Occasionally  Never 
Placement of a cutting seton: 
Almost always  Frequently  Occasionally  Never 
Excision of tract: 
Almost always  Frequently  Occasionally  Never 







At first scheduled EUA, how do you typically manage symptomatic Crohn’s fistulae without focal 
sepsis? 
Placement of draining seton: 
Almost always  Frequently  Occasionally  Never 
Placement of a cutting seton: 
Almost always  Frequently  Occasionally  Never 
Excision of tract: 
Almost always  Frequently  Occasionally  Never 
Fistulotomy: 
Almost always  Frequently  Occasionally  Never 
Faecal diversion (stoma): 
Almost always  Frequently  Occasionally  Never 














When using a seton in Crohn’s disease: 
What material do you use?              _____________________________ 
How do you insert the seton? _______________________________________ 

































Section 3: Questions in this section are related to the postoperative management after sepsis 
control 
Questions in this section are related to the management of patients after initial surgical 
assessment and management, including medical therapy. 
When you have found a fistula, do you routinely perform follow-up imaging? 
Almost always  Frequently  Occasionally  Never 
When you suspect but have NOT found a fistula, do you routinely perform follow-up 
imaging? 
Almost always  Frequently  Occasionally  Never 
If so, what modality do you use? 
MRI  EUS  CT  Other 
 Do you routinely perform follow-up examination under anaesthetic? 
Almost always  Frequently  Occasionally  Never 
 




Do you routinely give post-operative antibiotics? 
Almost always  Frequently  Occasionally  Never 
If so, which cases? ________________________________________________ 
 































Does your unit have an IBD Multi-disciplinary meeting? 
YES   NO 
 
 
Are patients with fistulating Crohn’s disease discussed in your IBD MDT? 
Always   Usually  Sometimes  Never   N/A 
 
Is there a pathway for access to a gastroenterologist after surgical treatment? 
YES   NO 
 
Do you arrange follow-up with a gastroenterologist after new diagnosis of fistulating 
Crohn’s disease? 
Almost always  Frequently  Occasionally  Never 
In your practice, are immunosuprresant drugs used to treat fistula in ano associated 
with Crohn’s? 
 Almost always  Frequently  Occasionally  Never 
Which immunosuppressants would you commonly use (circle as many as apply)? 
Steroid therapy 




Anti-TNF eg Infliximab, Adalimumab (Humira) 
Immunosuppression choices  managed by gastroenterologist 
Other (which?) ________________________________________ 
 
For how long do you leave a seton in situ? _______________________________ 
 
Who makes the decision to remove the seton? 
 
Surgeon Gastroenterologist Joint decision/MDT Patient  N/A 
 
Do you use multimodal (combined immunosuppression with surgical intervention) 
therapy? 


















Section 4:  Definitive management aimed at fistula healing/control 
 
If you were considering surgical options to try and heal perianal Crohn’s fistulae, what 
options would you most commonly use? Tick all that apply. 
Removal of seton only 
Fistulotomy 
Fistulectomy 
Anal fistula plug 
Mucosal advancement flap 
Fibrin glue 
LIFT procedure 
Over the Scope Clip 
Video-assisted anal fistula treatment (VAAFT) 
Fistula laser closure (FiLaC) 
Local perineal flap 
Other (please specify) 
 
Do you use a diverting stoma? 
 












Do you treat Crohn’s rectovaginal fistulae (RVF)? 
 
Yes    No 






 Would you perform a proctectomy for perianal Crohn’s disease? 
 Always   Often   Sometimes  Never 


















Optional: If you would like to sketch your management algorithm for perianal Crohn’s 




























Thank you for taking the time to complete this questionnaire. 
If you would like to be involved in a consensus exercise or be updated on the findings of this 















Appendix L: Audit approval for pathway mapping  
 
Dear Matthew Lee 
  
Your proposed Service Evaluation project, titled 'Pathway assessment in fistulating perianal 
crohn’s disease.', has been approved following our telephone conversation yesterday and I have 
registered it on the database as Ref 7130. Please use this reference number when corresponding 
with the unit about this project. 
  
It has been included on the Directorate's Clinical Audit and Effectiveness Programme to ensure 
that the project's progress can be monitored throughout all the stages of the cycle. It is placed 
on the programme as a P4 Locally Managed project. 
  
At this point I must remind you of the importance of the submission of a report for the project 
on completion. To help with this I will be able to provide you with a draft report template at that 
stage of the project. The Trust is required by the Department of Health to provide evidence of 
audit and evaluation in the form of written reports, not presentations, to maintain our 
Foundation status. We are also required to provide evidence of where and when results were 
reviewed so we also require you to identify in the report the group or meeting within your 
directorate where this happened or a timescale for when this would happen.  
  
The Trust has a legal obligation to preserve Service Evaluation reports for five years post date of 
submission to the Clinical Effectiveness Unit. However, any project relating to NICE is stored 
indefinitely within the Trust and any national audit will be kept for ten years. The Clinical 


















Appendix N: Ethical approval for qualitative interviews 
 
Telephone: 0207 104 8002 
 
23 August 2016 
 
Mr Steven Brown 
Department of General Surgery 
First Floor, Old Nurses Home, Northern General 
Hospital Herries Road 
S5 7AU 
 
Dear Mr Brown 
Study title: Patient experience of information around surgery for 
fistulating perianal Crohn’s disease 
REC reference: 16/NW/0640 
Protocol number: STH19512 
IRAS project ID: 210158 
 
Thank you for your letter of 23 August 2016 responding to the Proportionate Review 
Sub-Committee’s request for changes to the documentation for the above study. 
 
The revised documentation has been reviewed and approved by the Chair. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this favourable opinion letter. The expectation is that this information will be published 
for all studies that receive an ethical opinion but should you wish to provide a substitute 
contact point, wish to make a request to defer, or require further information, please contact 
the REC Manager Mrs Kieran Hall, nrescommittee.northwest- gmsouth@nhs.net. Under 
very limited circumstances (e.g. for student research which has received an unfavourable 
opinion), it may be possible to grant an exemption to the publication of the study. 
Confirmation of ethical opinion 
 
Please note: This is the 
favourable opinion of the REC 
only and does not allow 
you to start your study at NHS 
sites in England until you 





On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised. 
 
Conditions of the favourable opinion 
The REC favourable opinion is subject to the following conditions being met prior to the start 
of the study. 
Management permission must be obtained from each host organisation prior to the start of the 
study at the site concerned. 
Management permission should be sought from all NHS organisations involved in the study 
in accordance with NHS research governance arrangements. Each NHS organisation must 
confirm through the signing of agreements and/or other documents that it has given 
permission for the research to proceed (except where explicitly specified otherwise). 
Guidance on applying for HRA Approval (England)/ NHS permission for research is available in 
the Integrated Research Application System, www.hra.nhs.uk or at http://www.rdforum.nhs.uk. 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
Sponsors are not required to notify the Committee of management permissions from host 
organisations. 
 
Registration of Clinical Trials 
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database. This should be before the first participant is 
recruited but no later than 6 weeks after recruitment of the first participant. 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment. We will audit the registration details as 
part of the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered 
but for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to request a deferral for study registration within the required timeframe, 
they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will 
be registered, however, in exceptional circumstances non registration may be permissible with 
prior agreement from the HRA. Guidance on where to register is provided on the HRA website. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of 






Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see “Conditions of the favourable opinion” above). 
Approved documents 
 
The documents reviewed and approved by the Committee are: 
 
Document Version Date 
Interview schedules or topic guides for participants [Interview 
guide] 
1 08 June 2016 
IRAS Application Form [IRAS_Form_15082016]  15 August 2016 
IRAS Checklist XML [Checklist_15082016]  15 August 2016 
Participant consent form 4 23 August 2016 
Participant information sheet (PIS) 4 23 August 2016 
Referee's report or other scientific critique report [reviewers report] v4  
Research protocol or project proposal [Protocol] 5 21 July 2016 
Response to Request for Further Information  23 August 2016 
Summary CV for Chief Investigator (CI) [CV for CI]   
Summary CV for student [CV for PhD Student]   
Summary CV for student [CV student]   
Summary CV for supervisor (student research) [CV for 
supervisor] 
  
Summary CV for supervisor (student research) [CV Supervisor]   
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees 
in the UK. 
 




The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Notification of serious breaches of the protocol 





• Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
Feedback 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure. If you wish to make your views 
known please use the feedback form available on the HRA website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/ 
 
 
With the Committee’s best wishes for the success of this 
project. Yours sincerely 
 






Enclosures: “After ethical review – guidance for researchers” 
 
Copy to: Mr Luke Barron, 









Appendix O: Participant information sheet for qualitative interviews 
 
Patient experience of information about surgery for perianal Crohn’s fistula 
 
You are being invited to take part in a research project to explore patient experience of surgical 
treatment of perianal Crohn’s fistula. Before you decide whether you wish to take part it is 
important for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with others if you wish. Please 
feel free to ask us if there is anything that is not clear or if you would like more information.  
 
What is the project’s purpose?   
Perianal fistula in Crohn’s disease can be challenging to manage. There is sometimes more than 
one option for surgical treatment, which can depend on patient and surgeon preference. We 
would like to help people understand their options by providing better information. We first need 
to understand the information we are currently giving. 
 
Why have I been chosen?   
You have been identified by your clinical team as someone who has been treated for perianal 
Crohn’s fistula. 
  
Do I have to take part?   
You do not have to take part in this research project. Your care will not be affected whether or 
not you choose to participate. 
 
What will happen to me if I take part?  
At the bottom of this form is an opt-in sheet which allows you to register an interest. If you choose 
to register an interest in the study your contact details will be passed to the research team who 
will telephone you to discuss the study further. They will answer any questions about what is 
involved in the project during that phone-call. They will arrange to meet you at either the Royal 
Hallamshire Hospital or the Northern General Hospital at a convenient time. When you arrive, we 
will ask you to complete a consent form. We will then undertake an interview that will last for 
about one hour. The interview will be recorded on a digital recorder. During the interview, we will 
ask questions about your experience of surgery in the management of your fistula, and ask you 
about how you made decisions about your treatment. Afterwards, the researchers will analyse a 
transcript of your interview, along with others, to understand important themes about 
information about surgery. You are free to withdraw from the study at any point. Withdrawing 
will not affect the care you receive. 
 
What do I have to do?   
We would like you to participate in the interview and share your experience of discussions about 
surgery for perianal Crohn’s fistula. You will have to arrange your own transport to the meeting, 
but we will reimburse travel expenses. 
What are the possible disadvantages and risks of taking part?   
Some people may be upset at discussing previous health-care experiences. If this happens, we 
will offer to pause or end the interview. If you want further help or support as a result of this, we 
will ensure that you are put in contact with the Inflammatory Bowel Disease Nurse Specialists. 
 





There are no direct benefits to you for participating, but the information we get from this 
interview will help us to give better information about operations to patients with this condition. 
This might improve experience and help 
 
What should I do if I have concerns about the project?   
If you have any concerns about the project please do not hesitate to contact the following:  
Mr Matthew Lee 




Will my taking part in this project be kept confidential?   
All the information that we collect about you during the course of the research will be kept 
strictly confidential. You will not be able to be identified in any reports or publications.  Excerpts 
from transcripts will use pseudonyms. 
 
What type of information will be sought from me, and why is the collection of this information 
relevant for achieving the research project’s objectives?   
The information collected is preferences in management of aspects of the condition and results 
of votes. These are counted at group level, not individual level.  
 
What will happen to the results of the research project?   
Following this research, the results may be published in a medical journal and/or presented at an 
academic meeting. All data presented in either format will be anonymised and you will not be 
identified in any report or publication.  We will share the results with you when the project is 
completed.  
We may use the results of this work to help us to design further research such as surveys, or to 
develop information resources.  
It is possible that researchers in this field may wish to access data from this project. If this is the 
case, we would allow access to interview transcripts, but would ensure that any identifiable data 
(names, places, etc.) are censored. 
 
Who is organising and funding the research?   
The research is being organised by the following; 
Mr Matthew Lee 




Mr Steven Brown 
Consultant Colorectal Surgeon, Sheffield Teaching Hospitals 
steven.brown@sth.nhs.uk 
0114 243 4343 
 










Who has ethically reviewed the project?   
This project has been ethically approved by the Research and Ethics committee (REF XXXXX)   
 
Contact for further information   
Should you require any further information please do not hesitate to contact the following 
Mr Matthew Lee 




Thank you for your time.  
Should you agree to take part in the research you will be supplied with a copy of this information 





CUT OFF SLIP 
 
I WISH TO REGISTER AN INTEREST IN THIS STUDY  
SIGNED………………….  DATED………………………….. 




























Appendix P: Interview Schedule 
 
Introduction:  
Hello, my name is XXXXXX from the Medical School, at the University of Sheffield. Thank you very 
much for agreeing to talk to me today about your experiences of surgery for anal fistula in 
Crohn’s disease. 
 
If you are happy I would like to record the conversation. I just wanted to reassure you that 
anything with say to me will all be anonymised. It will not be possible to identify you on any of 
the publications or transcripts arising from this research as only your age and gender will be 
reported. The digital recording will not include your name (just your study ID and initials) and it 
will be erased after transcription  
 
As this interview will be exploring issues around your experiences of living with and being 
treated for Crohn’s disease, this may result in the discussion of sensitive, upsetting or 
embarrassing topics. If at any point in the interview you are concerned about confidentiality or 
are uncomfortable in discussing these issues, then please tell me and we can discuss stopping 
the recording or withdrawing from the study.  
 
Context/Background: 
Tell me about yourself. 
Prompts 
• How long have you had Crohn’s disease? 
• When did you have your first anal fistula? 
• What problems did it cause you? 
• How did we treat it? 
• How may operations have you had for your fistula? 




Can you tell me about your experiences of receiving information about your procedure? 
Prompts 
• Did you receive any information prior to undergoing surgery? 
• Explore what the patient was told, by whom, at which time point in the pathway. 
• What risks were you told about?  
• What were you told about the aims of the operation? 
• What were you told about things such as incontinence, need for more operations? 
• Explore the time points this was received e.g. well in advance of treatment, just before 
surgery 
• Explore what type of information this was e.g. paper format, web-based, app etc 
• What did you think about this information? Explore content e.g. if too 
long/short/complex/clinical? 
• In terms of your own experiences, did the information you receive and read cover all 
aspects of your operation? 
• Discuss information about recovery and future care plan. 







Did anyone discuss the option of a stoma (bag on the tummy wall) with you? 
Prompts 
• What did they say? 
• How did you find this discussion? 
• Why did you choose to have it/not to have it? 
• Did anyone discuss the option of removing your back passage (proctectomy)? 
• What did they say? 
• Why did you choose to have it/not to have it? 
 
Information sources: 
Did you access any other information about your procedure outside of that given to you by your 
doctor? 
Prompts 
• Explore where they looked for additional information e.g. Internet, Friends and Family, 
Books, Library, Apps. 
• Explore if the Internet what resources e.g. Youtube, Charity websites, NHS website etc? 
• Explore what they felt about these resources in terms of quality of information, content, 
ease of understanding. 
 
 
If we were to give you information about treatment options, what would be the best way? 
Prompts 
• Explore formats e.g web-based, app, booklets etc 
• Explore what is the optimal time in the pathway from the patient’s perspective to be 
given such information. 
• Explore what type of content they would find it helpful to include in any new information 
resource? 
• Explore if anything has been missed from existing resources they have accessed that from 






Appendix Q: Interview Coding 
 
 











I: Thank you for coming to talk to me. As I started to say, this conversation is completely confidential 
and anonymised. If at any time you feel uncomfortable and you want to stop or need a break, let 




I: First of all, as I said I don’t have your notes or know anything about you. Could you tell me a bit 
about yourself? 
 
P: Oh I don’t know where to start… 
 
I: It’s a blind date type question. 
 
P: Oh you don’t want to know everything like that about me on a blind date! [laughs]. Do you want 
me to start from my first…when my problems started? It was about… I’ve had five operations to do 
with this and I’ve literally just had one on the 16th October. So I’ve always had like Crohn’s 
symptoms, but I ignored my symptoms for way too long. I’ve got a little girl and she’s 5. After I had 
her, things got worse. I developed something like a cyst, and they diagnosed me with a Bartholin’s 
gland first. Erm, at the same appointment, I told my GP about these other symptoms – I was losing 
mucous, and I got to the toilet a lot. So they put me on mebeverine. I was referred to gynae with 
my cyst. I had an operation – marsupialisation – on that. Immediately after that operation I got so 
so poorly. Erm, and I came back up to urgent care, I came back up to A&E, and I saw the surgeon 
that did the intial surgery. And he said ‘I can’t understand why you’re so poorly, everythings fine, 
everything appeared normal’. I was getting pain in my right bum cheek, erm, and I just felt like I 
wasn’t being listened to. I went back to my gynae and she asked for an MRI, and another MRI, a 
more intense one, and she said ‘this is beyond my knowledge’. That’s when she realised it was 
connected to my bowel. So ‘this is beyond my knowledge now, I don’t know what to do with you’. 
So she referred me to Mr X – I don’t know if you’ve met him, he’s a general surgeon…I think he’s a 
colorectal surgeon actually. And he…what did he do? I think it was March….so that was in 2014…the 
end of 2014. March 2015 he had me in and put setons in – he was the first person to ever mention 
Crohn’s to me. He was like ‘I’m 99.9% sure you’ve got Crohn’s’, so he referred me to gastro. It was 
really really quick. Like, I had to go for all the colonoscopies kind of stuff, erm, and in August time I 
was diagnosed with Crohn’s. At the same appointment they told me I needed to have a stoma. So 
I’ve got a defunctioning colostomy.  I had that done in 2015 – so I’ve had it for two years now. And 
that was basically to divert my bowel, to help the bottom end clear up….that’ didn’t help, I’m still 
really bad. Erm, they started me on azathioprine.errm…that was the beginning of 2016, and 
Infliximab at the same time. They’ve never managed to stablise my levels so they gave me double 
dose, then back to normal, then they put me on six-weekly trying to get my levels right. And now 
because of the last operation I’ve had, they’ve put me back on double dose – I’m due some 
infliximab next week. Erm, how many operations have I mentioned there, three? 
 







P: Yeah. I’ve had five though. So I kept going back to Mr X, and he kept saying ‘I think we just need 
to take everything away, all the badness, all the bad bowel away, sew me up, give me the bag 
permanently’. But then Dr Y, I’m under here, my gastro, he said – because I want more children – 
he doesn’t want me to go to that final route yet. So he referred me to [teaching] hospital – I’m 
under [teaching] hospital. And I had Mr Y – he did an EUA and like scraped loads of badness away, 
replaced some setons, took some away...the maximum I’ve had is four at once. Like, rectovaginal 
as well all connected. He left me with a wound that was draining… or actually, did Mr X? There was 
a wound on my right bum cheek, basically where I sit, and it’s been draining for two years. It’s 
horrible, I hate it. It’s worse than my bag. I can deal with my bag, that’s easy. But this drain.. That’s 
my worst symptom – pain and draining…constant draining from the fistulas around the setons and 
stuff. That operation that[teaching hospital] did, didn’t help, my sypmtoms didn’t change, in fact I 
was probably in more pain. So then, I’ve had loads of MRIs in between to check on it all. And the 
last one that they did, they just did a fistulectomy. So at the moment I’m having daily wound 
packing. It’s horrible. It’s the worst operation I’ve ever had, but I’m bouncing….the first two weeks 
after it I though I was dying. I’ve never been in so much pain – out of all the operations I’ve ever 
had, I’ve never been in that much pain, I just couldn’t see the light. But I feel back to my normal self 
now, as close to normal as I can be. That’s pretty much it. 
 
I: That’s quite a… 
 
P: I see my consultant like every month – they know my face when I walk in reception, I don’t even 
need to book in. That’s how common I see them. 
 
I: And this is all in three years? 
 
P: Yeah, three years now. 
 
I: You’ve had these problems with your bowels beforehand and… 
 
P: Yeah, I did, but it’s not down on paper because I just ignored my symptoms. It’s not something 
you want to talk about. I’ll talk about it now, I don’t care. Obviously I was a bit younger and I didn’t 
want to talk about bowel habits. And I’d just go through….like….constant bouts of 
diarrhoea/constipation/bad diarrhoea/constipation, losing mucous, losing blood…and I just ignored 
it. Which is why I think I’m so bad now. 
 
I: And it was the gynaes that spotted that something wasn’t quite right 
 
P: Yeah, as soon as she saw it was connecting to the bowel, she was like ‘this is beyond my 
knowledge’. She was dead honest with me. 
 
I: So when she said this to you, did you go off and look on the internet? 
P: Yeah. 
 
I: So what sort of things did you go looking for? 
 
P: Erm…I don’t know, I can’t remember. But people always ask me ‘how do you deal with it?’, but 
my head was already half way there because I’d researched my symptoms and my condition, and 





bag. So I was already halfway there, I knew I was going to have it. I used to say to my mum, like 
when I was really poorly, that I was gonna end up with a bag. My mum told me like, stop being silly. 
I said I’m telling you now I’ll end up with a bag  And the same day I got my diagnosis was the same 
day that they told me. So, dunno. Obviously it was a bit of a shock still, but it’s my normal now…easy 
to deal with. 
 
I: So when you went looking, you looked for what your symptoms were and what they might be? 
And you were looking for what treatments people might give you, is that right? 
 
P: Yeah, it was hard looking like…at the beginning…cause I didn’t know what I was looking for. I 
didn’t know what a fistula was. So yeah it was hard looking. But now I know what’s wrong with me, 
I’m on so many support groups on facebook- there’s so many people going through what I’m going 
through. It’s crazy. 
 
I: You saw Mr X, didn’t you? He was your first general surgeon or colorectal surgeon. What do you 
remember about… you probably won’t remember much because there will have been quite a lot 
happening, but do remember what he said about what he expected to find in the operation, or 
what might be involved? 
 
P: Erm… I remember he first mentioned a bag, and he was like it’s temporary, it’s temporary. And I 
asked ‘What’s temporary?’ and he said it could be six months, it could be six years. He said ‘the 
longest patient I’ve got is seven years with a temporary bag’. So he did mention that a few times. I 
think he always knew where I was going to end up, like, even though my gastro consultant had sent 
me to [teaching hospital]…I can’t remember who said it to me, I think it was Dr Y ‘ Mr X just thinks 
we are delaying the inevitable’. I’m probably going to end up with a  bag for life, I’m gonna have 
everything taken away and be sewn shut, but he [Dr Y] wants to explore everything first. I think Mr 
X is dead matter of fact, like, he just says it how it is and he’s dead stern and like…he just tells you 
straight [laughs]. 
 
I: So you’ve got one person saying ‘this is a thing we should do’ and another person saying ‘we 
should look at everything else’. Where are you with that?  
 
P: Initially….So Mr X tells me that it won’t affect my fertility. If I had the – is it proctectomy? If I had 
the proctectomy, it wouldn’t affect my fertility. And when I went to [teaching hospital] they said it 
would massively affect me having children in the future. That’s all that’s in the back of my mind, 
having more children [laughs]. So, then it’s like what do I do? Do I just not take anymore treatment, 
try for a baby and then go for the proctectomy? Or do I just keep trying? I feel like I’m wasting my 
life now with these operations. My daughters five now. It’s a big thing to me. And the surgeon I saw 
in [teaching hospital] said ‘well what’s more important? Your life or having more kids?’. Then it puts 
it in perspective doesn’t it? So… 
 
 I: Having a bigger family is important to you, that’s what I’m hearing. What other things matter to 
you here? 
 
P: Quality of life. Definitely. 
 






P: Erm. Well I’ve have a constant draining fistula for over two years. It’s horrible. I feel dirty all the 
time, even though I’m not. And now I’m having wound packing – it’s gross. It obviously affects my 
sex life cause it’s all closely linked isn’t it. I feel like I can’t walk very far because I’m in pain all the 
time. That’s quality of life. And not having to take painkillers every day.  
 
I: Are you working at the moment? 
 
P: Yeah. I work here. 
 
I: What kind of work do you do? 
 
P: I work in a production unit in pharmacy, making up Chemo, stuff like that. Erm, so it varies sitting 
and standing. There was a point where I couldn’t even sit like I’m sitting now – like – I used to have 
to sit like this [demonstrates], so things are better definitely. If I sit for too long, I’m in pain. If I stand 
for too long, I’m in pain. Work are really understanding, and they say ‘if you need to change job, 
just tell me’.  They are really understanding. 
 
I: We’ll get to the stoma in a minute – that’s something I want to talk about. But if we could talk 
about the seton first. When that was done, it was put in, were you told what to expect with it? 
 
P: No.  I wasn’t told anything when I was discharged. And, I was like…it was a cutting seton as well. 
So when I took the dressing off and looked in the mirror, I was like ‘Oh my god, there is a massive 
hole in my bum cheek’. Like, it was this big, it wasn’t deep but it was a big hole. I remember saying 
to my mum, you want to see this, it’s huge. And she was like don’t be silly. They didn’t even tell me 
that I had a wound like. I don’t think a lot of the nurses know a lot about it, so they didn’t really 
know. I don’t remember seeing the surgeon immediately after my operation. I didn’t know about 
cleaning, care…didn’t know anything. 
 
I: People have mentioned things about setons before. Were there any side effects or problems you 
notices?  
 
P: Draining. Definitely. It was just always wet, and it affects your skin. I was having to wear pads all 
the time. It’ s gross, really gross. Erm, obviously that cost more cause of having the pads all the 
time. Cause of where it is, it’s not easy to wear a dressing. It’s just pointless, I was wearing a pad all 
the time, so that affects your quality of life, what you’re wearing, stuff like that. Yeah they didn’t 
really say anything on discharge.  
 
I: Did you google anything about the setons? 
 
P: Definitely, I google everything. It was hard to find stuff at the beginning, but now it’s dead easy 
to find stuff that I need to find, it’s just way more common that I thought. 
 
I: From what you said, that was quite a quick move from having setons to a stoma, is that right? 
 
P: Yes, March when Ihad the seton, and I must have been really unwell with loads of drainage. I 
remember there was one point before I got the setons… I had like 10 courses of antibiotics in the 





GP was giving me co-amoxiclav all the time basically. But, yeah, erm, it was quite quick. The same 
day I got diagnosed was the same day they told me. It was about 2 months.  
 
I: One of the things you’ve said is your stoma is probably temporary, but that’s quite a big window 
from what you’ve said. Did they tell you anything else about the risks or benefits of having a stoma?  
 
P: I understood that idea was to divert it, to reduce all the inflammation and stuff. But, it’s easy for 
me to sit hear and say it’s not helped me, but it has. It’s stopped me from getting worse, but I still 
don’t feel any better. But, I do remember before the stoma, after every bowel movement, I used 
to be in the most agonising amount of pain. And because I have Crohn’s I go to the toilet quite a 
lot, so I was in pain all the time., I was in tears after every bowel movement, so it definitely helped 
there – that was a massive relief. Erm, yeah. 
 
I: From the otherside, you said the bag doesn’t bother you much now – did it bother you much at 
the start?  
 
P: No. I handle it well really. I just get on with it, it’s what I do.  
 
I: You’ve talked about proctectomy, removal of the back passage, and you’ve told me a couple of 
things that matter to you about it. Have you gone and tried talking to other people about it?  
 
P: Erm, yeah. It’s a mixture. Some people have said you can have children, some people have said 
you can’t. so… My consultant has once said to me ‘well I’d be very surprised if you got pregnant 
because of how under pressure your body is anyway’. He’d be very surprised. People that don’t 
understand around me are just like ‘try for a baby’, and I know I’d be stupid to put my self through 
that. I can barely look after my daughter and myself now, what am I going to be like with a new 
born? I’m not stupid. 
I: The next thing I wanted to ask about. You mentioned about using support groups online, are they 




I: I don’t know what happens on them as they are closed aren’t they? What sort of questions are 
people with fistulas asking?  
 
P: Anthing, like, anything goes. People talk about sex, like anything. Any advice that you need it’s a 
port of call. You’ll get an answer because people have been through it. I’ve even helped people. I 
never imagined me. Even on the stoma sites I’m on, like, at the beginning, me asking all these silly 
little questions, now I can answer them for other people. It’s like, you get to help other people. It’s 
really nice, it’s nice to be in  it.  
 
I: What do you think the two or three most common things people are asking about are? 
 
P: Setons, definitely. Erm… 
 






P: If someone new comes on, they say I’m booked for this surgery, what can I expect? Cause they 
don’t give you a lot to go on, and the nurses on discharge don’t know much. Erm. Yeah,  I think it 
really helps. 
 
I: That’s fine. And…just looking at my notes. Have you used youtube as well? 
 
P: No…I could easily go on youtube and watch an operation that I’ve had done, but I’m just not 
ready to do that. Like, I can picture in my head what it would be like, but no, I’m not interested in 
that. 
 
I: One of the things we’ve noticed on youtube is that sometimes patients go on and talk about their 
experiences – do you think it’s useful to hear about other peoples experiences even if they are 
different to what you’ve had? 
 
P: Yeah, on the stoma sites, a lot of people do Vlogs, like, so I’ve watched them before. There’s 
some good ones that are helpful. 
 
I: In an ideal world – you’ve told me that you don’t think we give good information about operations 
two or three times – if we were going to talk to you about an operation, what are the main things 
you would want to know? 
 
P: Aftercare, definitely. Like, because of this fistulectomy, I’ve had conflicting advice about 
showering daily. They didn’t say anything on discharge about showering, I’ve been showering daily 
just before I get my dressing changed. And then the other day in clinic, a nurse said I shouldn’t be 
showering because it affects healing. Well…I’m healing, no one has told me up to this point. How 
can I not shower? What am I supposed to do? So yeah, aftercare definitely. Dunno, signs of 
infection. I’d know that, maybe a lot of other people wouldn’t. Like, I dunno, I’d like to think I’m 
quite wise when it comes to my health and that I know what to look out for. I know where to get 
help, but not a lot of people might. 
 
I: Especially if you get someone who hasn’t been to the doctors much before. I guess that was 
someone like you were? 
 
P: Yeah, I’d never seen  a doctor up until…I don’t see my doctor now, I just see the consultants all 
the time rather than my GP. I never used to see my GP, then all of a sudden I was there every week. 
So yeah. 
 
I:The bits of information we need to give to people, what’ the best time and place to give it? And 
how should we give it? 
 
P: Maybe at pre-op? I remember being at pre-op and asking questions and they just didn’t know. A 
lot of my operations have come under EUA with plus or minus, so they never knew what they were 
doing until I was under, but…I dunno, I know it’s a preop clinic and it’s just general nurses, but if 
they were more like… theres so many operations that would go through there so it’s impossible, 
but. I dunno, I even feel like my IBD nurse doesn’t know much about it, so maybe she should read 
up on it… 
 








I: What about written stuff? 
 
P: Yeah or a leaflet. Send me away with a leaflet, that would probably be better. 
 
I: What about a website done by a hospital? 
 
P: Yeah. That’s a good idea. 
 
I: If we were having a chat about stoma or proctectomy – this is usually down the line with 
treatment – when do you think we should talk to people about stomas, and when do you think we 
should talk to them about it? 
 
P: You mean if the doctor thinks in their mind that it might come to that? I don’t know. My doctor 
knew way efore he told me. I did too in the back of my mind. The stoma nurses are great here, so 
like they gave me all the information. It was really rushed with mine as well, because they gave me 
a date and I said I can’t take that, my mums on holiday, so they gave me a date two weeks later. 
Then they called me up the day before my original operation and said ‘I’m sorry, you can’t have 
that date now, you’ll have to come in tomorrow’. I literally broke down in tears. I left work and 
came up to the stoma nurses on their clinic. And they were good and calmed me down. I still had it 
done, even though my mum was away. Erm, so it was all very rushed then. I wasn’t ready for it. But 
it all got changed dead quick. Like yeah, the stoma nurses were great. 
 
I: I guess what I’m asking is: If we think a stoma is a good idea for someone, should we say that right 
at the start the first time we meet them? Or try other things? 
 
P: Try other things. But I guess that if someone has Crohn’s it’ll always be in the back of their mind, 
having a stoma. 
 
I: You think people might have thought about it anyway? 
 
P: Yeah. Like me researching. 
 
P: I think that’s covered most of what I wanted to chat about. Is there anything important you think 












Appendix S: Ethical approval for questionnaire 
 
 
London - Westminster Research Ethics Committee 
 
23 August 2017 
 
Dear Mr Lee, 
 
Study title: Patient informational preferences in surgical therapies of 
perianal Crohn’s disease 
REC reference: 17/LO/1446 
IRAS project ID: 230885 
 
The Proportionate Review Sub-committee of the London - Westminster Research Ethics 
Committee reviewed the above application on 22 August 2017. 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the date of 
this favourable opinion letter. The expectation is that this information will be published for all 
studies that receive an ethical opinion but should you wish to provide a substitute contact point, 
wish to make a request to defer, or require further information, please contact 
hra.studyregistration@nhs.net outlining the reasons for your request. Under very limited 
circumstances (e.g. for student research which has received an unfavourable opinion), it may be 
possible to grant an exemption to the publication of the study. 
 
Favourable opinion  
On behalf of the Committee, the sub-committee gave a favourable ethical opinion of the above research on 
the basis described in the application form, protocol and supporting documentation, subject to the 
conditions specified below. 
 
Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
1) Please make the following changes to the Participant Information Sheet: 
 
a) Under the heading ‘Why have I been chosen’ change the word chosen to “invited”. 
b) Under the heading ‘Do I have to take part’ being the first sentence with “No”. 





‘Participants can withdraw from the focus group at any point without giving a 
reason and care will not be affected in any way’. 
 
2) Please make the following changes to the Invite Letter: 
 
a) In the first sentence of the second paragraph insert “always” between the words 
“not” and “very good”. 
 
 
You should notify the REC once all conditions have been met (except for site approvals from host 
organisations) and provide copies of any revised documentation with updated version numbers. Revised 
documents should be submitted to the REC electronically from IRAS. The REC will acknowledge receipt 
and provide a final list of the approved documentation for the study, which you can make available to host 
organisations to facilitate their permission for the study. Failure to provide the final versions to the REC 
may cause delay in obtaining permissions. 
 
Management permission must be obtained from each host organisation prior to the start of the 
study at the site concerned. 
 
Management permission should be sought from all NHS organisations involved in the study in 
accordance with NHS research governance arrangements. Each NHS organisation must confirm 
through the signing of agreements and/or other documents that it has given permission for the 
research to proceed (except where explicitly specified otherwise). 
 
Guidance on applying for HRA Approval (England)/ NHS permission for research is available 
in the Integrated Research Application System, www.hra.nhs.uk or at 
http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought from 
the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with 
the procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of management permissions from host 
organisations. 
 
Registration of Clinical Trials 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered on 
a publically accessible database. This should be before the first participant is recruited but no later 
than 6 weeks after recruitment of the first participant. 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment. We will audit the registration details as part of 





To ensure transparency in research, we strongly recommend that all research is registered but for 
non-clinical trials this is not currently mandatory. 
If a sponsor wishes to request a deferral for study registration within the required timeframe, they 
should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will be 
registered, however, in exceptional circumstances non registration may be permissible with prior 
agreement from the HRA. Guidance on where to register is provided on the HRA website. 
It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of 
the study or its initiation at a particular site (as applicable). 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
“Conditions of the favourable opinion”). 
 
Summary of discussion at the meeting 
 
• Informed consent process and the adequacy and completeness of participant  information 
 
The member of the Sub-Committee requested minor changes to the Participant information sheet 




The documents reviewed and approved were: 
 
Document Version Date 
Copies of advertisement materials for research participants [Twitter 
advert] 
1 14 June 2017 
Interview schedules or topic guides for participants [discussion 
prompt sheet] 
1 14 June 2017 
IRAS Application Form [IRAS_Form_04082017]  04 August 2017 
Letters of invitation to participant [Participant Invite letter] 1 14 June 2017 
Non-validated questionnaire [patient questionnaire] 3 17 July 2017 
Other [CV for co-investigator]   
Other [CV for co-investigator]   
Other [CV for co-investigator]   
Other [CV for co-investigator]   
Participant consent form [informed consent form] 1 14 June 2017 
Participant information sheet (PIS) [Participant Information Sheet] 1 14 June 2017 
Referee's report or other scientific critique report [Independent 
Scientific review] 
  
Research protocol or project proposal [Research Protocol] 2 13 July 2017 






Membership of the Proportionate Review Sub-Committee 
 
The members of the Sub-Committee who took part in the review are listed on the attached sheet. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 




The attached document “After ethical review – guidance for researchers” gives detailed guidance 
on reporting requirements for studies with a favourable opinion, including: 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Notification of serious breaches of the protocol 
• Progress and safety reports 
• Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of changes 
in reporting requirements or procedures. 
User Feedback 
 
The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received and 
the application procedure. If you wish to make your views known please use the feedback form 





We are pleased to welcome researchers and R&D staff at our training days – see details 
at http://www.hra.nhs.uk/hra-training/ 
With the Committee’s best wishes for the success of this project. 
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Appendix T: Invitation letter to participants 
 
Participant Invite Letter V1 14/06/2017 STH19994 





This letter has been sent to you by surgeons at your local hospital, because you have been treated 
for an anal fistula (connection between the back passage and skin) related to Crohn’s disease. 
We know that surgeons are not very good at talking to patients about choices, and what operations 
help your fistula. We would like your help to change this, by designing a decision aid for patients. 
This questionnaire will help us to understand what information needs to be in this, and how it 
should be presented. 
Enclosed is a questionnaire, which we have designed after interviewing patients about their 
experiences with Crohn’s anal fistula. We would appreciated it if you could complete it – it should 
take no more than 15 minutes. We’d be grateful if you could send this back to us within a month 
of receiving it. 
When you have completed it, please put in in the enclosed PREPAID envelope, and put it in a 
post box. 
You do not have to complete this, and whether you complete it or not, it won’t affect the care 
you receive. Each questionnaire has a code number– this means that we can tell your local 
hospital that one of their patients has completed the questionnaire, and they will get some 
research funding for this. All your responses come to the team in Sheffield, and we cannot 
identify you – this means no-­‐one knows what you have said in your questionnaire. 
We are not going to ask you to sign a consent form – if you complete and return the 
questionnaire, we will assume you are happy to participate. 
If you have any questions, we would be happy to answer them. I 
hope you are willing to participate in this study. 
Yours faithfully 
Mr Matthew Lee, 
Research Fellow in General Surgery, Sheffield Teaching Hospitals 
m.j.lee@sheffield.ac.uk 





Appendix U: Final questionnaire 





Thank you for helping us with this study. 
 
The aim of our study is to find out what you thought about your surgical treatment for your 
anal fistula. We are interested in finding out how you wanted decisions about your 
treatment to be made, and what information and support you felt may have been of help to 
you at the time. 
 
There are no right or wrong answers to these questions. We would like to hear about your 
personal experiences, views and opinions and so any information you provide will be of real 
value to us. All the information collected is anonymous. This questionnaire should take 
about 20 minutes to fill in. 
 
By returning the questionnaire you are giving consent for your anonymised data to be used 
in this study. Whether you agree to participate or not, your care will not be affected and 
your doctors will not be told about your answers. 
 
When you have finished, please return it to us in the pre---paid envelope. There is no need to 
use a stamp. 
 
Thank you for your help. 
 





Section 1: About you 
 
How old are you? Please write your age in years   
Please indicate your sex below 
Male    Female   
Other   
Prefer not to answer   
 
How long since you were diagnosed with Crohn’s disease? Please write in years and 
months   




Examination under anaesthetic only (examination of my bottom, with no 
other procedures performed) 
 
Placement of a seton (insertion of a band into the fistula to allow infection 
to drain) 
 
Advancement flap (moving part of the lining of the back passage to cover 
the inside hole of the fistula) 
 
Fistula plug (insertion of a plug to block the fistula)  
Formation of stoma (bringing the bowel to the tummy wall and using a bag 
to divert faeces away from the back passage) 
 
Proctectomy (removal of back passage)  
I’m not sure  





Please tell us about your level of education (please tick one) 
 
I have one or more GCSEs  
I have one or more A---levels  
I have a Bachelors degree (e.g. BSc, BA)  
I have a Post---graduate degree (Masters/Doctorate)  
I do not have any qualifications  
Other  
 
(Optional) Which ethnic group do you belong to? Please tick one box only 
 
White British  
Mixed or multiple ethnic groups  
Asian or Asian British  
Black, African Caribbean or Black British  
Prefer not to answer  
Other ethnic group (please specify below)  
 





Section 2: What information did you use before surgical treatment? 
 
 
In addition to information from doctors and nurses at the hospital, did you find any of the 
following information helpful when deciding on your treatment? Please tick all relevant 
answers. If you used an information sheet, please rate how useful this was from 1---9, with 1 
being not helpful, and 9 being very helpful. 
Information source Please tick 
 
if used 
Usefulness 1---9 (1=not 
 
important, 9=essential) 
Discussions with my GP   
Internet forums/chat rooms   




Wikipedia   
Online videos (e.g. Youtube/Vlogs)   
Charity websites   
NHS Choices   
Leaflets/booklets provided by the hospital   
Friends or family   
Other (please specify below)   
 





When discussing treatments with you, which of the options below would be helpful in 
deciding about surgery? Please rate these from 1---9, with 1 being not important, and 9 
being essential. 
Information 
Importance 1---9 (1=not 
important, 9=essential) 
How long I would be in hospital  
Will the operation close my fistula?  
About risks of the operation  
How much pain I would have after the operation  
How ‘invasive’ the procedure was  
Whether I will need help with my wound when I go 
home from hospital 
 
Whether I would need to attend my GP 
practice/community clinic after my operation 
 
Whether I would need to attend hospital frequently 
after my operation 
 
Whether I would need further operations in the 
future 
 
Whether the treatment would stop discharge around 
my back passage 
 
Whether the treatment would affect my continence 
(i.e. would it cause leakage from my back passage?) 
 
Whether the treatment would affect my ability to 
work 
 
Whether the treatment affect my ability to sit down  
Whether the treatment affect sexual activity  
Whether I would still need to take medications to 







Section 3: How did you make decisions about your treatment? 
 
When you discussed your fistula with the surgeon, did they offer you a choice of 
operations? 
 
Yes, I was offered a choice of operations  
No, I was not offered a choice of operations  
I am not sure/don’t know  
 
Please tick the box next to the statement that best describes the situation that ACTUALLY 
HAPPENED during your consultations. Please tick one only 
 
I made the final selection about which treatment I had  
I made the final selection of my treatment after I had seriously considered 
 
my doctor/nurse’s opinion 
 
My doctor/nurse and I shared the responsibility for deciding which 
 
treatment was best for me. 
 
My doctor/nurse made the final decision about which treatment was used, 
 
but seriously considered my opinion. 
 






Please tick the box next to the statement that best describes the situation that you 
believe would be IDEAL. Please tick one box 
 
I prefer to make the final selection about which treatment I will have.  
I prefer to make the final selection of my treatment after seriously 
 
considering my doctor/nurse’s opinion 
 
I prefer that my doctor/nurse and I share responsibility for deciding which 
 
treatment is best for me. 
 
I prefer that my doctor/nurse makes the final decision about which 
 
treatment will be used, but seriously considers my opinion. 
 
I prefer to leave all decisions regarding my treatment to my doctor/nurse.  
 
 
What information helped you decide on treatment? (Please tick) 
 Yes No Unsure 
I was helped by talking to the surgeons in surgical clinic    
I was helped by talking to the doctors in gastroenterology 
clinic 
   
I was helped by talking to the specialist nurses (e.g. IBD 
nurse or colorectal nurse) 
   
I found the written leaflets in hospital helpful    
I was helped by talking to other patients in person or on 
the internet 
   
I was helped by talking to support groups    
 










Section 4: How would you like to make decisions about your treatment? 
 
Did you feel that you had enough information to decide what treatment to choose? 
(Please tick one) 
 
Yes, I had all the information I needed  
No, I would have liked more information  
Not applicable  
 
Whom would you prefer to talk to, about making a decision about your treatment? Please 
tick all that apply 
 
A surgeon from the surgical clinic at the hospital  
A doctor from my gastroenterology clinic at the hospital  
A specialist bowel disease nurse from the hospital  
My GP or a practice nurse  
My family  
My friends  
Patients who have been through the same treatments  
No one  
Other (please specify)  
 





We would like to know whether you were happy with your treatment decision 
 
















It was the right decision      
I regret the choice that I made      
I would go for the same choice if 
I had to do it over again 
     
The choice did me a lot of harm      





Section 5: How would you like to be given information about treatment for your fistula? 
 
How would you like to receive information to help you decide about Crohn’s anal fistula 
treatment? Please tick all that apply 
 
Booklet or leaflet  
DVD or video  
From others with experience of the condition/treatment  
Interactive website  
Webpage with information  
Face to face chat with a doctor/surgeon  
Face to face chat with a nurse  
I do not require/want this information  
Support Group  
Not sure  
Other (please specify)  
 
Other:   
 
 
Do you have access to the internet? (Please tick one) 
 
I have my own computer/smart phone and use the internet at home  
I can access the internet e.g. at someone else's house or at the library  
I cannot use a computer/smartphone myself but friends and relatives can 
use them for me 
 
I have no access to a computer/smartphone or the internet  





If information was available on the internet which could give you the pros and cons of 
your fistula treatment options, how likely would you be to use this? 
Very likely  
Somewhat likely  
I’m not sure  
Somewhat unlikely  
Very unlikely  
 
Please tick the box next to your preferred way of being given this information 
 
A statement in words: e.g. Anal fistula affects many people with 
Crohn’s disease 
 
A number: e.g. 1 in 3 people with Crohn’s disease will develop an 
anal fistula 
 
A percentage: e.g. 30% of people with Crohn’s disease will develop 
an anal fistula 
 
A fraction: e.g. 1/3rd of people with Crohn’s disease will develop an 
anal fistula 
 
A chart e.g. to show what fraction of people with Crohn’s disease 





A graph to show what fraction of people with Crohn’s disease 
develop an anal fistula 
 
   
Represented as a picture for example, 1 in 3 people with Crohn’s 








We want to make any information we give to you relevant and interesting. The 
following are some suggestions of things that we can do. Please tick the relevant 
answer. 
 
 Yes No Unsure 
I would like to see/hear the stories of other patients 
who have had an anal fistula in Crohn’s disease 
   
I like to see pictures of relevance to make the 
information more real and useful 
   
I prefer lots of factual information    
I prefer lots of diagrams    
I would like to see diagrams of what an operation 
involves 
   
I would like to see a video of what happens when you 
come into hospital for an operation 
   
 
 
Thank you for completing this questionnaire. Please return it in to us in the PRE---
PAID envelope. 
If you cannot find the pre---paid envelope, please return the questionnaire 
to: Professor Brown’s Secretary 
Dept of General Surgery 
First Floor Old Nurses 
Home Northern General 
Hospital Herries Road 
 
Contact: 
Mr Matthew Lee, Clinical Research Fellow, Sheffield Teaching 
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